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ABSTRACT 
Regulation of splicing networks in neurodevelopment 
Sebastien M. Weyn-Vanhentenryck 
 
Alternative splicing of pre-mRNA is a critical mechanism for enabling genetic diversity, and is a 
carefully regulated process in neuronal differentiation. RNA binding proteins (RBPs) are 
developmentally expressed and physically interact with RNA to drive specific splicing changes. 
This work tests the hypothesis that RBP-RNA interactions are critical for regulating timed and 
coordinated alternative splicing changes during neurodevelopment and that these splicing 
changes are in turn part of major regulatory mechanisms that underlie morphological and 
functional maturation of neurons. I describe our efforts to identify functional RBP-RNA 
interactions, including the identification of previously unobserved splicing events, and explore 
the combinatorial roles of multiple brain-specific RBPs during development. Using integrative 
modeling that combines multiple sources of data, we find hundreds of regulated splicing events 
for each of RBFOX, NOVA, PTBP, and MBNL. In the neurodevelopmental context, we find that 
the proteins control different sets of exons, with RBFOX, NOVA, and PTBP regulating early 
splicing changes and MBNL largely regulating later splicing changes. These findings 
additionally led to the observation that CNS and sensory neurons express a variety of different 
RBP programs, with many sensory neurons expressing a less mature splicing pattern than CNS 
neurons. We also establish a foundation for further exploration of neurodevelopmental splicing, 
by investigating the regulation of previously unobserved splicing events.
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Chapter 1. Introduction 
RNA splicing 
For protein-coding genes, the path from gene to gene product includes the formation of an RNA 
intermediate via transcription. This RNA must be appropriately modified for its given context 
through a collection of events collectively grouped under “post-transcriptional processing and 
modification,” which results in a fully mature messenger RNA (mRNA). One of these events, 
RNA splicing, is the process by which non-coding internal portions of the RNA, introns, are 
removed in order for the mature mRNA to consist only of the exons. The exons together make up 
the 5′ UTR, protein-coding regions, and 3′ UTR.  
Splicing is performed by a large RNA-protein complex called the spliceosome. The 
spliceosome is built up on the RNA in a series of steps. First, U1 snRNP recognizes and binds 
the GU sequence located at the 5′ end of every intron, SF1 (splicing factor 1) binds to the 
branch-point A located near the 3′ end of the intron, U2AF1 (U2 auxiliary factor) binds to the 
polypyrimidine tract near the 3′ splice site, and U2AF2 binds to the AG sequence at the 3′ end of 
the intron (complex E). Next, U2 snRNP binds the branch-point assembly (complex A). The 
U4/U6.U5 tri-snRNP interacts with U2 to bring the 5′ and 3′ ends of the intron together, and 
leads to cleavage of the 5′ exon-intron boundary when the 2′ hydroxyl of the branchpoint A 
attacks the splice site to form a lariat intermediate. The free 3′ hydroxyl of the 5′ splice site then 
attacks the 3′ splice site to ligate the two exons and release the intron lariat. 
In lower eukaryotes, introns are very short, and the splicing machinery can simply 
recognize and remove the introns, a model termed intron definition (De Conti et al., 2013). 
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However, in higher eukaryotes such as mammals, introns are generally 10 or more times longer 
than exons, ranging from 1-100 thousand nucleotides compared to an average length of 120 nt 
for exons (Hong et al., 2006). It is thus believed that there exists an exon definition model 
instead, where splicing factors coordinate across an exon prior to intron splicing. Possible 
exceptions to this model include microexons, exons shorter than ~30bp (see below). 
 
RNA alternative splicing 
A special form of splicing, and the major focus of this work, is that of alternative splicing (AS). 
Alternative splicing is the process by which certain splice sites are chosen in specific contexts, 
leading to regulated inclusion, exclusion, and alteration of specific exons. Exons that have thus 
far only been observed to be included (note that this depends on exhaustive observation, as 
discussed below) are termed constitutive exons. 
Alternative splicing takes several forms. The most common form in mammals, and the 
most well-studied, is that of the cassette exon, where a specific exon that can be either included 
or excluded, surrounded by two (usually) constitutive exons. More complex forms include 
tandem cassette exons, a series of two or more consecutive exons that are always included or 
excluded at the same time, and mutually exclusive exons, where exactly one exon at a time from 
a set of 2 or more exons is included (a special case of these exons are dual-specificity exons, 
which allow for mutually exclusive inclusion of one of two parts of an exon (Zhang et al., 
2007)). In addition, individual exons can be lengthened or shortened when they are flanked by 
alternative 3′ splice sites or alternative 5′ splice sites. Finally, introns may remain included in the 
mature mRNA, resulting in intron retention. 
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Alternative splicing can play critical roles in altering the final protein product. At an 
extreme, an exon can harbor an entire protein domain, and excluding the exon effectively 
eliminates the domain. AS may also create alternate versions of a domain (Liu and Grigoriev, 
2004), which can change protein activity, add or remove regulatory sites (e.g. phosphorylation 
sites), or change protein localization (Black, 2003). AS can also cause degradation of an mRNA 
via nonsense-mediated decay (NMD) by introducing a premature termination codon (see below). 
AS events that play some biological role are referred to as "functional" splicing events. 
AS is a key component of gene regulation, and it is estimated based on currently 
observed data that more than 90% of genes are alternatively spliced (discussed further 
below)(Pan et al., 2008; Wang et al., 2008). Indeed, the extensive use of AS in mammals is 
believed to have been a key for increasing organismal complexity. For example, mice and 
humans have roughly the same number of genes, but the human brain is undeniably more 
complex; the brain is one of the tissues experiencing the most distinct RNA splicing (Wang et 
al., 2008). 
 
Evolution of RNA splicing 
In addition, AS has evolved much more rapidly than gene expression; there is much greater 
consistency in tissue gene expression levels across species than there is for AS and AS more 
significantly identifies species rather than organ type (Barbosa-Morais et al., 2012). Even more 
recently, splicing events diverge significantly. For example, there are many alternative splicing 
events specific to primates which are not present in rodents (Modrek and Lee, 2003). 
Alternative exons are believed to evolve in one of three ways (Keren et al., 2010). First, 
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by direct insertion of a new exon into a transcript. This generally occurs as a result of duplication 
of an existing exon. Second, by exonization of intronic regions. This is often caused by the 
insertion of a transposable element containing a sequence similar to a splicing signal. For 
example, primates, including human, possess Alu elements that are only a few mutations away 
from an optimal splice site sequence. Third, by weakening a constitutive exon into an alternative 
exon. This occurs when the splice sites are mutated into sub-optimal sequences and nearby 
splicing enhancer and suppressor sequences are created or strengthened.  
When an exon is created, it typically is rarely included (<20% of transcripts) as the 
organism "tests" its functionality (Zhang and Chasin, 2006). Productive splicing events may 
become fixed over time, and inclusion levels will tend to increase as well. Ancient alternative 
exons (as well as alternative exons derived from constitutive exons) are typically included in the 
majority of transcripts (>80%). In addition, as AS events mature, they will typically have higher 




Nonsense-mediated decay (NMD) is a regulatory pathway in eukaryotes used to eliminate 
transcripts containing a premature stop codon (PTC) (Maquat, 2004). This process is used to 
correct errors in transcription, because a PTC suggests that the transcript will not code for any 
functional protein. NMD is also used as a regulatory mechanism when PTCs are intentionally 
created; when an alternative splicing event creates a PTC it is known as AS-NMD. 
NMD occurs during translation in the cytoplasm. After splicing occurs in the nucleus, an 
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exon junction complex (EJC) remains at each exon-exon junction. The EJCs are exported along 
with the mRNA into the cytoplasm, but are pushed off by the first (pioneering) ribosome during 
translation (up to 50-55nt downstream of the codon it is currently translating). If there is a PTC, 
the ribosome will not push off one or more EJCs, which then trigger NMD. UPF proteins 
recognize the transcript, which in turn recruits cleavage, deadenylation, and decapping factors to 
eliminate the mRNA. 
 
Microexons 
An important group of cassette exons are the microexons, which are shorter than ~30bp (the 
exact definition varies). Based on splicing assays, exons smaller than 50 nt are inefficiently 
spliced, presumably due to a lack of space for the splicing factors (Dominski and Kole, 1991). 
However, recent improvements in experimental and computational tools have revealed that 
microexons are much more common than anticipated, with numbers ranging from 700 (Irimia et 
al., 2014) to 2,000 (Yan et al., 2015) alternatively spliced microexons and up to 13,000 total 
microexons (Li et al., 2015). These studies found that microexons are strongly regulated by a 
number of splicing regulating RNA binding proteins, including RBFOX, PTBP, and SRRM4 
(nSR100). In addition, microexons are potentially linked to several diseases, including autism 
(reviewed in ref. (Ustianenko et al., 2017)). 
Regulation of alternative splicing 
Proper control of AS is critical, and is typically performed by RNA-binding proteins (RBPs). 
There are potentially several hundred RBPs as identified by interactome capture studies, most of 
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which don't yet have clearly defined roles (Baltz et al., 2012; Castello et al., 2012). Many of 
these, but not all, contain one or more canonical RNA binding motifs (e.g. RRM, KH, zinc 
finger, and cold shock) that recognize short, degenerate sequences or specific secondary 
structures. A subset of RBPs are involved in regulating alternative splicing. 
To regulate splicing, splicing-regulatory RBPs modulate the preference of the 
spliceosome for specific splice sites. This is done by their binding to short RNA motifs, known 
as intronic and exonic splicing enhancers and splicing silencers (ISE, ISS, ESE, ESS) depending 
on how the binding affects splicing. Identification of these sites at the RNA level is done with 
splicing assays and correlation with splicing levels, which results in a (non-exhaustive) list of 
motifs but not in a mechanism of action. At the protein level, the binding sites of a single RBP at 
a time are deeply characterized, at the expense of breadth. Some general patterns have been 
observed, including that ISSs and ESSs are known to be typically bound by hnRNP-type 
proteins, while ESEs are known to be typically bound by SR-type proteins (Chen and Manley, 
2009). Several RBPs, including ones discussed below, bind to ISEs located downstream of an 
alternatively spliced exon. Indeed, splicing-regulatory RBPs appear to have a canonical 
positional-dependent effect, where downstream binding activates splicing and upstream binding 
represses splicing. The mechanisms of this regulation are unclear, although it is believed that the 
repression may involve physical blocking of spliceosomal assembly. 
Some RBPs are expressed ubiquitously and generally promote the splicing process, but 
others are tissue- or age-specific and determine specific isoforms to be expressed in that context. 
Among these splicing factors are a well-studied set of tissue-specific factors which are highly 
expressed in the brain: RBFOX, MBNL, PTBP, and NOVA. These factors form the bulk of this 
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work, so will be introduced in detail below. 
 
RBFOX 
The RBFOX family of RBPs consists of three family members: RBFOX1 (A2BP1), RBFOX2 
(RBM9), and RBFOX3 (NeuN). It is highly conserved, with the RNA recognition motif (RRM) 
domains in Rbfox1/2 identical between human and mouse and having 77% identity with the 
homolog in C. elegans (Kuroyanagi, 2009).  
RBFOX is most well known as a regulator of alternative splicing (although it may also 
regulate RNA stability (Conboy, 2017)). It binds (U)GCAUG motifs to regulate alternative 
splicing in a position-dependent manner: downstream binding typically causes activation of the 
exon while upstream and exonic binding typically leads to exon skipping. 
RBFOX is expressed in a tissue-specific manner. RBFOX3 is the most neuron-specific, 
and indeed is known as the neural marker NeuN. Meanwhile, RBFOX1 is expressed both in 
neuron and muscle, and is believed to have tissue-specific functions. Finally, RBFOX2 is the 
most widely expressed, including in embryonic stem cells.  
The RBFOX genes have several variants. For example, RBFOX1 and RBFOX2 contain 
two mutually exclusive exons that are extremely tissue specific; one is only expressed in brain 
(B40) while the other is only expressed in muscle/heart (M43). In addition, the genes contain 
alternate 3′ UTRs that dictate whether the protein will be localized to the nucleus or the 
cytoplasm. Finally, RBFOX proteins auto-regulate RBFOX mRNA either by causing exclusion 
of half the RRM domain, creating functionally null proteins (Damianov and Black, 2010b) or by 
causing frameshift mutations and triggering NMD (Dredge and Jensen, 2011). 
  
8 
Despite their different expression patterns, one of the biggest challenges in studying 
RBFOX is that cells compensate for lack of a specific RBFOX protein by overexpressing other 
RBFOX proteins. A clear difference in function between the different RBFOX proteins has yet 
to be identified, so this compensation is effective and greatly limits the effects of single-gene 
knockout studies.  
Indeed, RBFOX1 and RBFOX2 single knockout studies only showed a small number of 
alternative splicing changes (20 and 29, respectively) and relatively mild phenotypes (Gehman et 
al., 2012; Gehman et al., 2011), while an RBFOX1/2 double knockout is embryonic lethal with a 
severely underdeveloped brain (Gehman et al., 2012).  
The phenotypes are worth noting, however. The CNS-specific RBFOX1 KO (including a 
60% increase in compensatory RBFOX2 expression) resulted in mice prone to seizures and 
epilepsy (Gehman et al., 2011). Meanwhile, CNS-specific RBFOX2 KO (with a mild 12% 
increase in RBFOX1 expression) resulted in small, weak mice (males in particular often die 
within a month), hydrocephalus (accumulation of cerebrospinal fluid in the brain), and 
underdeveloped cerebellum with disrupted Purkinje cell migration (Gehman et al., 2012). 
RBFOX affects the splicing of Gabrg2a and Grin1, which have been previously 
associated with neurological defects. In addition, RBFOX regulates exons in Scn8a, which codes 
for the α subunit of the Nav1.6 voltage-gated sodium channel, possibly causing aberrant 
signaling. 
To assess the effects of RBFOX without interference from redundancy, we generated an 
Rbfox1/2/3 triple knockout (TKO) motor neuron cell line (Jacko et al.). We observed hundreds of 
splicing changes, many in cytoskeletal and plasma membrane genes, consistent with neuronal 
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projection and development. Intriguingly, RBFOX appears to play a critical role in the 
development of the axon initial segment, as many neurons have delayed formation of the AIS. 
This was specifically linked to an alternative splicing event in ankyrin G which needs to be 
skipped as neurons mature. 
Recent work has suggested that RBFOX regulates splicing as part of a larger complex. 
Two studies from the Black lab suggest that 1) RBFOX binds as part of a multi-protein, 
chromatin-associated complex known as the LASR complex (Damianov et al., 2016) and 2) the 
tyrosine-rich C-terminal domain of RBFOX allows for self-aggregation of RBFOX proteins and 
interaction with the LASR complex (Ying et al., 2017). These findings present intriguing new 
mechanisms for how RBFOX functions in the regulation of alternative splicing.  
 
MBNL 
Muscleblind-like (MBNL) were originally identified in Drosophila, where, as its name implies, 
deletion causes muscle weakness and blindness. There are three homologs in human each 
containing four highly conserved zinc-finger RNA-binding domains. MBNL proteins bind a 
YGCY motif (Y=pyrimidine=C/U), with a potential preference for a double-stranded interaction 
with sufficient gap between the sequences (Teplova and Patel, 2008). Binding downstream of an 
alternative exon tends to promote inclusion of the exon while upstream or exonic binding tends 
to promote exclusion. 
MBNL is typically recognized as a nuclear protein promoting adult alternative splicing 
patterns; loss of MBNL in disease (e.g. in myotonic dystrophy; see “Splicing in disease” below) 
is associated with a reversion to fetal patterns. MBNL is believed to interact with the CELF and 
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PTB families of proteins to regulate specific splicing events (Konieczny et al., 2014), and may 
play a cytoplasmic role in stabilizing later-expressed cytoskeletal and developmental gene 
transcripts (Wang et al., 2015). A recent study also proposes that MBNL proteins regulate 
alternative poly-adenylation of RNA transcripts (Goodwin et al., 2015). 
MBNL1 and 2 are both present in most tissues, with MBNL2 being the prominent 
member in the brain. MBNL3 is primarily expressed in placenta with significant expression in 
the liver, and may also have a more fetal expression program as it is upregulated by the iPSC 
factors NANOG, OCT4, and SOX2 (Kanadia et al., 2003b; Yuan et al., 2017). 
The MBNL1 knockout mouse presents with myotonia at 6 weeks of age, has centered 
muscle cell nuclei and split myofibers, and develops ocular cataracts, but has relatively few 
effects in the brain and with most changes in alternative splicing occurring in muscle (Kanadia et 
al., 2003a; Wang et al., 2012). On the other hand, the MBNL2 knockout exhibits few muscle-
related phenotypes but has neurological defects including an increased number of REM-sleep 
periods (particularly during the dark phase when mice are generally awake), loss of spatial 
memory, decreased NMDA receptor activity, and a higher propensity for seizures, as well as a 
small weaning size (Charizanis et al., 2012). MBNL2 knockout mice also displayed a larger 
number of alternative splicing changes compared to wild-type than did MBNL1 knockout mice. 
To avoid the compensatory effects of the other family member, a recent Mbnl1-/-; 
Mbnl2c/c; Nestin-Cre+/- mouse model was generated, which fully knocks out Mbnl1 and 
selectively knocks out Mbnl2 in the CNS (Goodwin et al., 2015). These mice exhibit early and 
severe motor defects and die at roughly 23 weeks. These mice exhibit dramatic splicing changes, 
reverting the splicing of many exons to the fetal level in the brain, including in Camk2d and 
  
11 
Grin1. These results were similar to changes observed in the brains of humans with mytonic 
dystrophy, where MBNL proteins are essentially knocked down. One particular misspliced exon 
in human is microtubule-associated tau protein (MAPT), which correlates with a known 
presentation in DM1 of tau neurofibrillary tangles.  
 
NOVA 
NOVA1 and NOVA2 (Neuro-Oncological Ventral Antigen) are neuron-specific RNA-binding 
proteins. The family was first identified in cancer patients with paraneoplastic opsoclonus-ataxia, 
an autoimmune motor neuron condition; these patients produce the Ri antibody, which binds 
NOVA in their tumors (Buckanovich et al., 1993). NOVA is specifically expressed in the nuclei 
of central nervous system neurons as demonstrated by co-staining with NCAM (neural cell 
adhesion molecule) and NSE (neuron-specific enolase) (Buckanovich et al., 1996). NOVA1 and 
NOVA2 tend to not be expressed in the same regions however, with NOVA2 being more broadly 
expressed, including exclusive expression in the neocortex and hippocampus (Yang et al., 1998). 
NOVA proteins have three KH RNA-binding domains that recognize clusters of the 
YCAY (Y=pyrimidine=C/U) motif (Lewis et al., 2000; Ule et al., 2003). Downstream binding of 
NOVA typically leads to inclusion of the exon while upstream or exonic binding typically leads 
to exon exclusion (Ule et al., 2006b; Zhang et al., 2010). 
While Nova1 knockout mice appear normal at birth, they develop a rapid loss of motor 
function and die after 7-10 days (Jensen et al., 2000). Cells that normally express Nova1 (ventral 
spinal cord, brainstem nuclei, and deep cerebellar nuclei) undergo apoptosis. Nova2 knockout 
mice display agenesis of the corpus callosum, defects in partial innervation (specifically to the 
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diaphragm and cochlea), defects in long term potentiation of slow inhibitory post-synaptic 
currents (IPSC), and die 14-18 days after birth (Huang et al., 2005; Saito et al., 2016b; Ule et al., 
2005c). Nova1 +/- and Nova2 +/- mice exhibit symptoms of epilepsy at 6 months (Saito et al., 
2016b). 
Despite their different expression patterns, the relatively mild phenotypes suggest that 
there is likely redundancy between the proteins. Indeed, Nova1/2 double knockout resulted in a 
much more drastic phenotype. They are born alive but paralyzed, and they die shortly after birth 
as a result of an inability to breathe (Ruggiu et al., 2009). This results from lack of innervation in 
the diaphragm: neuro-muscular junctions (NMJs) are non-functional as a result of missplicing of 
the Z+ agrin. Z+agrin is a neuron-specific isoform of agrin, a protein in the NMJ that leads to 
clustering of acetylcholine receptors at the synapse; the Z+ isoform attracts more AChR (Ferns et 
al., 1993). Double knockout mice also exhibit complete loss of innervation to the cochlea (Saito 
et al., 2016b). These phenotypes suggest that NOVA2, possibly in coordination with NOVA1, is 
critical for axonal pathfinding. 
The NOVA proteins use alternative splicing to promote regulation of synaptic activity, 
including long-term potentiation. In addition to its namesake disease, integrated modeling of 
NOVA regulation and the resulting 358 identified target genes suggest that NOVA may be 
involved in complex neurological disorders, including autism (Zhang et al., 2010).  
 
PTBP 
PTBP (polypyrimidine tract binding protein) was first identified as a UV-crosslinkable protein 
binding near 3′ splice sites within the polypyrimidine tract in HeLa cell extract (Garcia-Blanco et 
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al., 1989). It was initially believed that its binding to the polypyrimidine tract led to efficient 
formation of the U2 snRNP complex in conjunction with an unidentified U2 auxiliary factor 
(later named U2AF). A later study then suggested that the binding actually antagonizes U2AF, 
leading to the exclusion of the exon (Singh et al., 1995). PTBP was identified as part of a class of 
hnRNP proteins, which are generally known as splicing repressors (Ghetti et al., 1992). 
PTBP is a highly conserved protein, including through fly and worm (Keppetipola et al., 
2012). It contains four non-canonical RRM domains and recognizes clusters of the pyrimidine-
rich motif UCUY. The exact motif is unclear partly because the four RRMs have slightly 
different sequence specificities, and the preference for the full protein is unknown. In most cases, 
PTBP binds upstream of the exon, leading to exon repression, though it also binds exonically, 
which also usually leads to repression, and downstream, which leads to exon activation (Llorian 
et al., 2010; Xue et al., 2009). In addition, PTBP can recognize a CCU motif as part of a double-
stranded loop, which in the 5′ UTR creates an internal ribosome entry site (IRES) (Mitchell et 
al., 2005). 
Humans have three paralogs (Keppetipola et al., 2012). PTBP1 is the most ubiquitously 
expressed. PTBP2, also known as neuronal PTB or nPTB, is expressed mutually exclusively with 
PTBP1 (described below) and primarily in the neurons and testes. PTBP3 (ROD1) is expressed 
in hematopoietic cells. The target sets of PTBP1 and PTBP2 largely overlap, though there are a 
few differences (Vuong et al., 2016b);  these are more likely attributable to cofactors than 
difference in RNA-binding specificity.  
The PTBP proteins are themselves alternatively spliced and, together with miR-124, a 
neuron-specific miRNA that is one of the most abundant in the CNS, autoregulate each other via 
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alternative splicing coupled with nonsense-mediated decay to ensure their mutually-exclusive 
expression (Spellman et al., 2007; Wollerton et al., 2004). miR-124 is upregulated during neural 
differentiation and binds PTBP1, reducing its levels. As a result PTBP2 levels are no longer 
suppressed (Boutz et al., 2007; Makeyev et al., 2007). Perturbation of the PTBP-miRNA 
regulation network also appears to be sufficient to induce the conversion of fibroblasts into 
neurons (Xue et al., 2013). 
Germline deletion of Ptbp2 results in failure to breathe and death almost immediately 
after birth. The mice appear paralyzed and do not respond to touch (Li et al., 2014; Licatalosi et 
al., 2012a). A lack of synaptic markers suggests delayed maturation or synapse malformation. A 
neuron-specific knockout (Nes-Cre) displayed initial, albeit slow, breathing, and died an hour 
after birth (Li et al., 2014); PTBP1 levels were unchanged and brain morphology appeared 
largely normal. However, these mice did lack several axonal tracts which normally connect 
distant structures in the brain. PTBP2 knockout in projecting (older) neurons in the higher 
forebrain (Emx1-Cre) resulted in viable mice that grew much more slowly than wild-type mice 
(half weight at P14) and eventually died around P18-P21 (weaning age) as a result of widespread 
neuronal death (Li et al., 2014). Anatomical defects include thin cortices, enlarged lateral 
ventricles, absence of corpus callosum, reduced hippocampal size, and defective olfactory bulb 
lamination. In all cases, substantial changes in alternative splicing are observed. The phenotypes 
of the Emx1-Cre mice, but not the Nes-Cre or germline knockout mice, could be rescued with a 
Ptbp1 knockin (Vuong et al., 2016b).  
Mice with a germline deletion of Ptbp1 are non-viable; although they implant, at E7.5 




Measuring RNA regulation 
In order to determine the splicing regulatory programs of RBPs, we need to measure their 
biological effects. Here, I briefly describe the experiments used to measure RBP function. In 
addition, I describe the integrative modeling approach we use to incorporate evidence from 
multiple experimental sources. 
Measuring alternative splicing 
Splicing is currently measured by RNA-seq (Pan et al., 2008; Wang et al., 2008). With current 
short-read technology, we look specifically for the reads that span exon junctions, which are 
termed junction reads. Splicing is thus reported, in its simplest measure, as 
𝜓 = 𝑈𝐼_𝑒𝑥𝑜𝑛	 + 𝑒𝑥𝑜𝑛_𝐷𝐼2 ∙ 𝑈𝐼_𝐷𝐼 + 𝑈𝐼_𝑒𝑥𝑜𝑛 + 𝑒𝑥𝑜𝑛_𝐷𝐼 
where UI and DI are upstream and downstream intron, respectively, and each region pair 
represents junction reads spanning those regions. This results in a value between 0 and 1 and is 
termed percent spliced in (or psi, or Ψ; alternatively, may be referred to as the inclusion ratio). 
Being a ratio, Ψ benefits from being robust to several RNA-seq biases (in contrast to RPKM), 
but we do require a minimum number of junction reads in order to generate a reliable ratio 
(typically at least 20 junction reads, although for datasets with lower sequencing depth we may 
reduce this value to increase sensitivity). 
The effects of an RBP are measured by removing the RBP of interest from a biological 
context either by knockdown (KD) or knockout (KO). RNA-seq is performed on both conditions 
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and we measure the splicing effects of the RBP by comparing Ψ of a given exon in both 
contexts. ΔΨ is defined as (ΨWT	− ΨKO). Note that this is the opposite of a typical RNA 
expression experiment. The sign of ΔΨ is positive when Ψ is higher in the WT condition, which 
can then be interpreted as “activation” by the RBP; likewise, the sign is negative when Ψ is 
lower in the WT condition, which can then be interpreted as “repression” by the RBP. 
Almost all of our mRNA-seq processing is performed using the OLego-Quantas pipeline 
(Wu et al., 2013; Zhang et al., 2014). OLego is an aligner that is specifically designed to identify 
de novo exon junctions; its use of small seeds in its search helps to reliably identify exon 
junctions, including microexons. Quantas consists of several tools for quantifying alternative 
splicing. The gapless tool is used to predict whether intermediate exons are included or excluded 
in a read based on the known distribution of Illumina sequencing transcript sizes and distribution 
of isoform abundance from the other reads. The remainder of the pipeline counts gene, exon, and 
exon junction reads and performs statistical analysis to determine any significant changes 
between two conditions. 
Finally, some of the analyses presented here depend on microarray data. Two types of 
arrays are used to measure splicing: exon arrays and exon-junction arrays. Exon arrays measure 
the number of RNA molecules matching a given exon in each condition, while exon-junction 
arrays measure the number of RNA molecules matching a specific junction. For these 
experiments, the original quantification of array results provided by the authors was used. 
Measuring direct binding 
One of the most powerful techniques in RNA-protein biology is CLIP-seq (crosslinking and 
immunoprecipitation followed by high-throughput sequencing)(Darnell, 2010b). Multiple 
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variations of the protocol currently exist and continue to be developed, but the aim of each is to 
identify direct protein-RNA interaction sites.  
In brief, the cells of interest are exposed to ultraviolet (UV) light, which induces 
crosslinking between nearby molecules. Importantly, this covalently fuses RBPs to their 
currently-bound RNA. The cells are then lysed, partial RNase digestion fragments the RNA, and 
the protein of interest is pulled down using a specific antibody (tagged proteins can also be used 
to facilitate this step). The protein is then digested and the remaining RNA is extracted for 
reverse transcription, amplification, and sequencing. 
Raw CLIP tags are processed as follows (Moore et al., 2014; Shah et al., 2017). Reads 
are filtered to ensure quality and exact PCR duplicates are removed, taking advantage of the 
random barcode in the 5′ adapter. After adapter trimming, reads are aligned to the genome and 
are grouped into clusters. Note that in contrast to mRNA-seq, the length of sequencing reads is 
not a significant limitation and paired-end reads are unnecessary. 
An interesting “side-effect” of the CLIP protocol is that because UV-crosslinking leads to 
the formation of a covalent bond between amino acids and RNA, there typically remains an 
amino acid bound to the RNA even after protein digestion (Moore et al., 2014). This in turn leads 
to errors during reverse transcription of RNA into cDNA: the reverse transcriptase may cause a 
mutation at the crosslink site (deletion or substitution), which we refer to as crosslink-induced 
mutation sites (CIMS), or it may drop off entirely, leading to a crosslink-induced truncation site 
(CITS). CIMS can be detected in any CLIP dataset, but special consideration in the protocol 
design needs to be taken to identify CITS. The iCLIP protocol was the first to take advantage of 
this drop by incorporating a circularizeable adapter to “save” the truncated reads (Konig et al., 
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2010), and later protocols followed suit (Van Nostrand et al., 2016; Weyn-Vanhentenryck et al., 
2014). 
Both CIMS and CITS provide us with the exact binding site of the RBP at a single-
nucleotide resolution, and this has proven to be a powerful tool for our understanding of RNA-




One of the challenges in working with RBPs is the fact that they recognize short and degenerate 
motifs. As such, it is difficult to extract true binding regions from the RNA and differentiate 
them from a random occurrence of the motif. In addition, although a CLIP-seq experiment will 
identify direct targets, it does have several limitations to consider. First, it is only a snapshot 
reflecting binding at a given time point in a given biological context, meaning that there are 
likely many missing binding sites (e.g. if a targeted gene is not expressed)(Blencowe et al., 2009; 
Darnell, 2010b). Second, CLIP-seq protocols have technical biases and limitations that depend 
on certain experimental parameters, including the enzymes used, particularly the reverse 
transcriptase; stringency of purification; quality of antibody; efficiency of UV crosslinking and 
its preference for certain nucleotides. 
An observation that has been made in the field, however, is that true RNA-binding motifs 
tend to occur in clusters separated by a few dozen nucleotides; this presumably greatly increases 
the probability of binding by an RBP or allows the RBP to bind RNA with several domains 
simultaneously. Taking advantage of this observation, our lab developed the mCarts algorithm, 
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which uses a Hidden Markov Model to score motif sites and determine their likelihood of being a 
part of a motif cluster, taking into account sequence conservation and availability (Weyn-
Vanhentenryck and Zhang, 2016; Zhang et al., 2013a). 
In brief, the model is trained on intronic sequences that fall in one of two categories: 
those that are strongly bound by CLIP data and those that have no evidence of CLIP data. The 
motifs within those regions are then evaluated according to multiple parameters: their distance 
from each other, their conservation, and their likelihood of being double-stranded. The whole 
genome is then passed through the trained model to determine the final clusters. These form an 
unbiased, genome-wide set of likely-bound regions that complements and extends the results of a 
CLIP experiment. 
Integrative analysis 
Each dataset we obtain when investigating RBP regulation of RNA splicing is incomplete and 
subject to technical and biological error. The most notable limitations include the fact that CLIP 
datasets are constrained by the experimental context and that RNA-seq perturbation datasets 
cannot distinguish between direct and indirect targets (i.e. if RBP1 regulates RBP2, the knockout 
of RBP1 may reflect the splicing targets of RBP2). In addition, RBP motifs are very short and 
degenerate, making it difficult to conclusively identify regulatory sites within the genome. 
To help overcome these issues and to integrate as many datasets as possible, we use a 
Bayesian network framework for exon regulation by RBPs (Zhang et al., 2010). A Bayesian 
network is a graphical probabilistic framework that encodes relationships between variables and 
their conditional dependence on other variables. It is structured as a directed, acyclic graph 
where each variable is a node and dependencies are shown with arrows. The structure of the 
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network allows us to take advantage of conditional independence; a node is conditionally 
independent of all non-descendants. 
In the protein-RNA interaction context, we are looking to predict the probability that an 
exon is a target T of the RBP (Figure 1.1). We therefore are asking P(T|B,S), where B=binding 
refers to the probability that a given alternative exon region is bound by the RBP, and S=splicing 
refers to the probability that the RBP regulates the splicing of that exon. P(B) is in turn 
conditioned on the probability of a bound motif, and the probabilities of P(B), which affect 
binding, are trained on CLIP data. On the splicing side, the P(S) comes from the observed 
splicing changes in perturbation experiments and from sequence features including the 
conservation of the exon (if an alternative splicing event is functional and regulated it is more 
likely to be conserved) and whether an exon is symmetric (i.e. a multiple of 3; with the exception 
of exons that exist to trigger nonsense-mediated decay it is easier to regulate a context-specific 
exon if it does not cause a frameshift). 
The Bayesian network is trained with a combination of validated regulated exons, 
predicted target exons, and predicted non-target exons. A junction tree algorithm determines the 
maximum likelihood conditional probabilities, and overfitting is controlled with cross-validation. 
The final model not only predicts whether exons are targets of the RBP but provides insight into 




Figure 1.1. The Bayesian network framework for integrative modeling of RBP splicing targets. 
The splicing code 
One of the primary aims of the alternative splicing field is the ability to predict the context-
specific regulation of an alternative splicing event given its sequence. In turn, this will allow us 
to understand the effects of sequence mutations, potentially identifying disease-causing variants.  
The first large-scale effort at determining a splicing code was performed in 2010 by the 
Frey lab (Barash et al., 2010a; Barash et al., 2010b). In this work, a compendium of 1,024 
features was used to assess the inclusion levels of 3,665 exons across four types of tissues. The 
features considered include sequence-based features such as the presence of known and predicted 
motifs involved in splicing regulation, sequence conservation, and transcript structure motifs. 
The group was able to effectively predict the preferred preference for exon inclusion in each 
tissue for each exon. 
A follow-up to this work took advantage of recent developments in deep neural networks 
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to increase the power of the code (Xiong et al., 2015). Furthermore, the group was able to work 
with human data, taking advantage of the Illumina Body Map data. This allowed the group to 
extend their results to include disease-causing variants to determine their effects on splicing. In 
particular, they found that hundreds of intronic and synonymous (non-sequence-altering) exonic 
mutations, which are often excluded from association studies, could be linked to altered splicing 
levels. 
These efforts are currently limited by our lack of understanding of all splicing 
mechanisms, including the full compendium of splicing regulators and their binding motifs, the 
recognition of similar motifs in different cell types by different proteins (and unique cell type 
activities within a given tissue), and the link between splicing and transcription (splicing is 
affected by the kinetics of RNA polymerase). As such, these are the first steps toward our ability 
to fully understand and predict splicing in various tissues. Efforts such as the ENCODE 
consortium's large-scale RBP profiling efforts should improve these results in the future. 
Splicing in neurodevelopment 
The biological context for this work is mouse neurodevelopment, focusing on the cortex. 
Neurodevelopment refers to the ensemble of processes that lead to the formation of the brain and 
nervous system. It is highly complex and tightly regulated, because defects in development can 
be fatal or extremely inhibitory for adult animals (Sarnat et al., 2015).  
It has been observed that several brain-expressed RBPs are themselves developmentally 
regulated during neurodevelopment and that they regulate several critical alternative splicing 
events. In addition, a global RNA-seq analysis of E17 and P3-4 month mouse cerebral cortex 
(Dillman et al., 2013) revealed that, in addition to the expected gene expression changes, 387 
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splicing events changed significantly between adult and embryonic samples (evenly split 
between higher and lower inclusion), with the exons in genes involved in actin cytoskeleton, 
GTPases, and signal transduction. Critically, 31% of those events occurred in genes with steady 
gene expression levels, and the functional annotation categories of splicing-altered and 
expression-altered genes were quite distinct. These results highlight the additional, independent, 
and global level of regulation performed by alternative splicing during neurodevelopment. 
In this section, I will describe some key parts of the neurodevelopment process, including 
several observations already made concerning the role of alternative splicing and its regulation 
by RBPs. Selected major events in mouse development are listed in Table 1.1 for reference. 
 
Age Event 
E7.5 Neural plate forms 
E8.0 Neural tube closes 
E18.5/P0 Birth 
P2-P4 Hair begins to appear 
P3-P5 Ears open 
P11-P12 Eyes open 
 
Table 1.1. Selected major events in mouse development. 
Text and data adapted from ref. (Hill, 2017). 
 
The cerebral cortex 
The cerebral cortex is the outer layer of the anterior portion of the brain, derived from the 
anterior neural plate, and itself consists of six cortical layers. The human cortex contains an 
estimated 21-26 billion neurons (Herculano-Houzel, 2009)and the mouse cortex contains 
approximately 4 million neurons (Roth and Dicke, 2005). 
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The cortex has a broad range of functions, including basic sensory and motor processing 
as well as more complex thought processing. The primary sensory cortex receives visual, audio, 
and touch sensory input through the thalamus and the olfactory cortex receives input directly 
from the olfactory bulb. The pre-motor cortex, primary motor cortex, and supplemental motor 
area coordinate to signal movement. The remaining cortical areas, termed “association areas", 
have diverse roles in a variety of processes including memory, language, and abstract thought. In 
particular, the prefrontal cortex, which is particularly well developed in humans, is involved in 
mood, personality, planning, and judgement [this is the region that was damaged in the case of 
Phineas Gage, and the subsequent behavioral changes that occurred following his accident are 
well-documented]. 
Neuronal physiology is also dynamic as a neuron matures (Dehorter et al., 2012). 
Immature neurons have higher levels of intracellular chloride ([Cl-]) than mature neurons. As a 
result, GABA (γ-Aminobutyric acid; generally known as an inhibitory signal) was predicted to 
depolarize and potentially excite immature neurons. If this is the case, an interesting observation 
was made that suggests that during birth, maternal oxytocin triggers a flux in Cl-, leading to the 
change from excitatory to inhibitory activity and decreases fetal sensitivity to delivery (Tyzio et 
al., 2006). There is currently a debate over this model, however, as newer, in vivo optogenetic 
techniques argue that the observed excitation is an artifact of brain slicing where an injury 
response is captured (Ben-Ari, 2014; Bregestovski and Bernard, 2012). 
Regardless, immature neurons are characterized by stochastic “intrinsic” currents 
generated by the early ion channels (Dehorter et al., 2012). These currents are short and not 
triggered by any synaptic connections. Eventually, the development of organized currents leads 
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to activation of molecular cascades which trigger changes in gene expression. Overall this 
process serves to reorganize electric impulses from spontaneous, non-functional bursts to 
organized, synapse-driven currents necessary for behavior. RBPs play critical roles at several 
points during this process, summarized in Figure 1.2 and described in the sections below. 
 
Figure 1.2. Splicing regulators in cortical development. 
This figure portrays the birth of neurons, their migration along radial glia, and their settlement into their final layers. 
All of these processes involve regulation by RBPs and are described in the text. Figure from (Vuong et al., 2016a). 
Neural progenitor expansion 
The first step in neurogenesis begins with symmetric division of neural progenitor cells in order 
to be able to generate a sufficient population of neurons; neurons are post-mitotic and can only 
be generated from neural progenitors (Stiles and Jernigan, 2010). In mouse this occurs around 
E10 (Pilaz and Silver, 2015). 
PTBP1, the PTBP isoform expressed in non-neuronal cells (as well as neuronal stem cells 
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and neuronal progenitors), represses the neuronal state in part by suppressing the neuronal 
isoform of Pbx1 and the neuron-specific RBP Ptbp2 (Vuong et al., 2016a). Indeed, removal of 
PTBP1 is sufficient to promote the transformation of fibroblasts into neuronal cells (Xue et al., 
2013). In normal development, as cells turn neuronal, the expression of miR-124 increases. 
miRNA-124 suppresses Ptbp1, which in turn promotes suppression of the REST complex (a 
transcriptional repressor of neuronal genes) and removes the suppression of Ptbp2. An 
overlapping feedback loop involves SRRM4 (nSR100), which promotes the formation of a non-
functional isoform of the REST complex, and is critical for neuronal differentiation. Another 
mechanism is a cross-talk between PTBP and RBFOX. PTBP maintains expression of filamin A 
by preventing inclusion of a poison exon that triggers NMD; high filamin A maintains the 
progenitor state to ensure that neurons do not differentiate prior to migration (Zhang et al., 2016). 
Meanwhile, RBFOX promotes differentiation by switching the splicing of ninein, a centrosomal 
protein that anchors microtubules, from the neural progenitor-specific to the neuron-specific 
isoform. 
Neuronal migration 
After their expansion, neural progenitors begin to divide asymmetrically starting around E11 
(Bielas and Gleeson, 2004). Following mitosis and neuronal specification, these new neuronal 
cells migrate along radial glia to their proper location for forming neuronal circuits. The deepest 
layers of the cortex (VI and V) are generally formed first, followed by layers IV, III, and II. 
Layer I consists of the oldest cells, which form a pre-plate, as well as cells that migrate in 
throughout cortical genesis (Zecevic and Rakic, 2001). Layers and regions are connected by 
white matter bundles, including the corpus callosum which connects the left and right 
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hemispheres of the brain. 
NOVA is a critical RBP involved in this process. Nova2 knockout mice have defects in 
cortical migration; several neurons that should be present in layers II , III, and IV remain in layer 
VI (Yano et al., 2010)(Figure 1.2). This has been linked to a missplicing of Dab1, a regulator of 
the Reelin signaling pathway, where the incorrect inclusion of exons 7b and 7c (normally 
skipped in neurons) leads to defective migration. In addition, NOVA ensures proper cell polarity, 
critical for proper axon guidance, by regulating the splicing of Par3, a member of the polarity 
complex, and several of its regulators (Baralle and Giudice, 2017; Giampietro et al., 2015). 
Similarly, in the cerebellum, RBFOX is critical for Purkinje cell migration as a result of its 
regulation of the splicing of Lrp8 (Vuong et al., 2016a). 
 
Neuronal projection 
After migration, the neurons can begin to develop the processes important for their circuitry, 
axons (which send signals) and dendrites (which receive signals), transitioning to functional 
signaling. This first also requires rearrangement of the cytoskeleton (Jones and Svitkina, 2016). 
The axon initial segment (AIS) is the first portion of the axon to form; a growth cone at its end 
builds up into the final structure. Finally, axons and dendrites form connections, resulting in gap 
junctions that allow for the passing of signals via neurotransmitter release. Gap junctions are 
critical cell-cell junctions, particularly in the nervous system, as they allow for the passing of 
electrical signals, including GABAergic (inhibitory) and glutamatergic (excitatory) currents. 
RBPs play critical roles in this process as well. RBFOX is necessary for proper 
development of the axon initial segment (AIS), as a triple knockout of Rbfox1/2/3 in developing 
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motor neurons results in delayed and shortened AIS (Jacko et al.). This is a result of incorrect 
inclusion of an exon in AnkG, a component of the spectrin-actin cytoskeleton. At this stage, 
MBNL protein is also expressed and promotes adult splicing patterns, particularly by switching 
from fetal to adult isoforms in several ion channels genes including Kcnma1 (calcium activated 
potassium channel subunit 1), Cacna1d (Cav1.3, a voltage-gated calcium channel), and Grin1 
(NMDA receptor subunit) (Vuong et al., 2016a). MBNL is thus critical for synaptic plasticity 
and long-term potentiation of neurons. Finally, PTBP2 represses exon 18 of Dlg4 (Psd-95), a 
gene that codes for a postsynaptic scaffolding protein critical for synapse maturation, which 
causes NMD as a result of a premature stop codon (Zheng and Black, 2013). In late neuronal 
differentiation, PTBP2 is downregulated, allowing for increased expression of Dlg4. 
One interesting peptide involved in the development of organized currents is the NMDA 
receptor heterodimer, which consists of two molecules of NMDAR1 and two of 
NMDAR2A/B/C/D; the use of the two R2 subunits change over time. These genes are also 
known as GRIN1 and GRIN2A/B/C/D, and the splicing of Grin1 is regulated by RBFOX1 
(Gehman et al., 2011) and MBNL2 (Charizanis et al., 2012). 
Neuronal activity can also trigger regulation by RBPs. For example, depolarization of a 
cell is believed to cause an isoform change in Rbfox1, where exclusion of exon 19 results in a 
nuclear rather than cytoplasmic protein. As a result, RBFOX1 can help terminate the 
depolarization response by causing inclusion of exons that would otherwise be excluded as a 
result of depolarization (Lee et al., 2009). Depolarization can also trigger changes in chromatin 
marks, altering the rate of RNA polymerase II, which in turn can alter splicing (Norris and 
Calarco, 2012). A specific example is the Neural Cell Adhesion Molecule (NCAM), for which 
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exon 18 switches from included to skipped between neural progenitors and mature neurons. 
Summary 
These examples were individually determined, either by comparing embryonic and adult tissue 
or by performing studies on a single RBP. In this study, I will describe our efforts to examine 
alternative splicing changes in neurodevelopment on a global scale and with a higher time-point 
resolution. In addition, we examine the regulation by four major families of RBPs expressed in 
the brain using integrative modeling. 
 
Splicing in disease 
In addition to expanding our understanding of neurodevelopment, it is worth keeping in mind 
that improving our knowledge of alternative splicing regulation could become useful in a disease 
context. Much of the current focus on disease-causing mutations is on exonic and splice-site 
mutations, while intronic mutations affecting alternative splicing are not as well characterized. 
This is due to the difficulty in obtaining expressed from affected tissue (a particular concern for 
e.g. neurological disorders) and because many mutations that affect splicing are located in the 
intronic regions, which due to their length are often impractical to explore and more expensive to 
sequence (many clinical studies only sequence the "exome" to save on sequencing and analysis 
costs). 
Nevertheless, there are many characterized examples of missplicing in disease (Scotti and 
Swanson, 2016). A wide range of diseases, many neurological or musculatory, are caused by 
mutations within splice sites, within exons to create new splicing signals, and within the 
  
30 
spliceosome itself. Many sporadic mutations affecting splicing and splicing regulators have been 
found in cancer, and RBPs, specifically those regulating microexons, have been linked to autism 
(Quesnel-Vallieres et al., 2016). 
Perhaps the most dramatic and well-known example of an RBP in disease is that of the 
role of Mbnl in myotonic dystrophy. Myotonic dystrophy (DM) is characterized by myotonia, the 
inability of muscles to relax after contraction, which results from unstopped depolarization. 
While some of the specific symptoms in mytonic dystrophy are believed to be linked specifically 
to missplicing in the muscle-specific chloride channel 1, the overall disease appears to be caused 
by function loss of MBNL protein. DM1 patients have CUG repeat expansions in the Dmpk gene 
while DM2 patients have CCUG repeat expansions in the Znf9 gene. Both of these expansion 
motifs—which may number in the thousands—match the YGCY motif of the MBNL protein, 
causing the protein to be sequestered and functionally reduced. This reduces MBNL’s splicing 
activity genome-wide, potentially explaining the wide range of the disease’s effects. Recent work 
has suggesting using Cas9 to eliminate these repeats as a potential therapeutic (Batra et al., 
2017).  
Another well-known example of alternative splicing errors causing disease is spinal 
muscular atrophy (SMA). Humans normally have two copies of a gene that produces SMN 
protein: SMN1 and SMN2. However, 90% of SMN2 transcripts skip exon 7, the result of a single 
nucleotide difference (Monani et al., 1999), which results in a non-functional protein. SMA 
occurs in patients that have mutations in the SMN1 gene (causing deletion of the gene or loss of 
exon 7), which results in only a small fraction of normal SMN levels. The disease causes motor 
neuron death, leading to eventual loss of the muscles and, in the worst cases, death. A recently 
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approved breakthrough therapy, called nursinusen, uses antisense oligos (Nomakuchi et al., 
2016) to bind and mask a splicing suppressor site near SMN2 exon 7, leading to higher levels of 
SMN protein in treated patients, much increased survival (51% vs 0%), and much increased 
chance of meeting the primary endpoint of the trial (41% vs 0%) (Finkel et al., 2017). Another 
approach under consideration is a gene-therapy treatment that would insert the SMN1 gene 
directly into motor neurons, although that work is still ongoing. 
Taken together, the large number of known splicing-related disease coupled with those 
yet to be identified suggests that the therapeutic impacts of the splicing field are only just 
beginning.  
 
Goals of this thesis 
In this work, I will describe our efforts toward characterizing RNA-protein interactions to 
identify exons that are regulated by four tissue-specific RBPs. I will then describe our 
quantification and exploration of splicing changes in the developing cortex, and our investigation 
into RNA binding protein regulation of these changes.  
We found nearly 3,000 exons that show clear developmentally-regulated changes in 
organized patterns during cortical development, and these exons are substantially enriched in 
RBP-regulated exons. The RBPs precisely time the developmental splicing switches. In addition, 
we observed that specific types of neurons express specific RBP programs, with particularly 
strong differences between CNS and sensory neurons. Finally, I will address ongoing efforts to 
identify novel, regulated alternative splicing events, which could provide actionable targets that 
may be of biological or clinical significance. 
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Overall, this work sets a foundation by presenting a precise, global view of 
developmentally-regulated splicing regulation, and by identifying exons of interest for future 
functional studies.  
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Chapter 2. HITS-CLIP and integrative modeling define the Rbfox 
splicing-regulatory network linked to brain development and autism 
Authors 
Sebastien M Weyn-Vanhentenryck*, Aldo Mele*, Qinghong Yan*, Shuying Sun, Natalie Farny, 
Zuo Zhang, Chenghai Xue, Margaret Herre, Pamela A Silver, Michael Q Zhang, Adrian R 
Krainer, Robert B Darnell, Chaolin Zhang 
 
Introduction 
The Rbfox proteins are a family of neuron- and muscle/heart-specific RNA-binding proteins 
(RBPs) encoded by three genes—Rbfox1 (Fox-1 or A2bp1), Rbfox2 (Fox-2 or Rbm9), and Rbfox3 
(Fox-3, Hrnbp3 or NeuN)—that are conserved in vertebrates, flies and worms. Rbfox1 and 
Rbfox2 are exclusively or preferentially expressed in neurons, heart, and muscles, while Rbfox3 
is specifically expressed in post-mitotic neurons. In humans, chromosomal translocation or copy 
number variation affecting RBFOX1 has been found in patients with several neurological 
disorders, including epilepsy, intellectual disability (Bhalla et al., 2004), schizophrenia (Xu et al., 
2008), and autism (Martin et al., 2007; Sebat et al., 2007).  
At the molecular level, RBFOX proteins are known as tissue-specific splicing factors 
which bind to the (U)GCAUG element frequently conserved across vertebrate species (Jin et al., 
2003; Minovitsky et al., 2005; Ponthier et al., 2006; Underwood et al., 2005). We previously 
performed genome-wide bioinformatic prediction of RBFOX target exons based on 
phylogenetically conserved motif sites (Zhang et al., 2008), leading to the identification of 
  
34 
>1,000 alternative or constitutive exons that are potentially regulated by RBFOX, many found 
within transcripts encoding proteins important for neuromuscular functions. Characterization of 
the splicing pattern of the RBFOX targets revealed a position-dependent RNA map predictive of 
RBFOX action. According to this map, RBFOX binding in the downstream intron activates exon 
inclusion and binding in the alternative exon or upstream intron represses exon inclusion, 
consistent with observations from several tissue-specific exons (Jin et al., 2003; Underwood et 
al., 2005). Such a map was previously found for another neuron-specific splicing factor Nova, 
and is now recognized as a more general rule of alternative splicing regulation (Licatalosi et al., 
2008; Ule et al., 2006a). 
Despite recent progress (Barash et al., 2010a; Ray et al., 2013; Ule et al., 2006a; Zhang et 
al., 2013a), the small sizes of RBP binding motifs limit the ability of motif-based bioinformatic 
target prediction to achieve both high specificity and sensitivity. To map in vivo protein-RNA 
interaction sites on a genome-wide scale, crosslinking and immunoprecipitation followed by 
high-throughput sequencing (HITS-CLIP) has been developed to isolate RNA fragments directly 
bound by an RBP of interest (Darnell, 2010a; Licatalosi et al., 2008; Moore et al., 2014; Ule et 
al., 2005a). HITS-CLIP has been used to map the RBFOX2 binding sites in thousands of genes 
in human embryonic stem cells, including those important for splicing regulation as predicted by 
the RNA map (Yeo et al., 2009).  
To understand the physiological function of RBFOX proteins in the mammalian brain, 
knock-out (KO) mouse models have been generated. Central nervous system (CNS)-specific 
depletion of Rbfox1 results in an increased susceptibility of mice to seizures and in over-
excitability of neurons in the dentate gyrus (Gehman et al., 2011). CNS depletion of Rbfox2 
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results in defects in cerebellar development (Gehman et al., 2012). Comparison of wild type 
(WT) versus Rbfox1 or Rbfox2 KO brains using exon-junction microarrays has identified 
multiple Rbfox-dependent exons (Gehman et al., 2012; Gehman et al., 2011). However, the 
number of exons identified using this approach is quite small (20 and 29 exons, respectively), 
compared to the number of RBFOX binding sites determined by bioinformatic prediction or 
CLIP data, presumably due to compensatory upregulation of Rbfox2 in Rbfox1 KO mice and vice 
versa. Since different RBFOX family members have highly similar protein sequences, especially 
in their RNA-recognition motif (RRM)-type RNA-binding domain (RBD; ≥94% amino acid 
identity), they are expected to bind and regulate largely overlapping sets of transcripts (Gallagher 
et al., 2010; Gehman et al., 2012).  
Until now, a comprehensive and accurate target splicing-regulatory network of the 
RBFOX proteins has not been defined, due in part to the lack of a genome-wide high-resolution 
map of the RBFOX interaction sites in the brain and to the lack of effective computational 
methods to couple protein-RNA interactions with splicing changes as a means of identifying 
direct, functional targets. Here we used HITS-CLIP to globally map the RNA interaction sites of 
all three RBFOX family members, and complemented the CLIP data with RNA-Seq data to 
identify exons responsive to perturbation of RBFOX. Importantly, we probabilistically weighed 
and combined these and additional datasets to define the functional target transcripts directly 
regulated by RBFOX using an integrative modeling approach (Zhang et al., 2010). The resulting 
network allowed us to reveal the role of RBFOX proteins in regulating global dynamic splicing 




Rbfox1, 2 and 3 HITS-CLIP in mouse brain 
Considering the possibility that each RBFOX family member might differ in binding specificity 
despite their apparent functional redundancy, we performed HITS-CLIP experiments for all 
members of the family individually using mouse whole brain tissue. We first confirmed that the 
antibodies we used did not cross-react with different members and that they efficiently 
immunoprecipitated (IP) the targeted protein with minimal background under standard CLIP 
conditions. Next, we used two different strategies to clone and amplify the isolated RNA 
fragments (Figure 2.1A). The first protocol, denoted as standard CLIP, was performed as 
described previously (Darnell, 2010a; Licatalosi et al., 2008; Moore et al., 2014; Ule et al., 
2005a). In this protocol, RNA linkers are ligated to the 5´ and 3´ ends of the RNA fragments 
(Figure 2.1A, left branch) and are later used for RT-PCR amplification. We and several other 
groups have previously noted that after proteinase K digestion of the crosslinked protein-RNA 
complex, one or a few amino acids might remain attached to the RNA at the crosslink site, which 
cause informative errors at the crosslink site during reverse transcription (Granneman et al., 
2009; Ule et al., 2005a). These crosslinking-induced mutation sites (CIMS) provide a footprint of 
protein-RNA crosslinking, and can be leveraged to determine protein-RNA interactions at a 
single nucleotide resolution (Moore et al., 2014; Zhang and Darnell, 2011). However, reverse 
transcription can abort prematurely at these sites, resulting in truncated cDNAs that lack the 5´ 
adaptor required for PCR (Konig et al., 2010; Sugimoto et al., 2012). To capture both truncated 
and non-truncated cDNAs, we developed a second CLIP protocol named BrdU-CLIP (Figure 
2.1A, right branch). This protocol bears some conceptual similarity to individual nucleotide 
resolution CLIP or iCLIP (Konig et al., 2010). After ligation of the 3´ linker, purified RNA is 
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reverse transcribed to introduce 5´ and 3´ PCR adaptor sequences separated by an 
apurinic/apyrimidinic endonuclease (APE) cleavage site. This is followed by the circularization 
of both read-through and truncated cDNAs and relinearization of cDNA via the cleavage site to 
place the 5´ and 3´ adaptor sequences in the correct orientation. One key difference between 
BrdU-CLIP and iCLIP is the incorporation of BrdUTP into the cDNA during reverse 
transcription so that the resulting cDNA can be purified in a stringent manner using an antibody 
that specifically recognizes BrdU (Core et al., 2008; Ingolia et al., 2009). 
To evaluate the robustness of the RBFOX interaction sites, we prepared HITS-CLIP 
libraries for RBFOX1, RBFOX2, and RBFOX3 with 4, 4, and 5 biological replicates, 
respectively, which together resulted in about 870 million raw reads (CLIP tags). After stringent 
filtering, processing, and mapping (Moore et al., 2014; Zhang et al., 2010) (Experimental 
Procedures), we obtained a total of 4.6 million unique CLIP tags that represent independent 
captures of protein-RNA interactions, including 1,460,387 tags for RBFOX1, 868,366 tags for 
RBFOX2, and 2,308,632 tags for RBFOX3. Between 59-65% of these CLIP tags are located in 
introns, consistent with the known role of RBFOX proteins in regulating alternative splicing; an 
additional 23-28% unique CLIP tags are located in exons, mostly in the 3´ UTRs.  
Initial inspection of the CLIP tag distribution suggests that the interaction profiles of the 
three RBFOX family members are very similar. For example, the Rbfox1 transcripts contain a 
cassette exon of 93 nucleotides (nt) (Figure 2.1B) encoding part of the RRM of the protein. Its 
skipping as a result of autoregulation generates a dominant negative form that lacks RNA-
binding capability (Baraniak et al., 2006; Damianov and Black, 2010a). Our CLIP data show that 
all three RBFOX family members bind to the upstream intronic sequences harboring a cluster of 
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conserved UGCAUG elements, suggesting that this exon is under both auto- and cross-regulation 
by all family members. We also previously demonstrated that GABA receptor gamma 2 subunit 
(Gabrg2) exon 9 is under the synergistic regulation of RBFOX and NOVA when they bind near 
the 5´ and 3´ splice sites of the downstream intron, respectively, based on detailed mutation 
analysis and splicing reporter assays in cell culture (Dredge and Darnell, 2003; Zhang et al., 
2010). Our CLIP data now confirmed that RBFOX proteins indeed bind to the expected site in 
vivo in the brain (Figure 2.1C).  
To quantitatively compare the RNA-binding profiles of different RBFOX family 
members, we defined a non-redundant set of RBFOX-RNA interaction sites using all unique 
CLIP tags pooled together (Figure 2.1D; Experimental Procedures). A stringent set of 41,182 
genic CLIP tag clusters with at least one statistically significant peak (p<0.01) was obtained, 
70% of which are located in introns and the other 30% are in exons (Figure 2.1E). We then 
counted the number of CLIP tags per cluster for each protein. CLIP tags for different members 
are very well correlated in each pairwise comparison, especially between RBFOX1 and 
RBFOX3 (Pearson correlation R=0.97); the correlation between Rbfox2 and the other two 
members is somewhat lower (R=0.76-0.80; Figure 2.1F). In addition, we confirmed that the two 
CLIP protocols gave very reproducible results in the global profiles (R=0.97; Figure 2.1G). 
Based on these observations, we conclude that the three RBFOX family members have similar 
RNA-interaction profiles on a genome-wide scale, consistent with the notion that their binding 
specificity is largely determined by their very similar RRMs. Although it remains possible that a 
small proportion of the binding sites could be preferentially recognized by a specific member, for 




Figure 2.1. HITS-CLIP maps Rbfox-RNA interaction sites in mouse brain on a genome-wide scale.  
A. A schematic illustration of two HITS-CLIP protocols used to map Rbfox binding sites. B. A UCSC Genome 
Browser view of Rbfox1, 2, and 3 CLIP data in an alternatively spliced region of a 93-nt cassette exon in Rbfox1 is 
shown. Rbfox1, 2, and 3 CLIP data are shown in separate wiggle tracks above the coordinates of UGCAUG and 
GCAUG elements and the phyloP conservation score. C. Similar to (B), except that the alternatively spliced region 
of Gabrg2 exon 9 is shown. CLIP data of Rbfox1, 2, and 3 are pooled together and shown in a single track with 
different colors representing the CLIP tags obtained in independent CLIP experiments. The position of Nova 
binding is indicated by the arrowhead (top right). D,E. Genomic distribution of Rbfox1, 2, and 3 CLIP tags pooled 
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annotations, each gene is extended for 10 kb in both directions; these regions are listed as separate categories. F. 
Pairwise correlation of CLIP data among Rbfox proteins based on the number of CLIP tags per cluster. Each cluster 
is represented as a black dot positioned in three-dimensional (3D) space. Comparisons between each pair of proteins 
are shown in 2D planes, obtained by projecting the black dots into their respective 2D space (colored dots). Pearson 
correlation of each pairwise comparison is indicated. G. Correlation of CLIP tags derived from the standard and 
BrdU-CLIP protocols, based on the number of CLIP tags per cluster. 
 
A single-nucleotide resolution map of Rbfox binding sites by CIMS and 
CITS analysis 
Using two CLIP protocols in parallel allowed us to employ different strategies to pinpoint the 
exact RBFOX-RNA crosslink and interaction sites (Figure 2.2). For CLIP tags obtained by the 
standard protocol, we performed CIMS analysis using our established method (Figure 2.2A) 
(Moore et al., 2014; Zhang and Darnell, 2011). Nucleotide deletions were observed in 14% of 
standard CLIP tags, from which 1,424 reproducible CIMS were identified (FDR<0.001). A 
substantial enrichment of the RBFOX binding motif GCAUG was observed in the immediate 
vicinity of the reproducible deletion sites (Figure 2.2B). In contrast, when we analyzed 
substitutions and insertions using the same method, we did not observe elevated motif 
enrichment near the mutation sites (data not shown), suggesting that crosslinking predominantly, 
if not exclusively, introduces deletions rather than insertions or substitutions in RBFOX CLIP.  
We then examined the enrichment of UGCAUG or VGCAUG (V=non-U) relative to the 
crosslink sites with reproducible deletions in more detail (Figure 2.2B inset). UGCAUG is 
enriched 28-41 fold at positions -5, -4, and -1 relative to the crosslink site, corresponding to 
crosslinking at G2, U5, and G6 of the UGCAUG element. Interestingly, enrichment of 
VGCAUG is most predominant at position -1 relative to the crosslink site (64 fold), 
corresponding to crosslinking of G2 (Figure 2.2C). We also examined the base composition of 
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the sequences around CIMS regardless of the presence of (U)GCAUG, and observed a slight bias 
toward uridine compared to the flanking sequences (see Discussion below). De novo motif 
analysis using sequences [-10,10] around CIMS uncovered (U)GCAUG as the only motif with 
strong enrichment (36% of 1,158 non-repetitive CIMS in [-10,10], E<3.7×10-320). The first 
position of the motif is the most variable, which is consistent with previous findings that RBFOX 
binds to both UGCAUG and VGCAUG with high affinity (Jin et al., 2003; Ponthier et al., 2006). 
Additional deviations from the consensus appear to be tolerated to some extent (e.g., in positions 
3 and 4), providing a partial explanation for why (U)GCAUG is not present at all crosslink sites. 
Finally, we observed deletions in 6.2% of BrdU-CLIP tags, and analysis combining standard and 
BrdU-CLIP tags defined 2,298 CIMS (FDR<0.001). 
The sensitivity of crosslink site identification by CIMS analysis is limited by the 
relatively low deletion rate among tags that are read through. We therefore looked for 
reproducible cross-linking induced truncation sites (CITS) in BrdU-CLIP data (Figure 2.2D; 
Experimental Procedures). Overall, 6,606 robust CITS were identified (p<0.001). Among these, 
the UGCAUG element is enriched 319-fold at a single position (-5) relative to CITS, 
corresponding to predominant crosslinking at G6 of the motif (Figure 2.2E). The same position 
was crosslinked in the VGCAUG element, although there is less enrichment of the motif (88 
fold; Figure 2.2F). Analysis of the base composition [-10,10] around CITS revealed the 
UGCAUG motif directly, and this was confirmed by de novo motif analysis (60% of 1000 
randomly sampled non-repetitive sites; E<1.9×10-631). As a control, we repeated the same 
analysis in the standard CLIP data, which presumably lacked truncated tags, and did not observe 





Figure 2.2. CIMS and CITS analysis to map Rbfox-RNA interactions at a single-nucleotide 
resolution. 
A-C and D-F are for crosslinking-induced mutation sites (CIMS) and crosslinking-induced truncation sites (CITS) 
analysis, respectively. A,D. A schematic illustration of CIMS (A) and CITS (D) is shown. B,E. Enrichment of 
UGCAUG around CIMS (deletions, B) and CITS (truncations, E) is calculated from the frequency of UGCAUG 
starting at each position relative to the inferred crosslink sites, normalized by the frequency of the element in 
flanking sequences. The inset shows a zoomed-in view, with the most frequent crosslink sites in the motif 
highlighted in red. C,F. Similar to (B) and (E), except that the enrichment of VGCAUG (V=non-U) around CIMS 
(C) and CITS (F) is shown. G. NMR structure of RbFox1 RRM (surface, pale blue) in complex with the 
UGCAUGU heptanucleotide (cartoon, rainbow) [PDB code 2ERR; ref. (Auweter et al., 2006)]. Highlighted are the 
two guanines G2 and G6 (pink) with predominant crosslinking. 
 
Together, our data suggest that the two guanines G2 and G6 in the (U)GCAUG motif are 
particularly prone to crosslinking with the RBFOX protein. Consistent with this finding, 
examination of a previously determined NMR structure of the RBFOX1 RRM in complex with 
UGCAUGU RNA revealed that these two guanines are buried in two pockets of the RRM, and 
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each of these two nucleotides resulted in the largest increases in the free energy of binding 
(Auweter et al., 2006). Based on the single-nucleotide-resolution map of in vivo RBFOX 
interaction sites and on the characterized specificity of the proteins, we developed the motif 
enrichment and conservation score (MECS) of (U)GCAUG elements by comparing CLIP tag 
clusters and regions without CLIP tags. A motif site with higher conservation receives a higher 
score, especially if it is located in an intronic region. A UGCAUG element receives a higher 
score than a VGCAUG element with the same level of conservation, reflecting greater 
enrichment of the former in CLIP tag clusters. 
 
Identifying Rbfox-dependent exons using RNA-Seq 
We previously used HeLa cells with perturbed Rbfox1 or Rbfox2 expression to validate over half 
(55-59%) of bioinformatically predicted RBFOX target alternative exons tested with RT-PCR 
(Zhang et al., 2008). We therefore used this established experimental system to expand the list of 
RBFOX-dependent exons by RNA-Seq, which provides information complementary to the CLIP 
data. As we described previously (Zhang et al., 2008), HeLa cells were treated with a short 
hairpin RNA (shRNA) targeting Rbfox2 (shRbfox2) to generate stable knock-down (KD) of the 
protein, which is endogenously expressed at a level that is low but sufficient for splicing 
regulation; HeLa cells expressing the empty vector were used for comparison (control; Figure 
2.3A, left panel). In total, RNA-Seq of the control and shRbfox2 samples resulted in 60 million 
and 48 million paired-end reads, respectively, of which 62-65% were mapped unambiguously to 






Figure 2.3. Identification of Rbfox2-dependent exons using RNA-Seq. 
A. Left panel: Rbfox2 protein expression in HeLa cells with stable knockdown of Rbfox2 using a specific shRNA 
(shRbfox2) compared with cells treated with the vector (control), as evaluated by immunoblot analysis. The 
nucleosome remodeling complex protein SNF is used as a loading control. Right panel: the gene expression profiles 
in HeLa cells treated with shRbfox2 or control vectors are quantified by reads per kb/million (RPKM) using RNA-
Seq data. Rbfox2 is highlighted by the red circle. B. Proportional inclusion (I) of cassette exons in shRbfox and 
control HeLa cells. Exons with reduced and increased inclusion [FDR<0.1 and |ΔI|>0.1; ref. (Ule et al., 2005b)] in 
shRbfox2 compared with control HeLa cells are highlighted in red and blue respectively. C,D. UCSC Genome 
Browser views of two examples of Rbfox-dependent exon inclusion (PICALM, C) or exclusion (MAP3K7, D), as 
indicted by the arrowheads in (B). Below the RNA-Seq data are (U)GCAUG elements and phyloP conservation 
scores. The result of RT-PCR validation is shown on the right. 
 
Examination of the gene-expression level confirmed that Rbfox2 was specifically 
knocked down 3.3-fold (Figure 2.3A, right panel), consistent with the protein level changes 
observed from immunoblot analysis. Accordingly, we were able to identify 126 cassette exons, 
17 tandem cassette exon events, and 4 mutually exclusive exon events showing RBFOX2-
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(Ule et al., 2005b)] (Figure 2.3B). Among the 22 cases of alternative exons we tested by RT-
PCR (which includes 3 cases with a read coverage slightly below the threshold we used), 21 
showed RBFOX2-dependent splicing (Figure 2.3C,D), giving a validation rate of 95%. The 
direction of RBFOX2-dependent splicing of these exons can be predicted by the position-
dependent RNA map based on either the CLIP data derived from mouse brain or the 
bioinformatically predicted motif sites (data not shown), indicating that these RBFOX2-
dependent exons are enriched in direct RBFOX targets in the brain. 
Integrative modeling defines the Rbfox target splicing-regulatory network 
To comprehensively define the functional target network directly regulated by the RBFOX 
proteins, we took an integrative modeling approach which we recently developed and 
successfully applied to study the Nova target network (Zhang et al., 2010). This method uses a 
Bayesian network to probabilistically weigh and combine multiple types of data complementary 
to each other: bioinformatically predicted motif sites represented by MECS scores, protein-RNA 
interaction sites mapped by RBFOX HITS-CLIP, RBFOX1-dependent splicing identified by 
comparison of WT with Rbfox1 KO mouse brain using exon-junction microarrays (Gehman et 
al., 2011), RBFOX2-dependent splicing in HeLa cells as described above, tissue-specific 
splicing as measured by RNA-Seq [only for training; ref. (Brawand et al., 2011)], and 
evolutionary signatures including preservation of reading frame and conservation of alternative 






Figure 2.4. Integrative modeling predicts Rbfox target exons using a Bayesian network. 
The model is trained using cassette exons. A. Design of the Bayesian network (BN). The 17 nodes (variables) model 
four types of data, including (U)GCAUG elements and CLIP tag clusters in each cassette exon or flanking upstream 
(UI) and downstream introns (DI), splicing change of exons with Rbfox depletion or among different tissues, and 
evolutionary signatures. B. The probability of Rbfox binding to regions with varying motif scores. C. The 
cumulative probability of CLIP tag cluster scores across all regions with or without inferred Rbfox binding.  
D. The probability of exons showing Rbfox-dependent inclusion (red), exclusion (blue), or no effect (gray), given 
the indicated combinatorial Rbfox binding patterns in the exon (E), upstream (U), and downstream (D) introns.  
E. The distribution of proportional splicing changes (∆I) in Rbfox knockdown vs. the control as measured by RNA-
Seq for exons with inferred Rbfox-dependent inclusion, exclusion, or without Rbfox regulation. F. Rbfox-binding 
pattern for exons predicted to be activated or repressed by Rbfox, or exons for which the direction of Rbfox 
regulation cannot be determined unambiguously. In each group, exons are ranked by the confidence of prediction 
(left). (U)GCAUG motif scores, CLIP tag cluster scores, and inferred probability of Rbfox binding at different 
positions of the alternatively spliced region are shown in the gray-scale heat maps (darker colors represent stronger 
binding). UI5, E5, and DI5 represent regions near the 5´ splice sites of the upstream intron, exon, and downstream 
intron, respectively; Similarly, UI3, E3, and DI3 represent regions near the 3´ splice sites.  
 
Focusing initially on cassette exons, we found that the estimated model parameters 
confirmed, quantified, and extended our understanding of RBFOX splicing regulation (Figure 
2.4B-E, Figure 2.5A-E and Supplementary Notes). For example, stronger motif sites are more 
likely to be bound by the protein (Figure 2.4B), and regions inferred to be bound by RBFOX 
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was able to quantify the position-dependent RNA map: binding of RBFOX in the downstream 
intron is predicted to result in RBFOX-dependent inclusion with a probability of 0.99, while 
binding of RBFOX in the upstream intron or exon is predicted to result in repression with a 
probability of 0.75 and 0.61, respectively. Binding of RBFOX in both exon and upstream intron 
is expected to increase the probability of repression to 0.84 (Figure 2.4D). 
 
Figure 2.5. Conditional Probability Distributions of the Bayesian network 
A-C. Conditional probability distributions (CPDs) of splicing changes. For each panel, splicing changes were 
modeled using a normal distribution. The distributions for three groups of exons (activated by Rbfox, no effect from 
Rbfox and repressed by Rbfox) are shown in red, gray and blue, respectively. A. WT vs. Rbfox1 KO brain. B. brain 
vs. other tissues (liver, kidney and testis). C. heart vs. other tissues. D. CPD of reading frame preservation. E. CPD 
of alternative splicing conservation between mouse and human/rat. F. Evaluation of over-fitting. A total of 121 
validated target exons compiled from the literature were used for this evaluation. X-axis shows the FDR of each 
exon predicted by the full model, which was trained using the complete training dataset (including all validated 
exons). Y-axis shows the FDR of each validated exon predicted in 10-fold cross validation (CV). In this cross 
validation procedure, models were trained using 90% of the training data, then used to predict the remaining 10% of 
exons.  
 
The model was then applied to each annotated cassette exon in the mouse genome to 
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predict the probability of its activation or repression by RBFOX through direct protein-RNA 
interactions. After using 10-fold cross validation to ensure the model was not overfit (Figure 
2.5F), we predicted 772 cassette exons as direct RBFOX targets (FDR<0.05). Among these 
targets, RBFOX was predicted to activate 421 exons (probability of activation>0.7) and repress 
113 exons (probability of repression>0.7), respectively. For the remaining 238 exons predicted 
as RBFOX targets, the Bayesian network was unable to assign the direction of regulation 
unambiguously (Figure 2.4F, left panel). This uncertainty is presumably due to a lack of 
observed RBFOX-dependent splicing in the current experimental settings and to binding of 
RBFOX in both upstream and downstream introns simultaneously (Figure 2.4F, right panel). 
Based on comparison of the predicted exons with previously validated RBFOX-regulated exons 
compiled from the literature, we estimated that our Bayesian network analysis has a sensitivity of 
73-79%. We also compared the results of the Bayesian network analysis to our previous motif-
based bioinformatic predictions and to another recent study that predicted RBFOX target exons 
based on the presence of the RBFOX motif sites and the correlation of exon splicing with 
RBFOX expression (Ray et al., 2013). These comparisons gave substantial overlap between 
exons predicted by different methods, but also highlighted that the Bayesian network analysis 
effectively integrated features known to be consistent with regulated alternative splicing events, 
such as preservation of the reading frame and conservation of the alternative splicing pattern. 
After we confirmed the performance of the Bayesian network, we applied the model to 
other types of alternative splicing events, and predicted 212 events of tandem cassette exons (300 
exons) and 75 events of mutually exclusive exons (107 exons) as direct RBFOX targets. 
Altogether, 587 genes have one or more alternative splicing events directly regulated by 
  
49 
RBFOX. To understand the molecular function of these genes, we performed gene ontology 
(GO) analysis, and found very significant enrichment of genes with annotated function in 
“cytoskeleton” (Benjamini FDR < 3.8×10-17) and “neuron projection” (Benjamini FDR < 
3.8×10-8), compared to all brain-expressing genes. In addition, proteins encoded by RBFOX 
target transcripts are enriched in PDZ domains that are known to be important for anchoring 
transmembrane proteins to the cytoskeleton and for functioning as scaffolds for signaling 
complexes (Benjamini FDR < 7.2×10-8) (Ranganathan and Ross, 1997). 
 
 
Rbfox regulates global dynamic splicing changes during brain 
development 
It has previously been shown that all three RBFOX family members undergo increased 
expression in the mouse brain at prenatal stages between embryonic day E12 and E18 (Tang et 
al., 2009), and that the increase of Rbfox1 expression further extends into postnatal stages 
(Hammock and Levitt, 2011). In mouse and chicken, the differential expression of RBFOX 
proteins is correlated with splicing changes in several exons during CNS development (Kim et 
al., 2013; Tang et al., 2009), but how RBFOX proteins affect the global switch of the 
developmental splicing program is unclear. We found that RBFOX family members undergo 
dynamic expression change between E17 and adult mouse cortex, as evaluated from a published 
RNA-Seq dataset (Dillman et al., 2013). Rbfox1 and Rbfox3 show 1.6-fold (p<0.02; t-test) and 
3.1-fold (p<10-6; t-test) increases in the adult cortex compared to E17 cortex, respectively, while 
the expression of Rbfox2 is reduced 3.1-fold (p<10-4; t-test; Figure 2.6A). The expression 
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changes of the RBFOX proteins parallel the splicing changes of RBFOX target exons: 55% of 
RBFOX target exons with sufficient read coverage to quantify splicing show splicing changes 
between the two developmental stages, as compared to 32% for exons not regulated by RBFOX 
(odds ratio=2.4, p<7.6×10-16; Fisher’s exact test; Figure 2.6B). In addition, a majority (77%) of 
the exons activated by RBFOX have increased exon inclusion in the adult, while over half (57%) 
of the exons repressed by RBFOX have decreased exon inclusion (odds ratio=4.4, p<0.003; 
Fisher’s exact test; Figure 2.6C). This asymmetry indicates that increased expression of 
RBFOX1 and RBFOX3 predominates the developmental splicing change of their targets, and in 
general they promote the switch to the adult splicing program through direct regulation. 
	
Figure 2.6. Rbfox regulates global dynamic splicing changes during brain development. 
A. Rbfox1, 2, and 3 expression in embryonic (green) or adult cortex (blue) as quantified by RNA-Seq data. Error 
bars represent standard error of the mean. B. The proportion of Rbfox target exons and non-target exons with 
developmental splicing changes. The difference is evaluated by Fisher’s exact test. C. Rbfox target exons are 
divided into two groups depending on whether Rbfox activates or represses exon inclusion. For each group, the 
number of exons showing higher (blue) or lower (green) inclusion in the adult vs. embryonic cortex is shown. The 
direction of developmental splicing change is compared with the direction of Rbfox regulation, as assessed by 
Fisher’s exact test. 
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conserved motif sites have significant overlap with genes implicated in autism, supporting the 
notion that disruption of either RBFOX1 itself or of its targets observed in autism patients is 
likely pathogenic (Zhang et al., 2010). This hypothesis was further supported by recent findings 
that Rbfox1 lies in a hub in gene co-expression networks based on microarray profiling of autistic 
and control postmortem human brains and its reduced expression in a subset of autism patients is 
correlated with altered splicing of predicted RBFOX target exons (Voineagu et al., 2011). The 
comprehensive RBFOX target network defined by integrative modeling now allows us to 
examine the link between RBFOX1 and autism in more detail. 
Among the 235 RBFOX target cassette exons that are conserved in human and that have 
sufficient RNA-Seq read coverage to evaluate splicing change in autistic versus control brains 
(Voineagu et al., 2011), 97 (41%) show alteration of splicing in autistic brains (|∆I|≥0.1, and 
FDR≤0.05), a very significant overlap compared to random chance (odds ratio=3.4, p<1.4×10-
16; Fisher’s exact test; Figure 2.7A). The autistic brains compared here were selected to have 
low expression level of Rbfox1 (Voineagu et al., 2011) (4.1-fold down-regulation compared to 
control brains as measured by RNA-Seq; p<0.05, t-test; Figure 2.7B). However, the massive 
splicing change of RBFOX targets detected in autistic vs. control brains is somewhat surprising 
given the redundant role of the other RBFOX family members, as observed in Rbfox1 KO mice 
(Gehman et al., 2012; Gehman et al., 2011). Interestingly, we found that the expression of the 
other two family members, Rbfox2 and Rbfox3, was also down-regulated 3.3 fold (p<0.05; t-test) 
and 3.2 fold (p<0.09; t-test), respectively. Therefore, simultaneous down-regulation of all Rbfox 
family members might explain the massive splicing misregulation of RBFOX target exons 
observed in these autism patients. On the other hand, many of the splicing changes observed in 
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autism patients may not be regulated by RBFOX proteins directly. 
 
Figure 2.7. Rbfox target exons in candidate autism-susceptibility genes 
A. Overlap between Rbfox target cassette exons and exons with altered splicing in autistic vs. control brains. B. 
Down-regulation of Rbfox1, 2, and 3 expression in autistic vs. control brains as quantified by RNA-Seq. C. Rbfox is 
predicted to activate the inclusion of a 129-nt exon in the Tsc2 gene. Below the gene structure schematic are RNA-
Seq data of different tissues showing a higher inclusion of the exon in cortex and heart, pooled Rbfox CLIP tags, 
Rbfox-binding UGCAUG or GCAUG elements, and the phyloP conservation score. D. Rbfox is predicted to 
activate the inclusion of an 84-nt poisonous exon in the Scn2a1 gene, which creates an in-frame premature 
termination codon (PTC) conserved in vertebrates.  
 
To focus on RBFOX target genes that are likely genetic risk factors of autism, we 
examined candidate autism-susceptibility genes in the SFARI autism gene database (Basu et al., 
2009). Among the 519 candidate autism-susceptibility genes with mouse orthologs, 48 were 
identified as RBFOX targets by Bayesian network analysis (odds ratio=2.8, p<9.6×10-18, 
Fisher’s exact test; Table S.1). The list includes three genes that are currently regarded as causal 
in syndromic autism spectrum disorders (ASD): Shank3 (Phelan-McDermid Syndrome), 
Cacna1c (Timothy syndrome), and Tsc2 (tuberous sclerosis complex). For a specific example, 
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RBFOX is predicted to activate the inclusion of alternative exon 25 in the Tsc2 gene, which is 
conserved between human and mouse (Figure 2.7C). Although the function of this alternative 
exon has not been characterized, its inclusion was recently shown to be dependent on RBFOX2 
using cell culture models of epithelial-to-mesenchymal transition (Braeutigam et al., 2013).  
Inclusion or exclusion of RBFOX target exons mostly introduces alteration in local 
amino acid sequences. However, we identified several cases (Fat1, St7, Scn2a1, and Scn8a) in 
which alternative splicing is potentially coupled with non-sense mediated mRNA decay [NMD; 
ref. (Maquat, 2004)]. In Scn2a1 for instance, RBFOX is predicted to activate a cryptic exon 
harboring an in-frame premature stop codon via extensive binding to the downstream intron 
(Figure 2.7D). Inclusion of this exon is undetectable in the brain from RNA-Seq data, 
presumably due to NMD of the inclusion isoform. Interestingly, while this alternative exon is 
conserved in vertebrates, compensatory mutations in the stop codon have accumulated. This has 
resulted in different stop codons in different species, suggesting an evolutionary selection 
pressure to preserve a stop codon. Scn2a1 is one of the few genes with recurrent de novo gene-
disrupting mutations according to exome-sequencing of ASD patients (Sanders et al., 2012), and 
our analysis suggests that the same gene can potentially be disrupted in autism by different 
mechanisms.  
We tested a select set of exons in potentially autism-related genes for regulation by 
RBFOX1 in the mouse brain. The splicing level of these exons was measured in CNS-specific 
Rbfox1-KO mouse brains compared to WT controls by semi-quantitative RT-PCR. Among eight 
exons for which both the inclusion and exclusion isoforms can be detected, three exons showed 
altered splicing upon Rbfox1 depletion (ΔI ≥0.1), and these were not identified as RBFOX1 
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targets in the previous genome-wide analysis (Gehman et al., 2011). The relatively small number 
of validated exons is likely due to the redundancy of RBFOX proteins and the compensatory 
increase of RBFOX2 protein expression in g1 KO animals (Gehman et al., 2011), although it is 
possible that some of the predicted targets might represent false positives. 
 
Discussion 
The focus of this study is to define and characterize the RBFOX target splicing-regulatory 
network in the mammalian brain. An important piece of information missing in previous efforts 
toward this aim [e.g., (Fogel et al., 2012; Gehman et al., 2012; Gehman et al., 2011; Ray et al., 
2013; Zhang et al., 2008)] is a genome-wide, high-resolution map of in vivo RBFOX interaction 
sites in the brain. Such a map is especially essential due to the functional redundancy of different 
RBFOX family members, so that simultaneous depletion of more than one member is probably 
required to uncover a majority of RBFOX-dependent exons in a physiologically relevant 
condition. A critical aspect of this work is our ability to identify over 40,000 robust RBFOX 
binding sites using two HITS-CLIP protocols applied in parallel to each of the three RBFOX 
family members. These include 8,811 sites (2,298 CIMS and 6,606 CITS with 93 common sites) 
for which the exact site of protein-RNA crosslinking can be deduced, allowing for determination 
of protein-RNA interactions at a single nucleotide resolution.  
Detailed analysis of RBFOX-RNA crosslink sites provided insights into the biophysical 
principles of protein-RNA crosslinking. UV crosslinking of protein and RNA was thought to be 
most efficient for the nucleotide uridine. This presumptive preference was used to interpret the U 
stretch enriched in sequences around CIMS and in iCLIP data for several RBPs including Nova, 
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Ago, hnRNP C and TIA (Sugimoto et al., 2012), despite the fact that these proteins have a 
genuine binding preference for uridine. Therefore, the predominant crosslinking of RBFOX and 
substrate RNA at the two guanines in the (U)GCAUG motif, as suggested by CIMS and CITS 
analysis, is somewhat unexpected, especially given the presence of two uridines in the motif. We 
argue that these crosslink sites likely reflect the residues in closest contact with the protein or 
those interacting with specific amino acids, which agrees very well with a structure study of the 
protein-RNA complex (Auweter et al., 2006). Additional evidence supporting this argument 
comes from predominant crosslinking to different nucleotides for several other RBPs with 
distinct binding specificity (Moore et al., 2014). On the other hand, we also observed that a 
substantial proportion of RBFOX-RNA crosslink sites do not overlap with the canonical RBFOX 
(U)GCAUG motif. Paradoxically, when these sites were included for analysis, the base 
composition at CIMS identified in RBFOX CLIP data is slightly biased toward uridine. One 
possible interpretation for this discrepancy is that some of these sites without the RBFOX motif 
might have resulted from crosslinking of more transient protein-RNA interactions largely 
independent of the RBFOX specificity (e.g., recruitment by other interacting RBPs), which 
would suggest that preferential crosslinking to uridine indeed exists to some extent. However, for 
high-affinity protein-RNA interactions, such “background” preference does not prevent UV 
crosslinking at specific nucleotides in the core motif.  
It has been reported that the rate of cDNA truncation at the crosslink site during reverse 
transcription is as high as 82% for Nova and over 95% for several other RBPs (Sugimoto et al., 
2012). Based on the relative frequency of deletions in RBFOX CLIP tags obtained with standard 
and BrdU-CLIP protocols (14% vs. 6.2%), we estimated that 57% of RBFOX CLIP tags are 
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truncated at the crosslink sites (Experimental Procedures). Therefore, this parameter could vary 
substantially for different proteins, depending on the specific amino acid(s) and nucleotide(s) at 
the crosslink sites, and possibly also on different experimental conditions.  
The second critical aspect of this study is the use of an integrative modeling approach to 
combine multiple complementary types of data, so that individually weak bits of information can 
be integrated to make strong predictions of RBFOX targets (Zhang et al., 2010). As increasing 
amounts of high-throughput data are being produced for different RBPs, interrogating RNA 
regulation from different perspectives, such a method has the unique advantage of being able to 
identify direct, functional target transcripts with high specificity and sensitivity simultaneously. 
We were able to assign the direction of RBFOX regulation for a majority of RBFOX targets 
(69% of cassette exons), which allowed us to evaluate the impact of splicing regulation by 
RBFOX proteins in different physiological contexts, including brain development and autism.  
Our analysis extends previous observations regarding the differential expression of 
RBFOX family members during brain development (Hammock and Levitt, 2011; Kim et al., 
2013; Tang et al., 2009) by showing increased expression of Rbfox1 and Rbfox3 and decreased 
expression of Rbfox2 in adult compared to a late prenatal stage. Similar dynamic changes in 
Rbfox1 and Rbfox2 expression were previously observed in the heart during postnatal 
development (Kalsotra et al., 2008). Importantly, differential expression of Rbfox is paralleled by 
developmental splicing changes in over half of the quantifiable RBFOX target exons, frequently 
in the direction consistent with direct RBFOX regulation. Combined with neuro-developmental 
defects observed in cell cultures (Kim et al., 2013), animal models (Gehman et al., 2012; 
Gehman et al., 2011; Kim et al., 2013), and human patients (Bhalla et al., 2004) where RBFOX 
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proteins are disrupted, this presents a compelling case for RBFOX proteins playing critical roles 
in driving the global dynamic change of the developmental splicing-regulatory program.  
Given the strong implication of RBFOX1 in autism and the role of RBFOX proteins in 
neural development, we are particularly interested in the molecular mechanisms underlying ASD 
cases with mutations in RBFOX1. One hypothesis of the autism etiopathology is that many genes 
implicated in autism can be disrupted individually in cis by mutations in the genes themselves, or 
in trans by disruption of their upstream regulators such as RBFOX1. This hypothesis was 
supported both by the significant overlap between candidate autism-susceptibility genes and 
RBFOX target genes and by the significant overlap of predicted RBFOX target exons and exons 
altered in autistic brains with down-regulation of Rbfox1 (Voineagu et al., 2011). Importantly, 
we found that all Rbfox family members are down-regulated in some autistic brains, 
underscoring the potential clinical relevance of the RBFOX target network in autism. In addition, 
we were able to highlight 48 genes in the SFARI autism gene database as direct RBFOX targets. 
The functions of these genes, which include cytoskeleton and scaffolding, synaptic transmission, 
ion channels and transcription regulation, are potentially relevant to the neurobiology underlying 
autism. 
We note that this study is aimed at defining the pan-RBFOX alternative splicing target 
network as a means of elucidating their molecular functions. We are currently limited in our 
ability to comprehensively identify target transcripts differentially regulated by the three family 
members individually. An outstanding question is the extent to which the RBFOX family 
members have distinct physiological functions and the underlying molecular mechanisms for 
these potential differences. Our CLIP data suggest that all three members have very similar 
  
58 
protein-RNA interaction profiles, indicating that the highly conserved RRM is the major 
determinant of targeting specificity. However, the functional divergence of the different 
members could arise from the increased variation in the N terminal and C terminal regions, 
which were shown to also be important in splicing regulation (Jin et al., 2003; Nakahata and 
Kawamoto, 2005; Sun et al., 2011). For example, different members might recruit different 
cofactors and exert different regulatory effects depending on cellular context. However, 
addressing this question will require expression of different combinations of RBFOX proteins in 
physiologically relevant systems, a currently nontrivial experiment. Such data, when available, 
will nevertheless further improve the accuracy of our model by correlating them with protein-
RNA interactions and other types of data specific to individual RBFOX family members.  
Finally, another important question beyond the scope of this work concerns the roles of 
RBFOX in the regulation of other pathways in RNA metabolism. Several recent findings propose 
that RBFOX can also regulate alternative polyadenylation (Wang et al., 2008) and mRNA 
stability (Ray et al., 2013), based on analysis of RBFOX motif sites in 3´ UTRs that are 
correlated with transcript abundance in different tissues. Although the current data supporting the 
role of RBFOX in these processes are largely correlative, they are corroborated by our 
observation that almost 30% of RBFOX binding sites are in 3´ UTRs. A mechanistic 
understanding of the functional impact of RBFOX interacting with 3’UTRs awaits further 
investigation. We expect that the data presented in this work will provide a valuable resource to 
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Introduction 
Molecular diversity derived from alternative splicing (AS) is believed to be critical for the 
creation of different cell types and tissues with distinct physiological properties and functions 
(Nilsen and Graveley, 2010). This is particularly relevant to the central nervous system (CNS), 
which requires a large protein repertoire to generate its intricate and complex neural circuits (Ule 
and Darnell, 2006). Therefore, a comprehensive catalog of AS events and identification of those 
with potential functional significance are important steps towards understanding the complexity 
of the nervous system. 
Over the past two decades, discovery and characterization of AS events using different 
technologies have provided important insights into the evolution and regulation of AS 
(Blencowe, 2006; Xing and Lee, 2006). Earlier expressed sequence tag (EST)-based studies 
revealed the prevalence of AS in mammals (Kan et al., 2002). Investigation of these AS events, 
especially comparison of AS patterns in different species, led to an important observation that 
AS is rapidly evolving in mammals, with many alternative exons created after the split of 
primates and rodents (Modrek and Lee, 2003). Evolutionarily recent exons in general have low 
level of inclusion and frequently cause frame shifts — and hence premature termination codons 
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(PTCs) — in the resulting transcripts, which are then presumably eliminated by nonsense 
mediated decay (NMD) (Maquat, 2004). Interestingly, these “evolutionary intermediates” are 
strikingly different from a subset of potentially functional alternative exons with conserved 
splicing patterns in different species such as human and mouse, which mostly preserve the 
reading frame, and have substantially elevated level of conservation in flanking intronic 
sequences and in the wobble positions of alternative exons (Xing and Lee, 2006).  More 
quantitative analysis of the transcriptome using splicing sensitive microarrays (Castle et al., 
2008; Sugnet et al., 2006) and more recently RNA-sequencing (RNA-Seq)(Pan et al., 2008; 
Wang et al., 2008) further demonstrated a large number of alternative exons under tissue-specific 
regulation. Interestingly, tissue-specific exons are also associated with higher level of 
conservation in splicing pattern and sequences across different mammalian species (Sugnet et al., 
2006; Wang et al., 2008).  
Importantly, RNA-Seq allows for digital profiling of the transcriptome at a much greater 
depth, coverage and resolution, facilitating efficient discovery of undiscovered AS events. 
Recent RNA-Seq studies of different mammalian tissues, including the brain, have concluded 
that AS will be detected in >90% of multi-exon genes in mammals given sufficient sequencing 
depth (Pan et al., 2008; Wang et al., 2008).  However, this conclusion is based on extrapolation. 
The sequencing depth of each individual tissue and read length in these earlier RNA-Seq studies 
are relatively limited, so that a large number of hidden AS events remain to be discovered. In 
addition, as new exons are discovered it will be important to know how to separate functional AS 
events from those representing biological or evolutionary noise, which will be more likely to be 
detected as sequencing depth increases. 
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To address these questions, we performed systematic analysis of mouse and human 
cortex transcriptomes at different developmental stages by deep RNA-Seq. The functional 
significance of previously known and newly uncovered AS events was assessed by multiple 
measures, including protein coding potential, CNS cell type-specific regulation, targets of tissue-
specific RNA-binding proteins (RBPs) and signatures of strong purifying selection pressure. 
Information provided by these multi-dimensional analyses provided a unique opportunity to 
reveal the complexity of the mammalian brain transcriptome, assess its functional impact not 
fully appreciated thus far, and prioritize a subset of AS events for further investigation. 
 
Extending the mouse and human cortex transcriptomes by deep 
sequencing 
To survey the mammalian brain transcriptome, we performed deep RNA sequencing of mouse 
cortex at nine developmental stages spanning E14.5 to two years old, which resulted in 987 
million paired-end (PE) 101-nt reads. In combination with a second independent dataset from a 
recent study (1.88 billion single-end (SE) 101-nt reads (Lister et al., 2013)), our analysis 
included 390 billion bases in total that provide an unprecedented depth for discovery of AS in the 
brain (in comparison, the human BodyMap 2.0 dataset has 381 billion bases distributed over 16 
different tissues (Farrell et al., 2014)). All RNA-Seq reads were mapped back to the reference 
genome and exon junctions using OLego (Wu et al., 2013). In addition to a provided 
comprehensive database of annotated exon junctions (referred to as known exon junctions 
thereafter) derived from existing gene models (RefSeq and UCSC genes), cDNAs, and EST 
sequences, OLego searches for new exon junctions with high accuracy and sensitivity. In total, 
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OLego detected 878,526 unique exon junctions, and a majority of them (659,592 or 72%) are 
newly discovered junctions, as they are not included in 250,993 known junctions currently 
annotated in the mouse transcriptome (Figure 3.1A). Consistent with the depth of sequencing, 
92.3% of RefSeq exon junctions were detected in our analysis, suggesting the detection of new 
splicing in genes with low expression. 
To detect AS events, we developed a computational pipeline that uses splicing graphs to 
combine RNA-Seq and cDNA/EST sequences. This analysis detected 602,701 AS events of 
different types (single and tandem cassette exons, alternative 5´ and 3´ splice sites, and mutually 
exclusive exons). These events were compared to a comprehensive database of 33,795 annotated 
AS events identified using only cDNA/EST sequences, denoted known AS events (Methods). 
Inclusion of the RNA-Seq data allows identification of 568,906 new AS events, representing a 
>10-fold increase compared to previously annotated events (Figure 3.1B). Among these, 25,474 
known and 421,396 new events have both isoforms reproducibly detected in the cortex (≥ 2 reads 
supporting each of the exon junctions), suggesting that 71.8% of multi-exon genes express 
multiple isoforms through AS in this single tissue (Methods).  
For comparison, we also analyzed the human cortex transcriptome using an RNA-Seq 
dataset consisting of 980 million PE and 180 million SE 101-nt reads (Lister et al., 2013) (216 
billion bases in total). A similar expansion in the number of exon junctions (564,364 new vs. 
327,444 known junctions) and AS events (479,217 new vs. 90,543 known events) was observed. 





Figure 3.1. Discovery of new exon junctions and AS events by deep sequencing analysis of the 
mouse cortex transcriptome. 
A. Number of known and new exon junctions. B. Number of known and new cassette exons. Cassette exons with ≥2 
supporting reads in each AS junction are considered to be alternatively spliced in the brain and shown as a separate 
group. C. The Nrxn1 gene structure, RNA-Seq read profile and sashimi plot showing detected exon junctions (≥2 
supporting reads).  Exon numbers are labeled below the gene structure. Three alternative promoters are indicated 
above the read coverage profile. D. Selected AS events in the Nrxn1 gene. Solid and dotted lines represent known 
and new AS variants, respectively. The number of reads in the adult cortex is indicated for each exon junction. 
Variants of low abundance are not shown for clarity. E. A previously uncharacterized promoter (γ isoform, also 
indicated in panel (C)) produces a truncated form of Nrxn1. RNA read coverage at each developmental stage of the 
cortex is shown together with CAGE tags supporting the presence of the promoter. Extensive Rbfox binding 
downstream of the first exon at conserved (U)GCAUG elements is evident from Rbfox CLIP tags.  
 
To demonstrate how the transcriptome complexity is revealed by our analysis, we 
focused on the Neurexin gene family, which encodes presynaptic cell-adhesion molecules 
important for synaptic formation. Three members of the family have been studied in detail and 
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β isoforms) and extensive AS in each family member (Treutlein et al., 2014) (Figure 3.1C-E). 
For example, Nrxn1 was reported to have AS in six different regions of the gene. Our RNA-Seq 
analysis detected and quantified all these previously described AS events, as well as many 
additional events (Figure 3.1C and D), including an alternative exon denoted AS6 that was 
observed recently (Treutlein et al., 2014). Unexpectedly, we observed a third promoter, which 
we refer to as γ promoter, in a highly conserved region between exons 23 and 24 that would 
generate a truncated isoform lacking almost all extracellular domains (Figure 3.1E). To our 
knowledge, this isoform has not been previously characterized, but it is supported by ESTs (data 
not shown) and CAGE (cap-analysis gene expression) tags, which mark and identify the 5´ end 
of mRNA molecules (Carninci et al., 2005) (Figure 3.1E). Interestingly, the usage of this 
promoter increases during brain development (Figure 3.1E). The brain- (and muscle-) specific 
RBP Rbfox binds extensively downstream of the alternative first exon via a cluster of conserved 
(U)GCAUG elements as evidenced by a large number of cross-linking and immunoprecipitation 
(CLIP) tags (which capture in vivo protein-RNA interactions) (Weyn-Vanhentenryck et al., 
2014), although the functional significance of this interaction awaits further investigation.  
For more detailed characterization of known and newly discovered AS events, we 
decided to focus on cassette exons, the most prevalent type of AS in mammals. In total, our 
analysis identified 146,705 new cassette exon events (as compared to 16,034 known events; 
Figure 3.1B). Many cassette exons have alternative 5´ or 3´ splice sites or are spliced to different 
flanking exons, resulting in multiple cassette events overlapping with each other. To avoid 
potential over-counting, we conservatively defined a non-redundant subset by grouping 
overlapping cassette exons and selecting a representative for each group (Methods). This 
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filtering resulted in 13,500 known and 64,450 new cassette exons that were used for further 
analysis. The 64,450 non-redundant cassette exons can be further divided into three groups: 
36,225 (65.2%) cases representing skipping of known exons previously annotated as constitutive, 
3,490 (5.4%) cassette exons overlapping with known exons with altered exon boundaries, and 
24,735 (38.4%) cassette exons without overlapping exons or gene models in the previous 
annotations. 
Coding capacity and evolutionary history of known and new AS events 
To prioritize AS events for further characterization, we compared known and newly discovered 
AS events using several different measures relevant for functional significance. We first 
developed a pipeline to systematically evaluate their alternative coding capacity. For both known 
and new cassette exons, a substantial fraction (46% and 60%, respectively) introduces a 
frameshift or an in-frame stop codon in the alternative exon so that it is expected to trigger NMD 
upon exon inclusion (NMD_in) or exclusion (NMD_ex) (Figure 3.2). When we quantified exon 
inclusion levels, we found that for a majority of AS events (68% and 85% of known and new 
events, respectively), the minor isoform has low abundance (<10%) and is frequently targeted by 
NMD. We also examined the proportion of cassette exons with orthologous sequences including 
conserved splice sites in human, and how this proportion changes with respect to the exon 
inclusion level. A majority of known and new cassette exons with low inclusion level (<10%) do 
not have discernible orthologs in human (73.5% and 84.5.5%, respectively), suggesting they 
most likely arose after the split of mouse and human during evolution. Finally, 34.8% of known 
and 17.3% new cassette exons in mouse have conserved splicing patterns known or newly 
discovered in human. Similar results were obtained in the analysis of the complete set of cassette 
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exons in mouse or using human cassette exons as a reference in comparison to mouse exons.  
Implications from the observations above are three fold. First, based on the alternative 
coding capacity, abundance of the minor isoform, and presence of orthologous exons or 
conserved AS patterns between human and mouse, both known and new AS events represent a 
mixture of potentially functional events and events tolerated during evolution without affecting 
the fitness of the organism, confirming previous observations (Xing and Lee, 2006). Second, as 
evidenced by the quantitative differences between known and new AS events in the measures 
described above, a larger proportion of new AS events than known events might represent 
evolutionary intermediates or noisy splicing products. Third, given that a much larger number of 
new events was observed in total, the absolute number of new events that are likely functional 
might be on the order of or greater than the number of known events. Based on these arguments, 
we went on to estimate the number of new AS events that are potentially functional by taking 
several complementary approaches. 
 
Figure 3.2. Classification of known and new cassette exons with respect to alternative coding 
capacities. 
Non-redundant cassette exons were included for this analysis.  We analyzed known and new exons (all exons and 
exons with ≥2 reads for each junction in the minor isoform) to determine whether they could cause NMD upon 
inclusion (NMD_in) or exclusion (NMD_ex), or produce protein products from both isoforms (coding). 
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species (Merkin et al., 2012). Despite the fact that the brain is one of the tissues with the most 
cellular heterogeneity, few studies have addressed cell type-specific splicing in the CNS. We 
recently performed RNA-Seq to compare all major cell types in the CNS that are acutely isolated 
from mouse cortex, including neuron, astrocyte, oligodendrocytes at different maturation stages 
(oligodendrocyte progenitor cells, newly formed oligodendrocytes, and myelinated 
oligodendrocytes), microglia, and endothelial cells (Zhang et al., 2014). Each of these cell types 
has distinct molecular signatures at the gene expression and splicing levels, although previous 
analysis of AS was limited to known events. We therefore extended the analysis to both known 
and newly discovered cassette exons and identified 3,113 non-redundant cassette exons with cell 
type-specific splicing, including 1,095 (35.2%) new events (Figure 3.3A). These new AS events 
are distributed over different cell types, with the largest number in neurons.   
To obtain insights into the underlying regulatory mechanisms of these known and newly 
discovered neuron-specific exons, we investigated their regulation by several cell type-specific 
RBPs, with an initial focus on RBFOX and NOVA, whose specific enrichment in neurons as 
compared to the other cell types was confirmed in the RNA-Seq data. Rbfox and Nova are 
known to regulate AS of neuronal transcripts by activating or repressing exon inclusion 
depending on their binding position relative to the alternative exon (Ule et al., 2006a; Weyn-
Vanhentenryck et al., 2014; Zhang et al., 2008). We found that both known and new cassette 
exons with neuron-specific inclusion showed characteristic and strong enrichment of RBFOX 
binding motifs or CLIP tags (Weyn-Vanhentenryck et al., 2014) in the downstream introns 
(Figure 3.3B and Figure 3.4), which is consistent with activation of these exons in neurons by 
RBFOX. Similarly, NOVA binding sites are enriched in the downstream introns of exons with 
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neuron-specific inclusion and upstream introns of exons with neuron-specific exclusion for both 
known and new cassette exons (Zhang et al., 2010).  
 
Figure 3.3. Known and new cassette exons under tissue- or cell-type specific regulation. 
In each panel, only non-redundant cassette exons were included for analysis. A. The number of known and new 
cassette exons with cell type-specific AS.  OPC: oligodendrocyte precursor cells; NFO: newly formed 
oligodendrocyte; MO: myelinating oligodendrocyte. B. An RNA map correlating neuron-specific exon inclusion 
(red) or exclusion (blue) with the position of (U)GCAUG elements recognized by Rbfox proteins. 
C. The number of known and new cassette exons with altered splicing upon CNS-specific depletion of Ptbp2 (driven 
by Nestin-Cre, middle bar).   For each group, exons are further classified with respect to their alternative coding 
capacities. D. An RNA map correlating Ptbp2-dependent exon inclusion (red) or exclusion (blue) with the position 
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Figure 3.4. Expression of select RBP families in CNS cell types.  
Log- transformed, mean-centered RPKM values of RBPs are shown in the heatmap.  
 
The analysis above highlights the role of RBPs in determining cell-type specific splicing. To 
further investigate the specific regulatory effects of RBPs more directly, we examined targets of 
individual tissue- or cell type-specific RBPs for which deep RNA-Seq data are available to show 
splicing changes upon their depletion in the CNS. This also allows us to identify known and new 
AS exons that are under such regulation as a measure of functionality. We first analyzed targets 
of PTBP2, an RBP that primarily represses exon inclusion in the nervous system (Licatalosi et 
al., 2012b), using RNA-Seq datasets that compared wild type (WT) and Ptbp2 knockout (KO) 
brains (Li et al., 2014). Conditional depletion of Ptbp2 in the CNS altered splicing of 653 non-
redundant cassette exons, including 249 newly discovered exons (38.1%); a similar proportion 
(41.6%) was observed upon conditional depletion of Ptbp2 in the forebrain (Figure 3.3C). To 
determine whether these splicing changes reflect direct regulation by PTBP2, we correlated 
PTBP2-dependent splicing with PTBP2 binding sites as determined by CLIP data (Licatalosi et 
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al., 2012b). Both known and new cassette exons with PTBP2-dependent exclusion have 
characteristic enrichment of PTBP2 CLIP tags in the poly-pyrimidine tract, suggesting that the 
splicing changes reflect direct regulation by PTBP2 (Figure 3.3D). We also analyzed an RNA-
Seq dataset that profiled mouse hippocampi upon depletion of Mbnl2, an RBP implicated in 
myotonic dystrophy (Charizanis et al., 2012). Again, we observed that a sizeable proportion 
(53/223 or 23%) of MBNL2-dependent exons are newly discovered.  
Known and new AS exons under strong evolutionary selection pressure 
Since it is currently impractical to directly identify all exons regulated by specific RBPs, we 
explored an alternative approach to infer functionality by evaluating AS events under 
evolutionary selection in the mammalian lineage. We scored conservation of the wobble 
positions of the alternative exons together with flanking intronic sequences in 40 sequenced 
mammalian species, which achieves high statistical power for detecting selection pressure in 
mammals while avoiding bias towards either coding or noncoding exons (Figure 3.5, Methods 
and Methods).  
We initially considered a group of NMD_in exons with conserved AS in human and 
mouse which have no overlap with any coding sequences. In other words, the function of these 
exons was maintained simply to induce NMD upon exon inclusion during ~75 million years of 
evolution, so they provided a positive control set of functional AS events. As a negative control 
set, we used exons constitutively spliced in both human and mouse. We found that conservation 
scores of the wobble positions and intronic sequences together were able to largely separate the 
positive and negative control exons (Figure 3.6A). We then examined the non-redundant subset 
of known and new cassette exons in mouse with both orthologous sequences and intact splice 
  
71 
sites in human. A Gaussian mixture model (GMM) was used to decompose these exons into two 
populations: one under selection pressure similar to constitutive exons (C1 population) and the 
other showing distinct signatures of negative or positive selection to maintain AS (C2 
population) (Figure 3.6B and Methods). We estimate that 7,645 cassette exons (16%) are under 
selection pressure driven by regulated AS, including 2,287 (30%) known and 5,358 (70%) newly 
discovered AS exons. These evolutionarily constrained AS events accounts for 16.9% 
(2,287/13,500) and 8.3% (5,358/64,450) of all non-redundant cassette exons that are previously 
known or newly discovered, respectively. These observations highlight both the tolerance of AS 
events without apparent evolutionary fitness, especially among those new AS events, and the 
prevalence of previously uncharacterized, hidden exons under functional selection.  
 
Figure 3.5. Cross-species sequence conservation of orthologous cassette exons in human and 
mouse 
Conservation profile of 40-way phastCons scores (in placental mammals) in 30 nt exonic sequences and 200 nt 
intronic sequences flanking the 3 ́ and 5 ́ splice sites of different groups of cassette exons. 
 
To identify AS events with potentially conserved function in mammals, we used stringent 
thresholds on conservation scores to define a subset of 3,058 non-redundant, highly conserved 
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cassette exons, including 1,640 (52.7%) newly discovered cassette exons (Figure 3.6B and C; 
Methods). These exons are substantially smaller than constitutively spliced exons (85 nt vs. 114 
nt, median), a feature known to be associated with regulated AS exons (Xing and Lee, 2006). In 
particular, 272 AS exons (including 117 newly discovered) have a size ≤ 27 nt; microexons have 
been shown recently to be particularly relevant for neurodevelopment (Irimia et al., 2014; Li et 
al., 2015; Wu et al., 2013).  Therefore, deep survey of the transcriptome allows us to more than 
double the number of alternative exons that are likely functional. 
For instance, the Rbfox2 gene has a 93-nt cassette exon (denoted e6) encoding part of the 
RNA-recognition motif (RRM), which can be skipped to produce a dominant negative form 
(Baraniak et al., 2006; Damianov and Black, 2010a). Two cryptic exons (e5* and e6*) around e6 
were identified recently by detailed analysis of the region, and inclusion of these exons upon 
overexpression of Rbfox3 was demonstrated to trigger NMD (Dredge and Jensen, 2011). Our 
genome-wide analysis detected both exons de novo in both human and mouse and correctly 
annotated them as NMD_in exons, despite the very low inclusion level (<0.5% in each species; 
Figure 3.6D and E). In addition, we discovered a paralogous exon of e6* in the Rbfox1 gene in 
both human and mouse, suggesting the ancient origin of this exon, prior to duplication of the 
Rbfox gene family. Interestingly, another NMD_in exon (e5#) was discovered at an extremely 
low level in a conserved region between e5 and e5* in mouse Rbfox2 (Figure 3.6D). Although 
conservation of this exon is below the stringent threshold we used to define strong purifying 
selection, the conserved nature of the splice sites and the presence of two conserved PTCs 




Figure 3.6. Identification of cassette exons under evolutionary selection pressure. 
A. Conserved NMD_in exons (orange, positive control of functional AS exons) and constitutive exons (gray, 
negative control of AS exons) can be largely separated by conservation in the wobble positions of the alternative 
exon (y-axis) and flanking intronic sequences (x-axis).   B. Distribution of non-redundant cassette exons with 
respect to conservation scores as displayed by smoothed scatter plot.  The distribution can be decomposed into two 
populations (C1 and C2), with the percentage of exons in each population indicated.  The “+” signs indicate the 
mean conservation scores of each population of exons.  The dashed lines indicate two standard deviations from the 
means, the threshold used to detect strong purifying selection pressure.  The first quadrant, marked with the bold 






































A Positive & negative  
control exons 












































D E 5 kbmm10chr15 77,105,00077,110,000
Alternative Splicing
RefSeq Genes
Placental Mammal Basewise Conservation by PhyloP
e7 
e5 e6 e5* e6* e5# 
5 kbhg19chr22 36,165,00036,170,000
Placental Mammal Basewise Conservation by PhyloP
Alternative Splicing
RefSeq Genes
e5 e5* e6 e6* e7 
5 kbhg19chr22 36,165,00036,170,000






Placental Mammal Basewise Conservation by PhyloP
Alternative splici  Altern tiv  s lici  
  
74 
cassette exons under strong purifying selection. D-E. AS of the Rbfox2 gene in the region flanking exon 6 in both 
mouse (D) and human (E).  Two highly conserved cryptic NMD_in exons (e5* and e6*) were identified de novo in 
this region.  These exons were recently demonstrated to trigger NMD upon inclusion (Dredge and Jensen, 2011).  
An additional NMD_in exon (e5#) with a very low level of expression (<0.1% compared to the major isoform with 
inclusion of exon 6) was identified in mouse. F. Cross-species sequence conservation of e5#.  Splice sites and 
predicted premature termination codons (PTCs) are indicated.   
 
In total, 1,014 cassette exons under strong purifying selection (390 known and 624 new) 
are expected to trigger NMD upon exon inclusion or exclusion. NMD exons overlapping with 
highly conserved sequences were previously found in ubiquitous splicing factors such as SR and 
hnRNP proteins, core spliceosomal proteins, and, in some cases, tissue-specific splicing factors 
(Lareau et al., 2007; Ni et al., 2007; Saltzman et al., 2008), suggesting an autoregulatory 
mechanism for homeostatic maintenance of the splicing machinery. Our analysis confirmed and 
extended these observations by identifying 118 highly conserved NMD exons in 84 RBPs, 
accounting for 21.4% of all annotated RBPs (Cook et al., 2011) (Tables S.2 and S.3, and 
Methods). Interestingly, in addition to splicing factors, we identified NMD exons in RBPs 
involved in other steps of RNA metabolism such as 3´-end processing and translational 
regulation (Table S.3). Therefore, our analysis suggests that regulation of RBP expression 
through NMD is more widespread than previously recognized.  
 
AS-NMD exons in chromatin regulators and their evolutionary origin 
To investigate the function of highly conserved AS-NMD exons in a more unbiased manner, we 
performed gene ontology (GO) analysis. This analysis highlighted genes involved in “mRNA 
metabolic process” (Benjamini FDR<4.7×10-18), as expected. Unexpectedly, a second group of 
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52 genes encoding chromatin regulators, highly significantly enriched in annotations such as 
“chromatin organization” and “chromatin modification” (Benjamini FDR < 4.1×10-8 and 
1.0×10-6), was also identified (Figs. S19 and S20, Tables S.4 and S.5, and Methods).  
Finally, we investigated the evolutionary origin of NMD exons under strong selection in 
mammals. We focused on those without overlap with protein-coding exons, since these exons 
may have arisen de novo during evolution. For comparison, we used constitutive exons and 
highly conserved alternative coding and NMD_ex exons (Figure 3.7A-E). While conservation of 
a majority of constitutive and NMD_ex exons extends into lower vertebrates (Figure 3.7C and 
D), suggesting their ancient origin, conservation of de novo NMD_in exons are largely limited to 
placental mammals (Figure 3.7A and E), and alternative coding exons are in between (Figure 
3.7B and E). Intriguingly, there appears to be a transition period during the evolution from 
ancestors of fish to amphibians and land animals when these NMD_in exons were created, likely 
derived a fitness advantage, and were fixed in the mammalian lineage (Figure 3.7E). Two 
observations corroborate this finding. First, the size of introns flanking de novo NMD_in exons 
is roughly half that of those flanking other groups of exons (~1500 vs. 2500-3000 nt, median; 
Figure 3.7F), which is consistent with the notion that introduction of a de novo NMD_in exon 
splits an ancestral intron into two. Second, among the 34 exons (from 32 genes) with extended 
conservation into lower vertebrates, a majority (21 exons) are in genes involved in RNA 
metabolism, suggesting the ancient origin of the autoregulatory mechanism. In contrast, most, if 
not all, de novo NMD_in exons in genes currently annotated as chromatin regulators appear to 
have evolved in ancestors of placental mammals (Figure 3.7A), potentially correlated with more 




Figure 3.7. Evolutionary origin of highly conserved de novo NMD_in exons. 
A-D. Cross-species conservation of different categories of cassette exons under strong purifying selection in 
mammals is shown (A-C).  Constitutive exons (D) are used as a control.  In each panel, the heatmap indicates the 
conservation of each exon (rows) in each of the 60 vertebrate species (columns) ordered based on the phylogenetic 
tree (i.e. divergence from mouse, which is shown in the first column) with a gray box indicating the presence of the 
exon in the species.  Note that only exons with sequences conserved in mouse and human were included for the 
analysis.  In panel (A), exons from genes encoding RBPs or chromatin regulators are indicated on the right. E. The 
percentage of conserved cassette exons across 60 vertebrate species.  Only exons under strong selection pressure 
were included for this analysis.  The phylogenetic tree of the species is shown on the top.  The shaded species 
indicate the evolutionary period during which de novo NMD_in exons were invented and finally fixed in mammals. 
F. Median size of the introns flanking cassette exons under strong purifying selection pressure.  Exons are grouped 
by the exon coding capacities. Error bars represent standard error of the mean. 
	
Overall, 118 of the NMD exons under strong selection pressure are from 84 genes 
encoding RBPs. Among these are seven SR proteins (Srsf2,3,4,6,7,9, and 11) and at least 12 
hnRNP proteins (Hnrnpd, h1, h3, k, l r, Hnrpdl, ll, Ptbp1, Ptbp2, Rod1, and Dazap1) (Tables S.2 
and S.3). It was previously proposed that alternative exons in SR proteins trigger NMD upon 
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exon inclusion, while hnRNP proteins generally trigger NMD upon exon skipping (Ni et al., 
2007). This was interpreted as a consequence of SR proteins acting as splicing activators and 
hnRNP proteins as splicing repressors. Therefore, the NMD isoform is upregulated through 
autoregulation to form a negative feedback loop and to maintain the homeostatic protein level. In 
our analysis, we confirmed that NMD exons in SR proteins are indeed all NMD_in exons. 
However, both NMD_in and NMD_ex exons are detected in genes encoding hnRNP proteins. In 
fact, at least four cases (Hnrnpd, Hnrnpl, Hnrpdl, and Hnrpll) were identified as NMD_in exons 
under strong selection; furthermore, significant increase of the NMD exon was observed upon 
Upf2 depletion in the liver, suggesting the importance of these exons in regulating the expression 
of these genes. Therefore, these hnRNPs might positively affect the splicing of the NMD exons 
to form negative feedback loops, if the function of these NMD exons is also to maintain 
homeostatic expression of the protein products. Alternatively, these hnRNPs might negatively 
affect the splicing of the NMD exons to form a positive feedback loop to amplify expression 
changes of these genes in certain conditions. This notion is in line with a recent observation that 
NMD exons can contribute to stage-specific gene expression during terminal erythropoiesis 
(Pimentel et al., 2014).  
To demonstrate that these transcripts are real NMD targets, we first examined changes of 
these transcripts upon Upf2 deletion. Among the 67 NMD exons under strong purifying selection 
pressure from 52 genes annotated as chromatin regulators, five show detectable changes in the 
NMD exons upon Upf2 depletion (using the relaxed threshold |∆I|≥0.1, P<0.05, as described 
above). All five are NMD_in exons and show increase in the NMD isoform. Due to the limited 
sensitivity to detect changes at the exon level partly as a result of the moderate sequencing depth 
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of the dataset, we also examined changes in the mRNA steady state level and observed increase 
in 32/52 genes encoding chromatin regulators (fold change > 1.5; and decrease in only 1 gene); 
these changes are qualitatively comparable to those observed in RBPs (59/84 genes). 
One possibility is that changes in enzymes modifying histone structure and function can 
affect chromatin organization, which has widespread effects on downstream gene expression at 
the transcription level. Furthermore, it was proposed that histone modifications and nucleosome 
positioning can modulate co-transcriptional splicing through two mechanisms (Luco et al., 2011; 
Zhou et al., 2014). The first mechanism is through alteration of the transcription rate, since such 
kinetic changes have been shown to affect the efficiency of exon recognition. The second 
mechanism is through a chromatin-splicing adaptor system, in which an adapter protein 
recognizing specific histone modifications, such as trimethylation of lysine-36 of histone H3 
(H3K36me3), can recruit splicing factors to nascent transcripts associated with the chromatin in 
proximity. Therefore, regulation of chromatin genes through AS-NMD can potentially provide a 
feedback mechanism that links epigenetic regulation to RNA processing. 
One such example is the H2afy gene encoding variants of the macroH2A histone H2A 
family, a hallmark of mammalian heterochromatin that participates in stable X chromosome 
inactivation. AS of two mutually exclusive exons (100 nt and 91 nt) results in the macroH2A.1 
and macroH2A.2 variants with different functions.  This AS event is developmentally regulated 
with exclusive use of the 5´ exon encoding macroH2A.2 in embryonic stem cells and early 
embryos, and a gradual increase of the 3´ exon encoding macroH2A.1 during differentiation 
(Pimentel et al., 2014). Interestingly, macroH2A.1 is reduced in cancer cells, which has been 
suggested to have an implication in tumor invasiveness (Novikov et al., 2011). Our analysis of 
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the brain transcriptome shows that the two exons can be simultaneously included, resulting in a 
transcript with a frame-shift that is potentially targeted by NMD (Figure 3.8). The H2afy gene is 
also abundantly expressed in the liver. Depletion of Upf2 resulted in a significant increase of the 
NMD isoform (∆I =0.36, P<9×10-4, FDR<0.002). These observations suggest that the 
unproductive splicing pattern might serve as a regulatory mechanism for the homeostasis or 
developmental changes of macroH2A. This notion is also supported by the highly conserved 
nature of the flanking intronic sequences.  
 
Figure 3.8. H2afy is a highly conserved NMD exon in a chromatin regulator. 
RNA-Seq read coverage profile from this study and RNA-Seq data derived from control (green) and Upf2 KO (blue) 
livers are shown. The AS pattern (solid line: the coding isoform; dash line: the NMD isoform with PTC indicated) 
and cross-species sequence conservation are also shown below.  
	
A second example is the Setd2 gene, which encodes a histone methyltransferase that is 
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specific for H3K36me3. H3K36me3 is associated with active chromatin and, interestingly, an 
epigenetic marker enriched in exons compared to introns (Kolasinska-Zwierz et al., 2009). A 
mechanistic link between this modification and AS was revealed by the finding that it can be 
recognized by an enzyme named MRG15, which interacts with and recruits PTB to a select 
subset of nascent transcripts associated with chromatin to affect their AS (Luco et al., 2010). 
Depletion of PTB, MRG15, or SETD2, the three major components in this pathway, resulted in 
changes in hundreds of alternative exons with substantial overlap, suggesting that AS events 
regulated by this chromatin-splicing adaptor system are widespread. Recently, mutations in the 
SETD2 gene were identified in human kidney tumors and were found to be associated with 
increased chromatin accessibility linked with aberrant AS affecting ~25% of all expressed genes 
(Simon et al., 2014). We found that a PTC-containing exon is included in the brain transcriptome 
at a detectable level (~5% inclusion). The increase of the NMD isoform upon Upf2 depletion in 
the liver is not statistically significant, due in part to the limited sequencing depth, but the mRNA 
steady state level increases 1.9 fold. 
A third example is the Smg6 gene, which encodes a component of the telomerase 
ribonucleoprotein complex responsible for maintenance of telomeres. Interestingly, Smg6 also 
has endonuclease activity near PTCs and is required for the initiation of NMD (Eberle et al., 
2009), providing another potential link between chromosome organization and RNA metabolism. 
In this case, skipping of a 62-nt exon introduces a frame shift in the resulting transcripts that are 
potentially targeted by NMD.  Depletion of Upf2 results in a 1.7-fold increase in Smg6 




A first step to understand the complexity of the mammalian transcriptome is to reveal the atlas of 
AS events and prioritize the events that are likely functional. To our knowledge, this work 
represents the most comprehensive survey of AS in the mammalian brain transcriptome in both 
sequencing depth and the range of developmental stages included, which allows us to expand the 
list of AS events over an order of magnitude. Based on the current knowledge, there is no 
indication that a majority of observed AS events are functional, no matter if they were previously 
identified in cDNAs/ESTs or only detectable by deep sequencing, although the latter are more 
likely to include leaky splicing products. On the other hand, previous annotations based on 
cDNAs/ESTs may cover a minority of all the functional events due to the limited depth of the 
data. Our analysis demonstrated that that newly discovered AS exons from deep sequencing 
account for 23-40% of cassette exons under tissue- or cell type-specific regulation. This 
proportion is likely an underestimate because new AS exons are more likely found in genes of 
low abundance, e.g. due to restricted expression in specific cell types or clearance of the 
transcripts through NMD. Splicing regulation for these exons is more difficult to determine. 
Indeed, by analysis of evolutionary signature, we estimated that a majority (70%) of cassette 
exons under selection pressure in mammals were not annotated previously. Among highly 
conserved cassette exons, newly discovered events are more enriched in NMD targets compared 
to known events (38% vs. 27.5%). Many of these NMD exons reside in RBPs including, but not 
limited to, splicing factors, implying an extensive network of auto-regulation and cross-
regulation of RBPs involved in essentially all steps of RNA metabolism. The detected inclusion 
level of some of these NMD exons (e.g., those in Rbfox1/2 genes; Figure 3.6D-F) is extremely 
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low (<1%), and yet the high level of cross-species sequence conservation, independent detection 
in both mouse and human, and increased abundance upon inhibition of the NMD pathways 
strongly argues for their functional significance. An intriguing question is whether these exons 
serve only for fine-tuning homeostatic RBP expression or for regulating expression more 
dramatically in certain conditions we currently do not know. A potentially revealing experiment, 
for example, will be transcriptome analysis upon perturbation of tissue-specific splicing 
regulators in combination with suppression of the NMD pathway. 
In addition to a greatly expanded list of AS exons that are likely functional, our study led 
to an unexpected finding revealing the widespread regulation of chromatin regulators through 
AS-NMD. The impact of chromatin structure and its modifications on AS has been suggested by 
a number of recent studies (Luco et al., 2011). Our analysis implies another, much less 
characterized side of the coupling between the two processes. To our knowledge, this is the first 
time the general implication of AS coupled with NMD in chromatin regulators has been 
suggested. In support of this observation, a recent study noted changes in splicing of NMD exons 
in several genes encoding histone modifying enzymes during terminal erythropoiesis (Pimentel 
et al., 2014). Regulation of chromatin genes through AS-NMD can potentially provide a 
feedback mechanism that links epigenetic regulation to RNA processing. Importantly, our 
phylogenetic analysis tracing the evolutionary origin of these NMD exons suggest that this 
mechanism was likely introduced in the mammalian lineage during evolution, which is a more 
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Introduction 
During development of the mammalian nervous system, neurons mature through a prolonged and 
sophisticated process that involves dramatic morphological and functional changes in individual 
neurons as well as formation of synaptic connections between neurons to build intricate neural 
circuitries (Barnes and Polleux, 2009; Jan and Jan, 2010; Rasband, 2010). These changes must 
occur with very precise timing (Silbereis et al., 2016), which, at the molecular level, is achieved 
through tight temporal control of gene expression at multiple steps. To date, extensive efforts 
have been made to dissect the role of transcriptional regulation controlling specification of 
neuronal subtype identities during early neuronal development (Jessell, 2000; Molyneaux et al., 
2007). However, regulatory mechanisms that govern the distinct timing of various molecular and 
cellular events required for neuronal development and maturation remain poorly understood. 
Alternative splicing (AS) is an essential mechanism that allows the generation of multiple 
transcripts and protein variants, or isoforms, from a single gene (Black, 2003). This mechanism 
is increasingly recognized as a major source of molecular diversity, especially in the central 
nervous system (CNS)(Raj and Blencowe, 2015). Genome-wide transcriptomic studies based on 
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deep mRNA sequencing (RNA-seq) demonstrated that AS is ubiquitous; many alternative exons 
show specific splicing patterns in the brain when compared to other tissues (Wang et al., 2008), 
and in neurons when compared to other cell types in the brain (Yan et al., 2015; Zhang et al., 
2014). This neuron-specific splicing program must be established at specific stages of the 
neuronal differentiation and maturation process. Indeed, many alternative exons show dramatic 
changes during neuronal development, as revealed by several recent studies of developing 
cortices in primates (Mazin et al., 2013) and rodents (Dillman et al., 2013), different laminar 
cortical layers (Fertuzinhos et al., 2014), and specific neuronal subtypes purified in situ 
(Molyneaux et al., 2015) or differentiated in vitro from embryonic stem cells (ESCs)(Hubbard et 
al., 2013). While the functional significance of a majority of these developmentally regulated 
alternative exons has yet to be demonstrated, decades of studies have found multiple examples in 
which individual alternative exons play critical roles in many aspects of neuronal development, 
such as neuronal migration, axon guidance, and synapse formation (Vuong et al., 2016a). 
Therefore, elucidating the precise timing of developmental splicing switches and their underlying 
regulatory mechanisms is a key step toward understanding the molecular program governing 
neurodevelopment. 
Cell-type or developmental-stage specific AS events are largely controlled by recruiting 
RNA-binding proteins (RBPs) that recognize specific regulatory sequences embedded in the 
premature mRNA transcripts. For instance, neuron-specific or enriched RBPs, such as Nova, 
Rbfox, Ptbp2, nElavl, nSR100, and Mbnl2 have been demonstrated to regulate numerous 
neuronal transcripts (reviewed in ref. (Raj and Blencowe, 2015)). Technological advances have 
also made it possible to define the comprehensive target networks of individual RBPs with high 
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accuracy by integrating global splicing profiles upon depletion of each RBP and genome-wide 
maps of in vivo, direct protein-RNA interactions, as we demonstrated in our previous studies 
(Weyn-Vanhentenryck et al., 2014; Zhang et al., 2010). Importantly, such global and unbiased 
analyses allowed us to demonstrate that Rbfox proteins in general promote the adult splicing 
pattern in the developing cortex (Weyn-Vanhentenryck et al., 2014). Other groups also found 
that Mbnl2 and Ptbp2 promote and antagonize the adult splicing pattern, respectively (Charizanis 
et al., 2012; Li et al., 2014; Licatalosi et al., 2012b). However, how these and other RBPs 
contribute to the precise timing of developmental splicing switches has not been systematically 
investigated. 
The limited sampling resolution, incomplete coverage of developmental stages and the 
scope of analysis have impeded previous studies to uncover the precise timing of developmental 
splicing switches, the key regulatory signals, and the link to developmental cellular processes. To 
address these issues, here we systematically investigated the organization of the developmental 
splicing profiles in a large panel of developing mouse cortical tissues, different subtypes of 
neurons isolated in situ, as well as neurons differentiated in vitro from ESCs. In combination 
with integrative modeling of RNA-regulatory networks (Weyn-Vanhentenryck et al., 2014; 
Zhang et al., 2010), this approach allowed us to dissect the underlying regulatory mechanisms 
that control the splicing program at specific neuronal maturation stages and cell types in the 
central and more peripheral nervous system.  
Modular organization of the neurodevelopmental splicing program 
To determine the precise timing of developmental splicing changes, we profiled the 
transcriptome of mouse cortices at nine developmental stages ranging from embryonic day 14.5 
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(E14.5) to 21 months by RNA-seq. These time points were chosen carefully to best capture the 
dynamics of developmental splicing changes based on several individual alternative exons 
characterized in detail in previous studies. Using stringent criteria (changes in percent spliced in 
or |ΔΨ|≥0.2 and false discovery rate (FDR)≤0.05) applied to both known and novel AS events 
(Wu et al., 2013; Yan et al., 2015), we identified over 20,000 events representing 32% of brain-
expressing genes with significant changes between at least two stages, suggesting prevalence of 
developmental splicing regulation at an unprecedented scale.  
For detailed analysis, we focused on 2,883 non-redundant cassette exons under 
developmental regulation (1,909 known and 974 novel) that could be accurately quantified in ≥7 
of the 9 time points (Figure 4.1A). Compared to cassette exons overall, developmentally 
regulated cassette exons are much more likely to preserve the reading frame (68.7% vs. 43.2%) 
and to have a conserved AS pattern detected in the human brain transcriptome (63.4% vs. 
29.2%). We recently developed a method to identify exons under strong purifying selection 
pressure based on cross-species sequence conservation in the alternative exons and flanking 
intronic regions (Yan et al., 2015). A much higher fraction of developmentally regulated exons is 
under strong purifying selection pressure (31% vs. 3.9%; Figure 4.1B). For example, our analysis 
identified a highly conserved 12-nt microexon in the Kdm1a gene encoding LSD1 (histone 
lysine specific demethylase 1) (Figure 4.1C); this exon’s inclusion level peaks between postnatal 
day 0 (P0) and P7, a temporal pattern consistent with its previously reported role in modulating 
neurite outgrowth by altering the availability of a phosphorylation site (Toffolo et al., 2014; 




Figure 4.1. Modular organization of dynamic splicing switches during cortex development. 
A. The number of non-redundant cassette exons with differential splicing (|ΔΨ|≥0.2, Benjamini FDR≤0.05) in each 
pairwise comparison of developmental stages.  The numbers of exons with increased inclusion at later stages are 
shown above the diagonal (top right), and exons with decreased inclusion at later stages are shown below the 
diagonal (bottom left).  B. Mouse cassette exons with developmental changes are highly conserved in human, as 
measured by the percentage of exons with conserved splicing in human (left) or the percentage of exons under 
strong evolutionary selection pressure (right). C. An example of developmental splicing regulation in exon 8a of the 
Kdm1a gene.  Inclusion of this microexon peaks between postnatal days P0-P7. D. Four modules of developmentally 
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regulated exons identified by WGCNA analysis with distinct temporal patterns during cortex development.  A non-
redundant set of 2,883 known and novel cassette exons was included for this analysis, and their mean-substracted 
inclusion levels across developmental stages are shown in the heatmap. Exons in each module were ranked based on 
their correlation with the eigenvector of the module, and those with the strongest correlation are defined as core 
members (black bars on the right). Exons in each module are further divided into two groups (e.g., M1+ and M1-) 
depending on positive or negative correlation with the eigenvector. e, Enrichment of gene ontology (GO) terms in 
exons showing splicing switches with specific timing.  The timing of developmental splicing switches is 
parameterized by sigmoidal curve fitting, and exons are ranked based on the timing.  Exons in each sliding window 
(with a window size of 300 exons) were compared to all cassette exons with sufficient read coverage in the brain to 
identify significant GO terms.  Only GO terms significant in at least one sliding window are shown (Benjamini 
FDR≤0.05).  Broad categories and top GO terms in each category are highlighted on the right. 
 
To understand the timing of splicing changes on a global scale, we performed weighted 
gene co-expression network analysis (WGCNA)(Zhang and Horvath, 2005) on the 
developmentally regulated cassette exons. This analysis revealed four modules with distinct 
temporal patterns (Figure 4.1D). Among them, exons in module M2 show early splicing switches 
around birth and exons in M1 show late splicing switches between P4 and P15. These two 
modules, both characterized by monotonic splicing changes, account for 74% of 
developmentally regulated alternative exons, indicating that these are the predominant modes of 
regulation. The other two modules, M3 and M4, show more complex, non-monotonic changes, 
including abrupt splicing changes in M3 that appear to be induced by birth. We confirmed that 
this modular organization is highly reproducible using independent datasets (Figure 4.2 below). 
We also identified a subset of 1,266 (44%) exons that are most correlated with the module 




Figure 4.2. The modular organization of the developmental splicing program is pan-neuronal.   
A. The splicing profile of module exons in different neuronal subtypes.  Exons are shown in the same order as in the 
cortex reference.  DIV: days in vitro.  For differentiation of glutamatergic neurons from ESCs, cells on DIV 0 are 
enriched in radial glia committed to the neuronal fate, which becomes post-mitotic on DIV 1. B. Quantification of 
developmental splicng switches among module exons in different neuronal subtypes.  In each dataset, M1+/M1- and 
M2+/M2- core module exons also showing differential splicing (|ΔΨ|≥0.2, Benjamini FDR≤0.05) in each pairwise 
comparison were counted.  The number of exons showing increased inclusion at later time points is shown above the 
diagonal (top right), and the numbers of exons showing decreased inclusion is shown below the diagonal (bottom 
left). 
 
Given the importance of precise timing for neural development, we tested whether the 
timing of splicing switches reflects specific gene function. To this end, we performed a “sliding 
window” gene ontology (GO) analysis (see Methods). This analysis revealed three major clusters 
of GO terms associated with different timings of splicing switches (Figure 4.1E and Table S.7). 
Early-switch exons are enriched in genes related to ion channels, transmembrane transport and 




























In contrast, late-switch exons are enriched in genes involved in cytoskeletal remodeling, neuron 
projection and synaptic formation, which are critical for wiring of the neural circuitry. Exons that 
switch in between (E16.5-P6) are present in genes related to membrane depolarization and 
formation of the axon initial segment, hallmarks of the early stages of neuronal maturation. 
Interestingly, genes encoding proteins in different subcellular compartments, such as presynaptic 
proteins and post synaptic densities (PSDs), also show splicing switches in distinct time windows 
(Figure 4.3). Furthermore, the functional distinction of genes with early and late splicing 
switches is also evident from significant GO terms enriched in each module, confirming the 
robustness of the observations (Table S.8). These data suggest a clear link between the timing of 
regulated splicing switches and cellular events that occur during neural development. 
 
 
Figure 4.3. Functional enrichment of genes with splicing switches with specific timing. 
As in Fig. 4-2, exons in each sliding window (with a window size of 300 exons) were compared to all casette exons 
with sufficient read coverage in the cortex to evaluate enrichment of genes with specific functional annotations. 
The developmental splicing program is largely pan-neuronal in the CNS 
Although cortex tissues represent a mixture of different cell types, the developmental splicing 
changes we observed are not simply due to changes in cellular composition (ref.(Jaffe et al., 
2015) for similar conclusion from gene expression analysis). In a comparison of the splicing 











and endothelial cells12,13, we found that neurons show the most distinct splicing profiles and are 
the most similar to the cortex tissue. In addition, we did not observe any apparent global splicing 
switches during differentiation and maturation of oligodendrocytes that are correlated with the 
modules we identified. Cortical neurons are broadly classified as either excitatory pyramidal 
neurons or inhibitory interneurons, which differ in their abundance, developmental timing and 
migratory path. To assess whether the different representation of pyramidal neurons and 
interneurons can bias the developmental splicing profiles we observed in cortex tissues, we 
compared splicing profiles of 19 glutamatergic neuronal subtypes and 23 GABAergic neuronal 
subtypes defined by single-cell RNA-seq of the primary visual cortex of the adult mice (Tasic et 
al., 2016). We observed no global differences between the two broad categories of neurons that 
are correlated with the modules we identified.  
Nevertheless, an important question is how well the modular organization of 
developmental splicing switches discovered in cortical tissues captures dynamics in specific 
neuronal subtypes or cell populations. To address this question, we analyzed multiple datasets 
that profiled the developmental transcriptomes of specific subtypes of neurons isolated in situ 
from mouse CNS tissues or differentiated in vitro from ESCs. We found consistent early splicing 
switches (exons in M2-M4) in purified cortical pyramidal neurons (cPNs) between E15.5 and P1 
(ref.(Molyneaux et al., 2015)). Similarly, spinal motor neurons show early splicing switches in 
M2 exons between E12.5 and P1, as well as late switches in M1 exons between P1 and adults 
(Amin et al., 2015; Bandyopadhyay et al., 2013; Zhang et al., 2013b). Importantly, early splicing 
switches and, to a certain degree, late splicing switches were also recapitulated in differentiation 
of mouse ESCs to glutamatergic neurons (Hubbard et al., 2013) (Figure 4.2A). To be more 
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quantitative, we counted the number of exons with significant developmental splicing changes at 
different time points in each subtype of neurons by pairwise comparison (|ΔΨ|≥0.2 and 
FDR≤0.05). This analysis confirmed a large number of early-switch exons (M2) showing 
differential splicing in the cPNs and ESC-derived glutamatergic neurons, and changes of both 
M1 and M2 exons in motor neurons, depending on the compared time points (Figure 4.2B). 
Importantly, among M1 and M2 core module exons also showing monotonic splicing changes in 
each subtype of neurons, 92-94% have concordant changes in the same direction between the 
cortex tissue and the specific subtype of neurons. Taken together, our analysis revealed a pan-
neuronal splicing program that characterizes rich dynamics shared by both in vivo and in vitro 
neuronal maturation processes. 
 
Prediction of maturation stages of different subtypes of neurons derived in 
situ or in vitro 
Using the cortex tissue samples as a reference, we developed a computational method and 
software tool named Splicescope (http://splicescope.splicebase.net) to model the splicing profile 
of any neuronal sample and assign it to one of six maturation stages (stage 1-6) corresponding to 
the cortex reference at E14.5, E16.5, P0, P4, P7, and P15 or older, respectively. In combination 
with 2-dimensional projection, such analysis provides an effective summary and visualization of 
the developmental trajectory of splicing profiles.  
We initially applied Splicescope to the splicing profiles of 92 distinct neuronal samples 
(merged from 277 biological or technical replicates from 28 studies; Figure 4.4). These include 
41 tissue samples derived from the developing CNS (e.g., different brain regions, different 
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cortical laminae, and the spinal cord), 20 samples of specific subtypes of neurons purified from 
mice at different ages, and 31 samples representing different neuronal subtypes or their 
progenitors differentiated from stem cells. Among the 56 tissue or neuronal subtype samples 
with known ages, Splicescope assigned the exact stage for 45 samples (80%). An additional 9 
samples (16%) were assigned to the neighboring stage and were also considered correct 
predictions because of the ambiguity in determining the true stage when the age is between those 
of two reference samples. Therefore, Splicescope achieved an overall accuracy of up to 96% in 
predicting neuronal maturation stages. Importantly, several misclassifications can be explained 
by heterogeneity of different cell subpopulations due to neuronal migration and maturation (e.g., 
different germinal zones of embryonic brains) or unusual characteristics of certain neuronal 
subtypes (e.g., spinal motor neurons, which mature earlier than cortical neurons (Gotz and 
Huttner, 2005); Figure 4.4).  
For neurons differentiated from ESCs in vitro, samples at later time points of 
differentiation were predicted to be more mature than samples at earlier time points, as expected 
(Figure 4.4). It is also important to note that the ESC-derived neurons, even after extended 
culture to promote maturation, only reach a predicted maturation stage of 4 or 5, which 
correspond to P4 and P7 in the cortex, respectively. This is consistent with the observed partial 
splicing changes of late-switch exons (Figure 4.2 right panel), and reflects the technical 
challenge of obtaining fully mature neurons through in vitro differentiation. This analysis 
confirmed that the modular organization of developmental splicing profiles represents a “pan-
neuronal” program underlying a variety of neuronal subtypes and origins, which reflects and 




Figure 4.4. Prediction of neuronal maturation stages based on splicing profiles using Splicescope. 
Principle component analysis (PCA) of splicing profiles in the cortex reference was used to project high-
dimensional data into a 2D space for visualization. Different types of samples are indicated by different marker 
shapes with border color representing the predicted maturation stage using a regression model and filled color 
representing the true stage (when available).  The reference cortex samples are shown in large filled circles with 
color representing the developmental stage.  Highlighted are spinal motor neurons isolated from  E12.5, P1 and adult 


























































Figure 4.5. A set of tissue- or neuron-specific RBPs regulates the timing of developmental splicing 
switches. 
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Mbnl1/2.  RPKM values are normalized based on the maximum expression value in each family separately and 
shown in color scale.  B. Integrative modeling to define the target alternative exons regulated by each RBP family. 
The Venn diagram summarizes target exons regulated by each RBP family.  Note 11 exons regulated by all four 
RBP families and an additional 58 exons regulated by three RBP families. C. Regulation of WGCNA module exons 
by each of the four RBP families.  Activation and repression of an exon by each RBP resulting from integrative 
modeling analysis are indicated in red and blue, respectively.  The total number of regulators for each exon is shown 
in the bar on the right in gray scale (the darker, the more regulators). D-F. Gabrg2 exon 9 as an example in module 
M1 under combinatorial regulation by all four RBP families. The exon inclusion level in developing cotex is shown 
in (D) and changes upon depletion of Ptbp2 (P0) and Mbnl1/2 (adult) are shown in (E).  Inclusion of the exon in 
wild type (WT) and mutant (MUT) splicing reporters, in combination with overexpression of different RBPs, is 
shown in (F).  Rbfox and Mbnl binding site sequences are shaded.  RBP expression and exon inclusion were 
measured by immunoblot and RT-PCR, respectively. G. RBPs either antagonize (Ptbp2) or facilitate (Nova, Rbfox 
and Mbnl) the mature splicing pattern through activation or repression of exon inclusion. H. Time of the maximal 
splicing switch for target exons regulated by specific RBPs (*p<0.05, **p<0.001, t-test). Only exons showing a 
more mature (for Ptbp) or embryonic (for Nova, Rbfox and Mbnl) pattern upon RBP depletion were included for 
this anlaysis. I. Prediction performance of exon module membership based on regulation by each RBP family.  The 
probability of activation or repression as output by the Bayesian network analysis was used to predict early and late 
splicing switches, as well as the direction of switches (e.g., how well activation by Mbnl predicts M1+ exons from 
the remaining cassette exons).  The performance is measured by partial area under curve (pAUC) of the receiver 
operating characteristic (ROC) plot with a cutoff at false positive rate (FPR)≤0.1. J. Changes of predicted 
maturation stages of mouse brain tissues upon depletion of RBPs. 
 
Regulation of early and late splicing switches by distinct RBPs 
We next sought to elucidate the regulatory mechanisms that control the early and late splicing 
switches we observed in the developing CNS. Our initial analysis was focused on four families 
of tissue- or neuron-specific RBPs including Rbfox, Nova, Mbnl, and Ptbp. These RBPs have an 
established role in regulating tissue- or development-specific splicing (Charizanis et al., 2012; Li 
et al., 2014; Licatalosi et al., 2012b; Weyn-Vanhentenryck et al., 2014; Zhang et al., 2010), but 
the temporal specificity of such regulation and their contribution to neuronal maturation stages 
have not been determined. The choice of these RBPs is supported by their dynamic expression 
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changes during neural development (Figure 4.5A). Furthermore, binding motifs of these RBPs 
are enriched in flanking intronic sequences of the core module exons in M1 and M2, which is 
evident from de novo motif analysis, as well as analysis of established consensus sequences 
recognized by each RBP.  
To investigate their contribution to establishing the embryonic or mature splicing 
program, we defined target exons regulated by the four RBP families with high specificity and 
sensitivity, which were conservatively estimated to be 95-98% and 57-78%, respectively, using 
our established integrative modeling approach (Weyn-Vanhentenryck et al., 2014; Zhang et al., 
2010) (Figure 4.5B). An important feature of this approach is that it integrates altered splicing 
upon RBP depletion, direct protein-RNA interaction sites and additional genomic information to 
ensure that the identified target exons are directly regulated by the RBP under investigation. We 
found that these exons are disproportionally enriched in specific modules, especially among core 
members (Figure 4.5C); overall, 36% of module exons (or 50% of core members) are regulated 
by at least one of these RBPs, compared to 9% of all known cassette exons (p<2.2×10-16 in both 
cases; hypergeometric test). Among them, ~12% of module exons are regulated by more than 
one of the four RBP families, including 10 of the 11 exons regulated by all four families.  
To demonstrate the accuracy of the networks, we focused on GABA receptor gamma 2 
subunit (Gabrg2) exon 9, whose inclusion was previously reported to be altered in schizophrenic 
brains (Huntsman et al., 1998). In developing cortex, inclusion of the exon increases gradually 
between P4 and P30 (Figure 4.5D). We previously showed that this exon is activated 
synergistically by Nova and Rbfox (Zhang et al., 2010). Our new data suggest that the same exon 
is also repressed by Ptbp2 and activated by Mbnl1/2, and depletion of the RBPs individually 
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resulted in dramatic splicing changes (Figure 4.5E). The two Ptbp binding sites consisting of 
clustered UCUY elements we predicted were previously validated to be important for Ptbp-
dependent splicing using in vitro binding and splicing assays (Ashiya and Grabowski, 1997). 
Intriguingly, simultaneous overexpression of Nova, Rbfox and Mbnl in 293T cells, which have 
undetectable or low endogenous expression of these RBPs, resulted in dramatically increased 
inclusion of the exon in a splicing reporter, and the effect is much stronger than the activation by 
each individual or pair of proteins. This synergistic activation is due to direct regulation, as it 
was abrogated by mutation of the newly-identified Mbnl binding site, which is located four 
nucleotides downstream of the Rbfox binding site (Figure 4.5F).  
We found that Mbnl, Rbfox and Nova promote the mature splicing pattern of 
developmentally regulated exons in the vast majority (80-96%) of cases, while Ptbp mostly 
suppresses the mature splicing pattern (80% of cases), confirming and extending previous studies 
(Charizanis et al., 2012; Li et al., 2014; Weyn-Vanhentenryck et al., 2014) (Figure 4.5G). 
Importantly, targets of these RBPs show splicing switches at different times. Nova and Ptbp2 
targets tend to switch early (~P0), Mbnl targets predominantly switch late (~P7 or older), and 
Rbfox targets switch in between, which agrees well with the expression pattern of these RBPs 
(Figure 4.5H). Consistently, activation or repression of exon inclusion by these RBPs is 
predictive of an exon’s module and direction of developmental splicing changes (Figure 4.5I).  
Based on these observations, we built a variant of Splicescope which allows the 
prediction of neuronal maturation stages using only the splicing profiles of a subset of exons. We 
used this feature to assess the contribution of each RBP to specific stages of neuronal maturation, 
as evaluated by the overall splicing profile or the target exons an RBP directly regulates. 
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Analysis of RNA-seq datasets upon RBP depletion using the full Splicescope model shows clear 
shifts along the maturation trajectory based on the overall splicing profile (Figure 4.5J), 
suggesting that these RBPs have global impacts on neuronal maturation. Importantly, the shift is 
even more pronounced when we used the RBP-specific Splicescope models (Table 4.1). For 
example, depletion of Mbnl1/2 in adult mouse brain results in a shift from stage 6 to stage 5 
(corresponding to P7) based on the overall splicing profile, but to stage 4 (corresponding to P4) 
when only target exons directly regulated by Mbnl were used for analysis. Similarly, although 
Nova depletion results in a more embryonic splicing profile overall, the magnitude is not large 
enough to change the predicted maturation stage when using the full model; in contrast, the 
maturation stage shifted from 3 (corresponding to P0) to 1 (corresponding to E14.5) when only 
direct Nova targets were used for analysis. In combination with the specific enrichment of RBP 
targets in early or late switch exons, these data suggest an instrumental role for Ptbp, Nova and 
Rbfox in regulating early splicing switches and for Mbnl in regulating late splicing switches 
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Emx_nPTB_WT P1 3 3 3 3 3 3 
Emx_nPTB_KO  P1 3 4 4 3 3 3 
Nes_nPTB_WT P0 3 4 3 3 4 4 
Nes_nPTB_KO  P0 3 4 4 3 4 4 
Nova2_WT E18.5 3 2 3 3 3 3 
Nova2_KO E18.5 3 2 2 1 2 2 
Mbnl_WT Adult 6 6 6 6 6 6 
Mbnl_dKO  Adult 6 5 5 4 5 4 
Table 4.1. Predicted maturation stages of WT and RBP KO brains using the overall splicing profile 
or exons regulated by specific RBPs. 
 
A combinatorial developmental splicing code predicting early and late 
splicing switches 
To obtain optimized prediction of the timing of developmental splicing changes based on 
regulatory mechanisms, we developed random forest-based classification models (Breiman, 
2001) to predict exons with early and late splicing switches in modules M1 and M2 from all 
cassette exons. This analysis allowed us to compare and integrate the contribution of a large 
number of features related to splicing regulation including general splicing signals, regulation by 
the four RBP families that we focused on, and many additional RBPs. In addition, such models 




Figure 4.6. A neurodevelopmental splicing code predicts early and late splicing switches.  
A. Performance of prediction as measured by AUC.  Four models were trained to predict exons in modules M1 and 
M2.  Exons with increased inclusion or exclusion were predicted by separate models.  Different sets of features were 
used to build models. B. Importance of RBP motifs for prediction in each model.  Motif sites in the upstream intron 
(UI), exon (E) and downstream intron (DI) were scored separately.  Only motifs ranked among the top 100 features 
in at least one region are shown.  Motifs enriched in specific regions are shown in red and motifs depleted are shown 
in blue. c, Summary of prediction results for exons in module M4 indicating that the two developmental splicing 
switches of these exons can be predicted separately. 
 
The full models achieved high accuracy in prediction (area under ROC curve or AUC 
between 0.87 and 0.92; Figure 4.6A, the “All features” models). The models are less predictive 
when only sequence-based features were used (i.e., RNA-seq and CLIP data were excluded; the 
“Seq_all” models). Notably, the models constructed only using features related to the four RBP 
families (RBP4) we focused on achieved similar performance to the full models, suggesting 
limited extra information provided by motif sites of many additional RBPs. These results 
strongly suggest that the four RBP families are key players of the developmental splicing 
program to specify the precise timing, although lack of significant contribution from additional 





















M1+ M1- M2+ M2-
M4+ 0 8 10 1
M4- 5 1 0 10
Motif RBP Family M1+ M1- M2+ M2-
UI E DI UI E DI UI E DI UI E DI
GCUUGC MBNL1 (Hs) MBNL
AKGAVMR SRSF9 (Hs) SRSF9
UGUGDKG BRUNOL6 (Hs) CELF
VAAGAA TRA2 (Dm) TRA2A/B
ARAAGA PABPN1 (Hs) PABPN1
RAUSAWD RBM46 (Hs) RBM46
WGCACA CPO (Dm) RBPMS
MYAUUUU ROX8 (Dm) TIA1
WGCAUGM RBFOX1 (Hs) RBFOX
(U)GCAUG Rbfox (MECS) RBFOX
UWGCAC SNF (Dm) SNRPB2
MAUCUUR MATR3 (Hs) MATR3
WGCAUG EIF.2ALPHA (Dm) EIF2S1
UUDUUUU HuR (Hs) ELAVL
UUUDUUU ZC3H14 (Hs) ZC3H14
KKUDUGU ETR-1 (Ce) CUGBP
[YCAY]n Nova (mCarts) NOVA
[YGCY]n Mbnl (mCarts) MBNL
UUUYCC PCBP3 (Mm) PCBP3
[UCUY]n Ptbp (mCarts) PTBP
AUCAHG SNRNP70K (Dm) SNRNP70
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When we ranked sequence features based on their importance for prediction, the RBP4 motif 
sites are indeed among the top. Nevertheless, we also identified additional motifs, including U-
rich and UG-rich elements, which resemble binding sites of Elavl, Celf and nSR100 RBP 
families (Figure 4.6B). Indeed, depletion of Elavl3/4 (ref. (Ince-Dunn et al., 2012)) or nSR100 
(ref. (Quesnel-Vallieres et al., 2015)) led to specific impairment in M2 exons (Figure 4.7), 
suggesting that they are also part of the early splicing switch regulatory program, although 
detailed analysis of their contribution was not pursued in this study due to the limited number of 
datasets currently available for integrative modeling.  
 
Figure 4.7. Additional neuronal RBPs contributing to early splicing switches.   
A. Activation or repression of module exons by Elavl3/4 and nSR100.  Elavl3/4-dependent exons were identified by 
comparison of WT and Elavl3/4 dKO mouse cortices using exon-junction microarrays (Ince-Dunn et al.; |ΔIRank|≥
6.5).  nSR100 (SRRM4)-dependent exons were identified by comparison of WT and nSR100 KO mouse hippocampi 
using RNA-seq (|ΔΨ|≥0.1, Benjamini FDR≤0.05). B. Similar to Fig. 4j in the main text.  Prediction performance of 
exon module membership based on regulation by each RBP family.  Activation or repression by each RBP as 
determined from exon-junction microarrays or RNA-seq was used to predict early and late splicing switches, as well 
as the direction of switches.  The performance is measured by partial area under curve (pAUC) of the receiver 






















We also note that although our models were trained on exons with monotonic splicing 
changes and each model predicts only a single splicing switch, combinations of the models are 
predictive of more complex splicing patterns such as those in module M4. For example, M4+ 
exons are predicted to exhibit both early switch on (by the M2+ model) and late switch off (by 
the M1- model) while the opposite is true for M4- exons (Figure 4.6C; P<0.002, Fisher’s exact 
test). This observation suggests that these non-monotonic splicing changes result from 
independent regulatory events with the opposite direction. 
 
A unique splicing-regulatory program in the peripheral and sensory system 
We next investigated whether the pan-neuronal splicing program inferred from the brain is also 
shared by different types of neurons in the more peripheral nervous system, including those 
involved in sensation. For this analysis, we compiled RNA-seq data of 10 in-vivo purified 
samples representing 7 different neuronal subtypes. These include three types of sensory neurons 
(olfactory sensory neurons (OSN), rod and cone photoreceptors) and four types of sensory 
ganglions (dorsal root ganglion (DRG), trigeminal, jugular, and nodose ganglions). For 
comparison, we also included three types of sensory receptors in the gut and taste bud, which are 
non-neuronal cells, but nevertheless possess certain properties resembling sensory neurons, such 
as the enterochromaffin cells(EC) and taste receptor cells(TRC) are electrically excitable and can 
express voltage-gated ion channels; four types of CNS neurons isolated from the mouse brain 
were used as control. While all these samples represent mature cells or neurons derived from 
adult mice, we very unexpectedly observed the four categories of cell types in four distinct 
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clusters when Splicescope analysis was applied to determine their maturation stages (Figure 
4.8A).  
	
Figure 4.8. Distinct regulation of early-switch exons in mature peripheral and sensory neurons. 
A. The PCA scatter plot of splicing profiles in different subtypes of neurons isolated from adult mice. The circles 
represent the cortex reference samples and the triangles represent the four catorgries of cell types: non-neuronal 
sensory receptors, sensory neurons, sensory ganglion neurons and mature CNS neurons.  Samples are colored by the 
predicted maturation stage. B. The splicing profile of module exons in peripheral and sensory neurons, in 
comparison with non-neuronal sensory receptors and mature CNS neurons. Exons are shown in the same order as in 
the cortex reference. C. Expression levels of the four RBP families we focused on in our analysis as quantified by 
RNA-seq data.  Note the high abundance of the Mbnl and Ptbp families and lack of Nova1/2 in PNS sensory 
neurons.  Rbfox1-3 are absent or low in sensory neurons, but expressed in ganglion neurons. D. 
Immunofluorescence analysis of Rbfox1-3 expression in OSNs.  Red, Calmegin is a marker of mature OSNs; green, 
Rbfox; blue, DAPI staining the DNA.  Scale bar: 20 µm. E. Maturation stages of different types of neurons 
predicted using the overall splicing profile or target exons of each RBP family. F, The proposed model that explains 
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While correct maturation stages were assigned to all CNS neuronal subtypes (Bandyopadhyay et 
al., 2013; Brichta et al., 2015; Mellen et al., 2012), we found that sensory receptor and sensory 
neurons were predicted to be very immature. For example, olfactory sensory neurons (OSNs) 
were predicted to be in stage 1 (very immature), which was remarkable especially in light of the 
fact that the OSN samples used in this study were isolated by FACS using an olfactory marker 
protein (OMP) reporter (OMP is a marker of mature OSNs) from 3 week or 25 week old mice by 
two independent labs (Colquitt et al., 2014; Saraiva et al., 2015). The sensory ganglion neurons 
also deviate substantially from the adult cortex samples and the mature CNS neurons, although 
in this case they were still predicted as stage 6 of maturity.  
Given the pronounced difference of the maturation trajectory for the different cell types, 
we performed more detailed comparison of their splicing profiles. Strikingly, the sensory 
receptors, sensory neurons and ganglion neurons (denoted sensory cells; see Discussion) differ 
from mature CNS neurons in that their early-switch exons in module M2 retain the very 
immature splicing pattern. In contrast, all cell types show more similar adult splicing patterns 
among the late-switch exons in module M1 (Figure 4.8B). Quantitatively, among the M2 exons 
differentially spliced in sensory cells compared to mature CNS neuron subtypes, 88-98% of 
exons show an immature splicing pattern. In contrast, the M1 exons differentially spliced 
between sensory cells and CNS neurons showed much smaller bias (65-81%) towards the 
immature splicing pattern, and the magnitude of the differences is also much less pronounced. 
Therefore, neuronal subtypes in the peripheral and sensory system retain an immature splicing 
program specifically in early-switch exons, but show more or less mature splicing patterns for 
late-switch exons. This “chimeric pattern” is distinct from the CNS neuronal splicing profiles at 
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either embryonic or mature stages. To obtain functional insights into this distinct molecular 
program, we performed GO analysis using exons differentially spliced in sensory cells. This 
analysis revealed significant enrichment of genes involved in synapse, cell projection and neurite 
outgrowth and cell-cell junction.  
 
Figure 4.9. Only specific RBPs show distinct expression in peripheral neurons compared to other 
subtypes of neurons. 
A. Expression of RBPs (log2 transformed, median centered RPKM values) across different tissue or neuronal 
samples was used in the analysis.  This analysis included all RBPs compiled in RBPDB 
(http://rbpdb.ccbr.utoronto.ca).  The same list of 317 samples used to predict maturation stages (Supplementary 
Table 1) was analyzed.  Samples were ordered by the predicted maturation stage, and RBPs were ordered by the 
correlation of their expression with the predicted sample maturation stages.  PNS sensory neurons are highlighted. 
B. Differential expression analysis of RBPs in each category of sensory cells compared to other subtypes of CNS 
neurons purified from adult mice.  The Benjamini FDR (in log2 scale) with sign indicating the direction of 
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Nova1 (top) and Rbfox2 (bottom) expression in P4 mouse spinal cord using in situ hybridization.  Data were 
obtained from Allen Brain Atlas (http://mousespinal.brain-map.org).  In the spinal cord, gray matter and white 
matter are indicated due to neuron-specifix or enriched expression of Nova and Rbfox2.  Probes for Nova2 and 
Rbfox1/3 are not available.  SC, spinal cord; DRG, dorsal root ganglion; WM, white matter; GM, gray matter. Scale 
bar: 100 µm. 
 
We asked whether the regulatory program by neuronal RBPs we analyzed can explain the 
distinct splicing profiles in neuronal subtypes from the peripheral and sensory system. 
Intriguingly, although these RBPs are expressed abundantly in most CNS neuronal subtypes, we 
found no expression of Rbfox1/3 or Nova1/2 (and only a low level of Rbfox2) in sensory 
neurons, and no or very low expression of Nova1/2 in sensory ganglion neurons (Figure 4.8C 
and 4-9a,b). In addition, all these cell types abundantly express Mbnl and Ptbp family members 
at a level comparable to or higher than the CNS neuronal subtypes. To confirm these 
observations, we examined OSNs by performing immunofluorescence analysis of olfactory 
epithelium dissected from adult mice using antibodies recognizing each Rbfox family member. 
Indeed, mature OSNs (labeled by Calmegin) completely lack immunoreactivity with the 
Rbfox1/3 antibodies while a moderate expression of Rbfox2 is detectable (Figure 4.8D), 
confirming the RNA-seq data in single cells at the protein level. Furthermore, the low expression 
of Nova1 is confirmed using Allen Brain Atlas in situ hybridization data in P4 DRG (Figure 
4.9C; no Nova2 probe is available). On the other hand, no global deviation was observed in 
expression of the 372 assayed RBPs in the peripheral and sensory neurons compared to mature 
CNS neurons or adult cortical tissues (Figure 4.9A,B).  
Given the distinct RBP expression pattern in different neuronal subtypes, we predicted 
their maturation stages using only the splicing profile of target exons regulated by each RBP 
family. For sensory neurons, using only the target exons of Ptbp, Nova or Rbfox individually 
  
108 
resulted in prediction of very immature stages (stage 1 or 2), while using Mbnl targets resulted in 
prediction of stage 5. For sensory ganglion neurons, using Nova targets gave a maturation stage 
of 1, while using the targets of other RBPs including Rbfox proteins, which are abundantly 
expressed in DRG, all resulted in prediction of stage 5 or 6 (Figure 4.8E). These data suggest a 
model whereby sensory neurons have insufficient expression of “pan-neuronal” RBPs (Nova 
and/or Rbfox) to promote the mature splicing pattern of early-switch exons but overwhelming 
abundance of suppressors (Ptbp), which together results in retention of an immature splicing 
program. Sensory ganglion neurons show an intermediate state for early-switch exons because of 
expression of Rbfox but not Nova. On the other hand, the abundant expression of Mbnl is largely 
sufficient to promote the mature splicing pattern of late-switch exons in all neuronal subtypes we 
examined (Figure 4.8F).  
To validate the proposed model, we used rat embryonic primary DRG neuronal culture to 
test whether exogenous Nova expression in this system is sufficient to promote the mature 
splicing pattern of early-switch exons as observed in CNS neurons. For this purpose, we 
generated a lentivirus which expresses a Nova1-GFP fusion protein (Figure 4.10A). 5 days post 
infection of dissociated DRG neurons with the Nova-GFP expressing lentivirus, but not with the 
GFP (Mock) expressing lentivirus, we detected robust expression of Nova at the mRNA and 
protein levels (Figure 4.10B, C). Similar to the subcellular localization of the endogenous Nova 
protein in CNS neurons, Nova-GFP shows a predominant nuclear localization in DRG neurons, 
which is required for splicing regulation. We then examined splicing of five Nova target exons 
we identified previously (Zhang et al., 2010) with and without Nova over-expression. For all 
these cases, the exon inclusion level is high in WT mouse cortex, and is dramatically reduced 
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upon Nova2 depletion, suggesting Nova is essential to activate exon inclusion; all these exons 
show low inclusion in DRG sensory neurons, similar to the Nova2 KO cortex, presumably due to 
lack of Nova expression. Importantly, in all five tested cases, we found that introduction of Nova 
is sufficient to switch the splicing to the mature pattern as observed in the WT cortex (Figure 
4.10D).  These data confirmed that lack of Nova is essential to maintain the “embryonic” 
splicing pattern for a subset of early switch exons in DRG sensory neurons. 
	
Figure 4.10. Overexpression of Nova in DRG neurons promotes the “mature” splicing pattern 
observed in CNS neurons.  
A. Schmatic illustrating overexpression of Nova1 in rat primary DRG neuronal culture using a Nova1-GFP 
expressing lentivirus. A GFP-expressing lentivirus is used as a Mock control.B. q-RT-PCR of Nova1 mRNA 
expression level in DRG neurons transduced with Nova1-GFP or GFP  expressing lentiviruses.  The average relative 
expression level normalized to Mock transduced cells is shown.  Error bars represent standard deviation (n=3). C. 
Immunostaining of primary rat DRG neurons transduced with Nova1-GFP or GFP expressing lentiviruses. NOVA1 
protein has predominant nuclear localization.  Scale bar 50 µm.  The insert shows the zoom-in view of the cell. D. 
Changes in the alternative splicing of Nova target exons upon Nova1 overexpression in rat primary DRG neurons.  





























































RNA-seq, is shown in the barplot on the left.  Error bars represent the standard deviation (n≥3).  A representative gel 
image on the right shows inclusion of the alternative exon in Mock and Nova1 transduced cells detected using RT-




Coordinated regulation of gene expression at multiple levels dictates the numerous 
morphological and functional changes that occur at specific stages of neuronal development. 
Previous studies revealed a large number of AS changes in the developing brain, but the 
temporal resolution of these studies is low and the underlying regulatory mechanisms are 
elusive15,16,18. This work represents the first comprehensive analysis of the precise timing of 
dynamic splicing regulation during neuronal development on a global scale.  
Our analysis uncovered two major waves of splicing switches that occur in the mouse 
brain around birth and in the first two postnatal weeks. We focused on a time window after 
completion of neurogenesis, and thus the bulk of the observed splicing switches occur during 
neuronal maturation and likely contribute to this important process. The developmental splicing 
changes can be driven by intrinsic factors (such as a genetic program controlling dynamic 
expression of splicing factors) or extrinsic factors (such as changes in neuronal activity or 
connectivity that indirectly affects expression of splicing factors), and these two mechanisms do 
not have to be mutually exclusive (see Discussion below).  
A majority of the developmental splicing switches are monotonic and preserve the 
reading frame, suggesting that exon inclusion or skipping would generate specific protein 
isoforms in the adult brain relevant for the establishment and maintenance of homeostasis in 
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mature neurons. This hypothesis is supported by the observation that genes with early and late 
splicing switches have very distinct functions that are consistent with the cellular events that 
occur at the corresponding developmental stages. Interestingly, we also noticed that 
developmentally regulated exons more frequently have increased inclusion, as opposed to 
increased skipping (Figure 4.1A), so that in a majority of cases an additional peptide would be 
introduced into the protein product in mature neurons. The functional implication of this 
asymmetry is currently not clear, but it might be relevant for certain unique properties of the 
neuronal proteome. For example, phosphorylation sites, which play important roles in signal 
transduction, are enriched in peptides encoded by neuron-specific exons (Zhang et al., 2010). 
Analysis of a large panel of neuronal samples from diverse origins, including different 
subtypes of neurons purified in situ or differentiated in vitro suggests that the modular 
organization of the developmental splicing profiles we initially identified in cortical tissues 
reflects a pan-neuronal program in the CNS. At the tissue level, developmental splicing changes 
are much more dramatic than regional variations in different parts of the brain (refs.(Thompson 
et al., 2014) and data not shown). With regard to cellular heterogeneity (in a particular brain 
region), while some developmental splicing changes observed in brain tissues might occur in 
non-neuronal cells such as glia, neurons have a particularly large number of cell type-specific 
alternative exons (Yan et al., 2015; Zhang et al., 2014), and the inclusion of these exons must be 
established during development. Indeed, purified neurons of specific subtypes such as cortical 
pyramidal neurons and spinal motor neurons exhibit similar developmental splicing changes as 
compared to developing cortical tissues. Interestingly, when we examined specific types of glial 
cells at different developmental stages (e.g., myelinated mature oligodendrocytes vs. newly 
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formed oligodendrocytes (Zhang et al., 2014)), we did not observe systematic developmental 
splicing changes on a global scale.  
This study suggests a new dimension to the role of tissue-specific splicing factors in 
regulating the timing of developmental splicing switches and in defining neuronal maturation 
stages. Multiple neuron-specific RBP families including Nova, Rbfox and Ptbp, potentially 
combined with additional RBPs such as Elavl, Celf and nSR100, regulate early splicing switches, 
sometimes in a synergistic manner (Figure 4.5D-F). On the other hand, we have so far only 
identified Mbnl and, to some extent, Rbfox as major regulators of late splicing switches on a 
global scale. Together, we found that regulation of splicing by these RBPs can predict the timing 
of splicing switches with high accuracy. Although one would expect that such prediction might 
also be made from the steady-state mRNA level, due to coordinated regulation of gene 
expression at multiple levels, splicing-based prediction can provide critical insights into neuronal 
maturation that cannot be obtained by analysis of the steady-state mRNA level. This argument is 
particularly relevant because mutations in RBPs, including the ones we focused on, have been 
implicated in several neurological disorders (Scotti and Swanson, 2016). For example, 
sequestration of MBNL by repeat RNA expansion containing its binding sites is the cause of 
myotonic dystrophy, which manifests as global defects in splicing and polyadenylation in the 
muscle and in the CNS but only moderate gene expression changes (Charizanis et al., 2012; Du 
et al., 2010). Mutations in the Rbfox1,2, and 3 genes have been found in human patients with 
several neurodevelopmental or neurological disorders, including autism, schizophrenia and 
epilepsy (Conboy, 2017). In a recent study, we investigated the function of Rbfox during 
neuronal maturation by generating Rbfox1-3 triple knockout mouse ESCs, which were 
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differentiated into spinal motor neurons. These neurons retain an embryonic neuron-like splicing 
program, and the abnormality causes defects in neuronal electrophysiology that is normally 
established during neuronal maturation (Jacko et al., under revision). Interestingly, we found 
dramatic disruption in developmental splicing switches with very few changes at the steady-state 
mRNA level.  It also worth noting that these RBPs might link neuronal maturation and activity 
discussed above at the molecular level. It was previously reported that neuronal depolarization 
can induce expression of different Rbfox splice variants with preferable nuclear or cytoplasmic 
localization, leading to further changes in their downstream target exons (Lee et al., 2009). In 
similar experiments, we observed expression changes in Mbnl and Ptbp and correspondingly 
switch of their target exons to a specific direction (Qian et al. unpublished observation).  
One of the most surprising findings of this study is that multiple types of neurons from 
the peripheral and sensory system exhibit a distinct splicing program compared to CNS neurons 
in the brain in the set of early-switch exons, despite them functioning as mature neurons. This 
distinct splicing program is presumably because peripheral and sensory neurons do not express at 
least a subset of “pan-neuronal” RBPs including Rbfox and Nova; consequently, exons directly 
regulated by these RBPs do not undergo developmental splicing switches in these cell types, as 
one would expect from CNS neurons in the brain. We were able to validate the model by 
introduction of Nova into primary rat DRG neurons, which is sufficient to promote the mature 
splicing pattern of early switch exons as observed in CNS neurons.  
Why peripheral and sensory neurons have a distinct splicing program compared to CNS 
neurons in the brain? One hypothesis is that this molecular distinction could reflect the different 
embryonic origins of these cell types. The difference of CNS neurons and non-neuronal sensory 
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receptors in the splicing profile is not surprising given that the CNS neurons are originated from 
neural plate, while latter derive from epithelial cells of non-neurogenic origin. The 
“intermediate” profile of sensory neurons and sensory ganglions is very intriguing, because they 
arise from either the pre-placodal region or neural crest, which were derived from a zone of the 
ectoderm that borders the neural plate, or neural border (St-Jeannet and Moody, 2014). For 
example, OSNs in the olfactory epithelium originate from cranial olfactory placode region 
developing from the neural plate border (Graziadei and Monti Graziadei, 1985), the DRG 
sensory neurons develop from neural crest, and the trigeminal ganglion is thought to differentiate 
either from neural crest and the trigeminal placodes (Gans and Northcutt, 1983; Lopes et al., 
2017). Importantly, the pre-placodal region and neural crest remain in close proximity to the 
neural plate and subsequently coordinated throughout the development (Steventon et al., 2014). 
This common embryonic origin could provide one explanation for the intermediate splicing 
program in the sensory neuron and ganglion neuron populations. One might find the immature 
splicing pattern of rod and cone photoreceptors might not easily fit into the model, because 
photoreceptors are derived from optic vesicle originating from the neural plate. However, 
photoreceptors are very specialized neurons distinct from the “canonical” CNS neurons in that 
the optic vesicle originate from the “outgrowth” of the developing brain and it interacts with the 
lens placode in proximity, which could induce morphological and molecular level changes in 
both tissues during retina development (Lamb et al., 2007). 
Alternatively, the distinct molecular program in the peripheral and sensory neurons might 
have evolved to adapt to certain unique cellular properties of these cell types, such as the 
capacity of regeneration and plasticity. The mammalian CNS neurons in general have limited 
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capabilities of self-repair and regeneration upon maturation, while the peripheral neurons are 
more regenerative (He and Jin, 2016). For example, the continuous renewal of OSNs that 
reestablishment of the neural projection to the olfactory bulb is an salient feature of the olfactory 
system (Graziadei and Graziadei, 1979). Furthermore, the sensory ganglions neurons, such as 
DRG sensory neurons, can also regenerate their axons spontaneously after peripheral nerve 
injury, which activate their intrinsic growth capacity (Liu et al., 2011). Decades of efforts have 
been made to identify genes and signaling pathways that underlie the difference of CNS and 
peripheral neurons in their intrinsic growth capacity, with the hope that such knowledge can be 
leveraged to enhance the regenerative capability of CNS neurons. These include recent efforts to 
identify differential gene transcriptional programs involved in axonal regeneration (Chandran et 
al., 2016; Dulin et al., 2015; Tedeschi et al., 2016), but analysis beyond transcriptional regulation 
is more limited thus far. The distinct splicing program of peripheral and sensory neurons we 
identified might inform molecular pathways related to neuronal regeneration. Consistent with 
this notion, it was previously noted that Rbfox3 is transiently downregulated in motor neurons 
upon axotomy and recovery of the expression level correlates with peripheral axonal 
regeneration and muscle reconnection (Alvarez et al., 2011). Based on our results, reduction of 
Rbfox expression would potentially lead to a more immature splicing program in the injured 
neurons. In the same vein, we found that Ptbp1 is up-regulated in DRG sensory neurons with 
axon regrowth after sciatic nerve lesion (Chandran et al., 2016), and its expression also highly 
correlated axonal growth length of injured DRG sensory neurons in several genetically modified 
mouse strains (Omura et al., 2016).  We note that photoreceptors, like the other CNS neurons, in 
general have very limited regenerative capabilities in mammals. However, it is intriguing that 
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photoreceptors can readily regenerate in lower vertebrates such as fish upon injury (Wan and 
Goldman, 2016). It is possible that the overall molecular program relevant for retinal 
regeneration might be preserved in mammals during evolution, despite the inactivation of the 
regenerative pathway due to alterations in certain key factors (Barbosa-Sabanero et al., 2012).  
Finally, the distinct molecular program of in the peripheral and sensory neurons might 
reflect their plasticity to respond to the environmental stimuli. Compared to CNS neurons, the 
level of synaptic turnover from mature OSN presynaptic region is significantly greater than that 
of excitatory synapses in other regions of the adult brain (Holtmaat and Svoboda, 2009). In 
addition, the synapses of OSNs undergo rapid and continuous structural remodeling to rewire the 
connectivity with neurons in the olfactory bulb (Cheetham et al., 2016). While DRG sensory 
neurons maintain the ability to regenerate after injury by switching axon regrowth to new 
synaptic formation, the suppression of synaptic formation and stability could affect axon 
elongation and impair regeneration in the adult CNS (Tedeschi et al., 2016). The different 
splicing program we observed could reflect the distinct features of synaptogenesis along with 
regeneration between sensory neurons and mature CNS neurons. Interestingly, the genes with 
differentially spliced exons in peripheral and sensory neurons as compared to mature CNS 
neurons are highly enriched in GO terms such as “synapse”, “cell projection” and “cell junction”, 
which can be connected to the potential synaptogenesis in the more peripheral and sensory 
system during renewal or after injury.  
Taken together, our analysis warrants further investigation to explore the distinct splicing 
pattern of neurons in the peripheral and sensory system, which might shed light onto the 
molecular mechanisms underlying intrinsic capacity of regeneration, plasticity and function.  
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Chapter 5. Regulation of novel alternative exons 
Introduction 
As described above, we identified 64,450 non-redundant novel cassette exon events, many of 
which are highly conserved and regulated in a cell-type specific manner. In order to achieve this 
regulation, and in order to be biologically relevant, it is likely that a subset of these events are 
carefully regulated. To that end, we aimed to extend our regulatory analysis to these novel 
splicing events. We applied our Bayesian network integrative framework, described above, to 
identify exons that are likely under strong regulation by one or more of NOVA, MBNL, 
RBFOX, and PTBP, allowing us to nearly double the total number of regulated AS events. These 
novel events behave in a similar manner to known events, but the fact they were previously 
unidentified suggests that they may be of particular interest for cell-type specific studies. 
 
Integrative modeling predicts hundreds of regulated novel exons 
We processed our existing datasets, including CLIP, motif, and RNA-seq data, for the novel 
splicing events. We then used our trained Bayesian network models to generate target 
predictions, obtaining 523, 363, 23, and 201 targets for RBFOX, PTBP, MBNL, and NOVA, 
respectively (Figure 5.1A). With the exception of MBNL, whose targets are limited as a result of 
sparse CLIP data, these numbers are similar to the numbers of known exons, and the degree of 
overlap between the targets is similar as well. To confirm that these targets are indeed direct 
targets of the RBPs, we built RNA maps for each RBP to identify the location of CLIP tags or 
motif sites relative to the exons (Figure 5.1B). The binding patterns match the canonical 
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positional binding model for both known and novel exons, suggesting that we did indeed identify 
direct targets. The RNA maps for RBFOX motif cluster enrichment suggest that novel exons 
tend to be more often repressed via binding within the exon than known exons. Potential 
explanations for this observation include a greater number of microexons, a weaker splicing 
suppressor effect for exonic binding compared to intronic binding, or a greater impact of NMD. 
	
Figure 5.1. Integrative modeling defines novel exon targets of RBPs. 
Known exons are shown on the left, and novel exons are shown on the right. A. Overlap of the target networks for 
each of the RBPs. B. RNA map for Rbfox CLIP for known and novel exons.  
 
Novel regulated exons are conserved and define a functional subset 
We measured the conservation of regulated exons in two ways. First, we determined the fraction 
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of exons that are conserved between human and mouse for each category of exon (Figure 5.2A). 
Unsurprisingly, regulated events are approximately 3-fold more conserved than splicing events 
overall. In addition, novel exons are slightly less likely overall to be conserved than are known 
exons. Since most of the regulation of alternative splicing occurs in the flanking intronic regions, 
we also measured the intronic conservation across 40 mammalian species by averaging the 
phastCons score at each position (Figure 5.2B). We observed a similar pattern: regulated exons 
have much higher intronic conservation than non-regulated exons, and novel exons have slightly 
less intronic conservation than known exons overall. One possible explanation for this 
observation is that many novel exons were invented more recently, and as such their intronic 
regions have not been as strongly selected for, especially as AS is known to be less strongly 
fixed than expression. 
 
 
Figure 5.2. Conservation of known and novel regulated splicing events. 
A. The fraction of mouse exons in each category conserved between human and mouse. B. Average phastCons 
scores at each intronic position for each group of exons. 
	
To search for any functional differences between known and novel regulated exons, we 
performed Gene Ontology analysis. We find that the enrichment in GO categories is highly 
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consistent between both sets of exons, with some brain-specific terms slightly more significant in 
novel exons (Figure 5.3). This suggests that there are limited fundamental differences between 
the sets of exons, indicating that dividing the exons into regulated/non-regulated is more 
informative than dividing the exons into known/novel. However, there may be some interesting 
biases. The novel exons were all determined from the developing cortex dataset, so there is a 
preference for brain-specific splicing events. Another possible explanation is that the GO terms 
more strongly enriched in the novel events (which appear to be strongly enriched in 
synaptogenesis-related processes) reflect biological contexts that are understudied, or that 
contain a large number of poison exons that were previously not observed. 
 
Figure 5.3. Comparison of GO-term enrichment for known and novel regulated exons (-log FDR) 
 
In line with this thinking, we quantified the coding potential of each group of exons to 
determine their likelihood of triggering NMD. Overall, we estimate that approximately half of 
exons are NMD-exons, with the fraction of novel exons being slightly higher (Figure 5.4). In 
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both cases, exons triggering NMD upon inclusion and exclusion are roughly equal. However, 
among regulated exons novel exons are about twice as likely to cause NMD. In addition, the vast 
majority causing NMD upon exon inclusion, suggesting perhaps AS-NMD is more easily 
regulated via an exclusion mechanism than inclusion. In addition, PTBP and NOVA both have 
particularly high enrichment of NMD exons in their novel regulated set. Both are critical factors 
for major neural transitions (neurogenesis and migration, respectively), which perhaps can be 
relatively efficiently regulated via NMD. At the same time, these NMD transcripts are degraded, 
so these events were less likely to be observed. 
 
Figure 5.4. NMD potential of regulated exons. 
The coding potential of each category of exons is shown. Red=exon triggers NMD upon inclusion, Blue=exon 
triggers NMD upon exclusion, Green=exon is coding. 
	
As discussed above, we observed nearly 3,000 alternative splicing events that change 
during cortical development. Approximately one-third of these are novel exons (Figure 5.5A), 
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further suggesting that there exist critical splicing events that have not yet been identified. In our 
previous work, we were unable to generate the regulatory networks for the RBPs, but extending 
our current results to this data we observe strong RBP regulation of these exons as well (Figure 
5.5B). The RBPs appear to regulate the novel exons in a similar manner to the known exons, 
with NOVA, RBFOX, and PTBP driving the early splicing changes (M2) and MBNL and 
RBFOX driving the late splicing changes (M1) (Figure 5.5C). 
	
Figure 5.5. Developmental regulation of novel regulated exons. 
A. Developing cortex modules, as defined above, but only showing novel exons. B. Regulation of novel exons by 
RBPs. A red bar indicates the exon is activated by the RBP while a blue bar indicates the exon is repressed. C. The 






Figure 5.6. Inclusion levels (Ψ) of regulated exons in single-cell RNA-seq of the visual cortex. 
1,582 regulated exons with sufficient coverage in at least 15 samples. Missing values are set to the median for the 
purposes of visualization. Red=high inclusion; blue=low inclusion. At teach time point, the corresponding, row-
normalized levels of each RBP family are shown (RPKMs are shown for each family). GABAergic neurons are 
marked in yellow, glutamatergic neurons in teal, and non-neuronal cells in gray. 
Discussion: identification of potential cell-type specific exons 







splicing events. Here, we applied our integrative modeling framework to extend our RBP 
regulatory networks to our database of novel exons, nearly doubling the total number of 
regulated exons. These exons are functional, with many of them conserved, developmentally-
regulated, and/or involved in regulation via AS-NMD. Our next aim is therefore to identify 
exons that may be particularly interesting biologically.	
Fortunately, we are at a point in single-cell RNA-seq technology where datasets are 
starting to become more readily available. Using our database of regulated exons we have a 
filtered set of candidates that can potentially be regulated quite specifically. For example, most 
alternative splicing events are included at either a very low (Ψ<0.2) or very high (Ψ>0.8) level. 
With measurements from over 40 different visual cortex cell types, we can identify exons that 
are specifically differentially regulated in a minority of these. This type of regulation would 
suggest a particular function for that exon in a particular context, which is something we cannot 
capture with bulk RNA-sequencing. Clustering all regulated exons across samples suggests that 
these exons exist (Figure 5.6). However, a more quantitative approach will be taken, such as 
entropy or Gini impurity measurements (Kryuchkova-Mostacci and Robinson-Rechavi, 2017). 
Another interesting direction will be the study of combinatorial regulation. Currently, we 
are able to consider bulk RNA-seq from purified samples, but single-cell RNA-seq will allow us 
to parse out the data from individual neurons. For example, we can identify exons that are 
primarily regulated by a single RBP by looking for a strong correlation between their inclusion 
level and their regulator (Figure 5.7). More interestingly, we can also begin to look for evidence 
of synergistic regulation by taking advantage of the natural variation in RBP levels in each cell 
type, and how the inclusion levels correlate with the expression levels of all regulators (or their 
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activity levels; see below). 
	
Figure 5.7. Correlation between RBFOX expression and inclusion of a novel exon in NDRG4. 




Chapter 6. Discussion 
This work has focused on elucidating the splicing regulatory networks of a set of tissue-specific 
RNA binding proteins. The results obtained from these networks allow us to obtain informative 
results for a set of individual proteins, but the story is without a doubt much more complex. As 
such, we are still left with many questions. 
1) What is the purpose of RBP redundancy despite such strong similarities in binding 
domains and binding preferences? In the case of Rbfox, with three family members, we observed 
very high (though not perfect) correlation in the binding sites of all three members, and the 
members are known to be able to compensate for partial removal. Yet, the family members are 
regulated in very specific manners, with very defined expression. Future work may help 
elucidate the more subtle differences that exist. For example, careful analysis of single cell RNA-
seq data that considers expression levels (or activity levels) of each member and correlates those 
with inclusion levels could provide insights into member-specific splicing. 
2) How are alternative exons combinatorially regulated? It is clear that there is substantial 
overlap in the regulation of alternative exons. In particular, the developmentally-regulated 
module exons with the most dynamic changes tend to be regulated by more proteins. Does the 
regulation occur simultaneously? Is the combinatorial regulation additive or synergistic? This is 
again a question that could potentially be partially addressed with single cell data considering 
expression (or activity) levels of multiple proteins. However, the more detailed mechanistic 
questions will also need to be explored biochemically. 
3) How does sequence determine inclusion? The splicing code remains elusive. Are we 
missing more regulatory factors? Key regulatory mechanisms? The ENCODE data may be 
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helpful in identifying new regulators by highlighting those that perform key roles at given time 
points. In addition, several labs (including ours) are working to identify the specific binding 
motifs of many proteins (although more complex binding, such as recognition of secondary 
structure or binding requiring an adapter protein, cannot yet be addressed). 
 
Single-cell RNA-seq 
Recent technological improvements in single-cell RNA-seq may help provide answers to some 
of these questions. For example, one limitation with the bulk tissue RNA-seq (such as that used 
in this work) is that it is unable to capture the variations between different cell types. A recent 
study used immunopanning to isolate different CNS cell types, including neurons and multiple 
types of glia, allowing for the identification of thousands of cell type-specific events (Zhang et 
al., 2014). In addition, our work suggests that purified cell types, particularly sensory neurons, 
have unique RBP regulation profiles. More recently, a study performed single-cell RNA-seq of 
nearly 50 cell types in the visual cortex, including many types of neurons, highlighting the fact 
that there are substantial differences in gene expression and splicing even within neuronal cells 
(Tasic et al., 2016).  
This diversity suggests that by isolating individual cells, it might be possible to remove 
confounding noise and focus on the splicing events within a cell type. By selecting cell types 
with different levels of each RBP, one can devise a combinatorial code considering RBP 
expression level and inclusion levels of various exons. This could potentially identify exons 
under synergistic regulation by multiple RBPs, and could potentially even be used to identify any 
unique effects of specific family members; e.g. the difference in alternative splicing between a 
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cell expressing only Rbfox2 compared to a cell expressing only Rbfox3. 
RBP activity 
In both single-cell and bulk RNA-seq, a useful follow-up investigation that ties together the 
regulatory networks of RNA binding proteins and cell-type specific regulation would be to create 
a measure of RBP “activity” within a sample. This concept has been explored for the regulation 
of gene expression by transcription factors (Alvarez et al., 2016). This resulted in an algorithm, 
VIPER, which infers the activity level of a transcription factor (TF) in a sample based on the 
expression levels of its target genes (determined from some other method), which has been used 
to assess the activity of oncogenes and identify potential drug targets.  
We have generated some preliminary data for an analogous model that replaces DNA-TF 
interactions with RNA-RBP interactions (Figure 6.1). Minor modifications were made to the 
underlying statistical model to accommodate splicing data instead of expression data and the 
integrative modeling results instead of the default TF target prediction model. However, even 
this early version appears to be quite informative. First, the activities are relatively well 
correlated with expression levels, which we would expect. Second, we observe changes in RBP 
activity in the neurodevelopment dataset that are consistent with the predicted changes (stronger 
activity for RBFOX, NOVA, and PTBP in early stages, and stronger activity for MBNL in later 
stages). Finally, wild type experiments consistently have higher protein activity levels than do 
perturbation experiments. In all cases, the expression level of the protein is not considered. 
There are several potential insights that can be made from these data. First, activity is not 
dependent on RPKM, which can be subject to various biases. Second, aggregating the levels of 
hundreds of exons provides a more robust measure of activity than a single measurement of 
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expression. Finally, mechanistic insights might be obtained by determining if there are critical 
thresholds for RBP activity, or if there might be different levels of activity provided by different 
family members of a given protein. 
  
Figure 6.1. Comparison of RBFOX expression with predicted activity. 
Blue arrows show change in activity between WT (control) and knockout/knockdown samples. Green arrow traces 
Rbfox activity in cortical development, starting with E14. Red circles label some immature samples: OSN (no 
Rbfox) and DRG (low Rbfox). 
	
In addition, we wondered whether the aggregation of multiple target exons could allow us 
to relax the stringent requirements for determining the target set. One of the main drawbacks of 
integrative modeling is that it requires availability of many datasets. If we can simply use RNA-
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seq data, we would be able to much more easily create activity measurements. Indeed, we 
observe quite robust measurements of activity using only RNA-seq perturbation experiments. As 
such, we extended these results to perturbation data provided by the ENCODE consortium. This 
will allow us to measure the activity level of over 100 proteins in any dataset, providing, for 
example, the timepoint at which each protein has its maximum regulatory effect (Figure 6.2). 
 
 
Figure 6.2. Activity levels of several proteins during cortical development. 
Heatmap showing the measured activity of various proteins based on independent RNA-seq datasets (red is higher 
activity; blue lower). Samples labeled with “E_” were generated as part of the ENCODE consortium RBP 
characterization efforts. 
 
These results suggest that recent technological innovations, both biochemical and 
computational, will drive forward the study of alternative splicing and its regulation. The 
understanding of the splicing code may be closer than it appears, and that in turn will likely push 
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Appendix I: Methods 
Chapter 2 
All animal-related procedures were conducted according to the Institutional Animal Care and 
Use Committee (IACUC) guidelines at Columbia University Medical Center and Rockefeller 
University. 
 
Transient Transfection of Rbfox1, 2, and 3 in HEK293T Cells 
To test cross-reactivity of Rbfox antibodies, 1.5×106 HEK293T cells were plated onto 10 
cm dishes the day before transfection. Cells were then transfected with 2 µg of pRbfox1, 
pRbfox2, or pRbfox3 individually, or the empty pcDNA vector as a control, using FuGENE HD 
(Roche) as described by the manufacturer. After 48 hrs, cells were rinsed with ice-cold PBS and 




A total of 20 µg protein per lane was loaded into 10% or 4-12% Novex NuPage SDS-
PAGE gels (Invitrogen). After protein transfer onto nitrocellulose (Millipore) 0.45 µm 
membranes, the following antibodies were used for immunoblot: α-Rbfox1(Millipore), α-Rbfox2 
(Bethyl Laboratories), α-Rbfox3 polyclonal (In-house), α-Rbfox3 monoclonal (Millipore), and α-
GAPDH (Millipore). 
 
HITS-CLIP Experiments using Mouse Brain 
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RBFOX1, 2, and 3 CLIP experiments were performed with whole brain tissue lysate of 
about two-week old (P15) CD1 mice using two different protocols. Each CLIP experiment used 
approximately 1/4-1/3 of a whole brain (100-150 mg tissue lysate). The following antibodies 
were used: α-Rbfox1 (Millipore), α-Rbfox2 (Bethyl Laboratories), α-Rbfox3 polyclonal (in-
house) and monoclonal (Millipore). The standard CLIP libraries were prepared as described 
previously (Darnell, 2010a; Licatalosi et al., 2008; Moore et al., 2014). The BrdU-CLIP protocol 
is composed of the following steps. Protein-RNA complexes are immunoprecipitated using each 
specific antibody followed by stringent washes and ligation of the 3´ linker. After digestion of 
the protein, the RNA is purified and reverse transcribed using a dNTP mix where dTTP is 
replaced with BrdUTP. The RT primer has 5´ and 3´ anchor sequences used later for PCR 
amplification separated by an APE1 cleavage site. The BrdUTP incorporated into the resulting 
cDNA allows on-bead cDNA purification using an anti-BrdU antibody (clone IIB5; Santa Cruz 
Biotech or other vendors). The purified cDNA is then circularized and relinearized on-bead using 
CircLigase II and APE1, respectively, which places the two PCR anchors in the correct 
orientation. PCR is performed using a real time amplification system; SYBR green is added to 
the PCR reaction mix to monitor the concentration of DNA, and the PCR reaction is stopped 
when the fluorescence intensity (RFU) reaches an empirically-determined threshold. More 
details of the protocol are described in Supplemental Protocols. The resulting libraries prepared 
with both standard CLIP and BrdU-CLIP protocols were sequenced by Illumina Hi-Seq 2000 to 
obtain 51-nt reads. 
 
Optimization of RBFOX CLIP Conditions 
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Several RBFOX antibodies were tested to evaluate their specificity in recognizing the 
targeted proteins. To assess potential cross-reactivity of antibodies with different RBFOX family 
members, we transfected pRbfox1, pRbfox2, and pRbfox3 individually into HEK293T cells, 
which have little to no endogenous expression of the RBFOX proteins. Immunoblot was then 
used to detect each protein in these cells using different antibodies. We identified one antibody 
for each that recognizes the targeted RBFOX family member without discernible cross-
reactivity. For RBFOX3, in addition to a rabbit polyclonal antibody, a commercial monoclonal 
antibody is also largely specific despite minor cross-reactivity with RBFOX2.  
We then optimized the conditions for the immunoprecipitation (IP) of RNA-protein 
complexes using mouse brain tissue. Each antibody was able to precipitate its specific RBFOX 
paralog. When an increasing amount of antibody was used for IP, the IP eluate gave increased 
yield of the targeted protein as revealed by immunoblot and an autoradiogram labeling RNA 
crosslinked to the protein; reciprocal depletion of the specific protein, but not the other paralogs, 
was observed in the supernatant. As a control, we performed IP of crosslinked tissue using 
nonspecific IgG antibodies or non-crosslinked tissue using RBFOX antibodies, which resulted in 
minimal background.  Under high RNase concentrations, IP of RBFOX crosslinked with 
radiolabeled RNA using specific RBFOX antibodies resulted in a doublet band at around 50 kD, 
corresponding to the molecular weight of the proteins observed in several previous studies 
(Dredge and Jensen, 2011; Tang et al., 2009). At a lower RNase concentration, a smear of 
labeled RNA of varying sizes above the doublet band was observed, as expected in CLIP 
experiments (Moore et al., 2014). It is also important note that the size of the doublet band at 
around 50 kD is similar, but not identical, for different RBFOX family members. This 
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observation provides support for IP specificity since four different antibodies would not be 
expected to give nonspecific bands of such similar patterns. Instead, the result is consistent with 
the notion that multiple homologous variants are present in all RBFOX family members. We 
isolated crosslinked protein-RNA complexes roughly 20 kD above the molecular weight of each 
protein for further experimentation. 
 
RNA-Seq in HeLa Cells 
HeLa cells with or without Rbfox2 knockdown were generated previously (Zhang et al., 
2008). Briefly, an shRNA against human Rbfox2 (shRbfox2) was cloned into the MSCV 
retroviral vector (Dickins et al., 2005). To create stable cell pools, HeLa cells were infected with 
MSCV expressing shRbfox2 or the empty retroviral vector (control). We replaced the medium 
24 hrs after infection. 24 hrs later, infected cells were selected with puromycin (2 µg mL−1) for 
72 hrs. 
 
To reduce splicing precursors and intermediates, cells were fractionated to enrich cytoplasmic 
RNA. Specifically, cells were lysed in gentle lysis buffer (10 mM HEPES pH 7.4, 10 mM NaCl, 
3 mM MgCl2, 0.5 % (v/v) NP-40), and the nuclei were pelleted at 2,300 g for 5 min. 
Cytoplasmic RNA was extracted from the supernatant by Trizol and treated with DNase I 
(Promega). We used 4 µg of cytoplasmic RNA from each sample to prepare RNA-Seq libraries 
following the manufacturer’s instructions (Illumina). cDNA was size-selected using an agarose 
gel, and a band around 250 nt (corresponding to a fragment size of 185 nt with adaptors 
excluded) was excised for PCR amplification. The library was sequenced on Illumina GA IIx 
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sequencer to produce paired-end 32-nt reads. Each of the two samples was sequenced in three 
lanes to increase the coverage.  
 
Rbfox1 KO Mice 
Rbfox1 loxp/loxp mice (described previously by Gehman et al. 2011) and Nestin-Cre+/- 
mice were purchased from Jackson lab and bred to make heterozygous (Rbfox1 loxp/+/Nestin-
Cre+/-) mice. The heterozygous mice were then crossed with Rbfox1 loxp/loxp to obtain 
homozygous (Rbfox1 loxp/ loxp/Nestin-Cre+/-) offspring. Adult Rbfox1 KO mice at around 9 




Semi-quantitative RT-PCR in HeLa cells was performed as previously described (Zhang 
et al., 2008). For RT-PCR validation, total RNA was extracted from brains of WT and 
homozygous Rbfox1 KO (Rbfox1 loxp/ loxp/Nestin-Cre+/-) mice using Trizol reagent 
(Invitrogen) and treated with DNase I. Candidate exons for validation were selected to cover the 
whole range of prediction confidence, but exons with complex splicing patterns or very high 
(≥0.9) or low (≤0.1) inclusion levels in WT adult mouse brains (Dillman et al., 2013) were 
avoided. Semi-quantitative RT-PCR analysis of these exons was performed as previously 
described (Zhang et al., 2010). A total of eight exons with both alternative isoforms detected in 
WT or Rbfox1- brain samples were included in our quantitative analysis. Primers used in this 




Alternative Splicing Database 
The alternative splicing database used in this study was built by aligning RefSeq, mRNA, 
and EST sequences to the mouse genome (mm10), as described previously (Zhang et al., 2010). 
Alternative splicing events used in our Bayesian network analysis consist of 16,034 cassette 
exons, 4,074 events of tandem cassette exons, and 960 events of mutually exclusive exons. A 
similar database was generated for human (hg19) and rat (rn5) to determine conservation of 
alternative splicing patterns. 
 
Analysis of HITS-CLIP Data 
HITS-CLIP data analysis was performed essentially as described previously (Moore et 
al., 2014; Zhang and Darnell, 2011). In brief, 51-nt raw reads were first filtered by their quality 
scores. The standard CLIP reads have a 5-nt random barcode, and the BrdU-CLIP reads have a 
5-nt sample multiplexing index in addition to a 9-nt random barcode at the 5´ end. For reads kept 
for downstream analysis, we required a minimum score of 20 at these index/barcode positions 
and an average score of 20 for the succeeding 25 positions corresponding to the first 25-nt of the 
actual CLIP tags. Barcode and index sequences were then removed from the read sequences and 
the information was recorded separately. The remaining read sequences corresponding to actual 
RNA tags were mapped to the reference genome (mm9 at the time of the analysis) using the 
novoalign program (http://www.novocraft.com) and allowing ≤2 mismatches (substitutions, 
insertions, or deletions) per read. We used the iterative trimming mode of novoalign during 
alignment, which iteratively removes adaptor sequences and low quality bases at the 3´ end so 
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that CLIP tags of smaller sizes can be mapped properly. A minimum of 25-nt matches was 
required and only those reads mapped unambiguously to the genome (single hits) were kept for 
downstream analysis. Using an iterative expectation maximization-like statistical model (Darnell 
et al., 2011; Moore et al., 2014), we collapsed CLIP tags mapping to the same genomic positions 
into a single tag; tags with sufficiently distinct barcode sequences were kept, however. This step 
removed PCR duplicates while retaining genuinely unique CLIP tags (Darnell et al., 2011; 
Moore et al., 2014) and resulted in unique CLIP tags that represent independent captures of 
protein-RNA interactions. Deletions, insertions, and substitutions—collectively denoted as 
mutations—in unique CLIP tags were recorded for crosslinking-induced mutation site (CIMS) 
analysis. Coordinates of unique CLIP tags and mutations therein were then liftOver to mm10 for 
further analysis.  
CLIP tag clusters were identified by grouping overlapping CLIP tags (Moore et al., 
2014), and the statistical significance of CLIP tag cluster peak height was evaluated using scan 
statistics as described previously (Charizanis et al., 2012). This approach compares the observed 
peak height with the height expected by chance when CLIP tags are randomly shuffled on a 
gene-by-gene basis. CIMS analysis was performed as described previously (Moore et al., 2014; 
Zhang and Darnell, 2011).  
Crosslinking-induced truncation site (CITS) analysis was performed using a 
computational method similar to a previous method used to analyze iCLIP data (Konig et al., 
2010; Wang et al., 2010) with several modifications. We removed all CLIP tags with deletions 
since a majority of these likely represent tags where the crosslink sites were read through during 
reverse transcription. We clustered the remaining CLIP tags based on their potential sites of 
  
159 
truncation, defined as the nucleotide immediately 5´ of each CLIP tag. The key to identifying 
CITS is to distinguish tags that were read through from those with premature truncation. We 
used a stringent statistical test to evaluate whether the observed frequency of potential 
truncations in each site is significantly higher than that expected by chance. This was done using 
a random redistribution of potential truncations in each CLIP tag cluster, which is more stringent 
than the gene-by-gene permutation used in the previous analyses (Konig et al., 2010; Wang et 
al., 2010). The stringent permutation scheme is important because read-through is frequent for 
RBFOX CLIP data. Similar to identification of significant CLIP tag cluster peaks, scan statistics 
were used for statistical assessment. 
To estimate the rate of truncation at the crosslink site, we used the same method as 
described previously (Sugimoto et al., 2012), using the formula p(BrdU-CLIP)=f×p(RT)+(1-
f)×p(BG), where p(BrdU-CLIP)=0.062, p(RT)=0.14, and p(BG)=0.004 are deletion rates in 
BrdU-CLIP, standard CLIP (i.e., error of reverse transcription), and in RNA-Seq data 
(background), respectively, and f is the rate of reverse transcriptase read-through. The 
background deletion rate in RNA-Seq data was estimated based on our previous data (Zhang and 
Darnell, 2011). The estimated rate of read-through for RBFOX CLIP is f=43%.  
 
Motif Discovery and Enrichment Analysis 
De novo motif analysis was performed using 21-nt sequences [-10,10] around CIMS or 
CITS. For CIMS, all 1,158 sequences were used for analysis. For CITS, a randomly sampled 
subset of 1,000 sequences was used for analysis. Repetitive sequences were masked before de 
novo motif discovery using the MEME program with the following parameters: -mod zoops -
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nmotifs 10 -minw 6 -maxw 8, with the remaining parameters left at their default values (Bailey 
and Elkan, 1994).  To examine motif enrichment relative to protein-RNA crosslink sites, the 
starting positions of UGCAUG, VGCAUG (V=nonU), or additional variants of the RBFOX 
consensus binding motif were recorded in sequences flanking the crosslink sites. Background 
motif frequency was estimated from control sequences of positions -500~-401 nt and 398~497 nt 
relative to the crosslink sites, to normalize the observed motif frequency.  
 
Motif Enrichment and Conservation Score 
We previously used branch length score (BLS) (Stark et al., 2007) to evaluate the 
strength of RBFOX motif sites (Zhang et al., 2008). This scoring method considers only the 
conservation, but not the overall enrichment, of motif sites. For example, a site present only in 
the reference species without orthologs in any other species receives a BLS score of zero, even if 
the motif is specific and enriched in CLIP tag clusters. To address this caveat, we defined a new 
scoring metric of motif-site strength reflecting both enrichment and conservation of motif sites in 
CLIP tag clusters compared to regions without any CLIP tags. Specifically, we obtained 6,101 
CLIP tag clusters satisfying the following criteria as foreground sequences: i) peak height ≥10; 
ii) located in exons or flanking intronic regions (exon+1kb extension on each side, or 
exon+ext1k); and iii) no overlap with repeat-masked regions. We also obtained a list of 
sequences in 90,637 exon+ext1k regions without any CLIP tags as background. The UGCAUG 
elements were then searched in foreground and background sequences, respectively, and the 
branch length score (BLS) was calculated for each site. A distribution of BLS was estimated in 
CLIP+ and CLIP- sequences, respectively, denoted as P(BLS|CLIP+, region) and P(BLS|CLIP-, 
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region), where the type of region can be introns, coding exons or noncoding exons. The overall 
frequency of motif sites in foreground and background sequences, denoted as f(CLIP+) and 
f(CLIP-), respectively, were calculated and normalized by the length of sequences in each set. 
The preliminary motif enrichment and conservation score (MECS) for each UGCAUG site was 
calculated as log2[f(CLIP+)/f(CLIP-)]+log2[P(BLS|CLIP+, region)/P(BLS|CLIP-, region)].  We 
then performed a 3rd-order polynomial regression between the preliminary MECS score and 
BLS score. The fitted value for the given BLS score was then used as the final MECS score for 
each motif site. The same procedure was used to estimate the MECS scores for VGCAUG 
elements. 
 
RNA-Seq Data Analysis 
For the HeLa cell RNA-Seq data, raw 5´ and 3´ reads were mapped independently by 
Eland (Illumina) to the human genome (hg18 at the time of analysis) with iterative 3´ trimming. 
We required a minimal matched region of 22 nt and ≤ 2 mismatches for alignment. Reads were 
also mapped to an exon-junction database with the same criteria, in addition to requiring ≥ 4 nt 
overlap on each side of exon junctions. Only reads unambiguously mapped to unique loci in the 
genome or exon junctions (single hits) were kept for further analysis. The downstream analysis, 
including inference of transcript structure and quantification of gene expression and splicing, 
was performed as described previously (Charizanis et al., 2012) except that the proportional 
change of exon inclusion between the two conditions was estimated using the ASPIRE algorithm 
(Ule et al., 2005a).  
In addition to the HeLa cell RNA-Seq data, we also analyzed three published RNA-Seq 
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datasets: one dataset profiled six different mouse tissues including cortex, cerebellum, heart, 
kidney, liver and testis (76-nt reads; each tissue has 2-6 biological replicates; GEO accession: 
GSE30352) (Brawand et al., 2011); one dataset profiled E17 and adult mouse cortex (80-nt 
single end reads, 4 biological replicates for E17 and 3 biological replicates for adult; GEO 
accession: GSE39866) (Dillman et al., 2013); and one dataset profiled autistic and control 
postmortem human brains (74-nt reads; 3 biological replicates for autistic and control brains, 
respectively; GEO accession: GSE30573) (Voineagu et al., 2011). These datasets were analyzed 
with the same pipeline (http://zhanglab.c2b2.columbia.edu/index.php/Quantas). Reads in each 
dataset were mapped to the mouse (mm10) or human (hg19) genome by OLego 
(http://zhanglab.c2b2.columbia.edu/index.php/OLego) (Wu et al., 2013) with 14-nt non-
overlapping seeds, requiring ≤ 3 mismatches per read. An exon-junction database was provided 
for alignment. Only reads unambiguously mapped to the genome or exon junctions (single hits) 
were used for downstream analysis. Since these are single-end reads, the resulting mapped reads 
were counted in each exon or exon junction to quantify splicing changes, as described previously 
(Charizanis et al., 2012). Fisher’s exact test was used to evaluate the statistical significance of 
splicing changes, and the false discovery rate was estimated by the Benjamini-Hochberg 
procedure (Benjamini and Hochberg, 1995). An alternative splicing event was called in the two 
compared conditions if the event had sufficient read coverage (coverage≥20), |∆I|≥0.1, and 
Benjamini FDR≤0.05 (Charizanis et al., 2012), unless otherwise indicated. 
 
Integrative Modeling using Bayesian Network Analysis 
We initially focused on cassette exons using our established Bayesian network 
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framework (Zhang et al., 2010). For evidence of RBFOX-dependent splicing in the Bayesian 
network analysis, we considered the following datasets: i) differential splicing between WT and 
Rbfox1 KO mouse brain, as measured by exon-junction microarrays (GEO accession: 
GSE28421) (Gehman et al., 2011) where we estimated the splicing changes, denoted ∆Irank, 
using the ASPIRE3 algorithm (Wang et al., 2010); ii) differential splicing (∆I) between HeLa 
cells with or without Rbfox2 expression, as described above; iii) tissue-specific splicing (∆I) of 
exons in cortex and cerebellum compared to several other tissues (liver, kidney and testis) using 
a published RNA-Seq dataset (Brawand et al., 2011); iv) tissue-specific splicing of exons (∆I) in 
heart compared to several other tissues (liver, kidney and testis) (Brawand et al., 2011). For 
RNA-Seq data, only those exons with sufficient coverage (≥ 20 reads) were used; missing values 
were assigned to the other exons. Tissue-specific splicing of exons are indirect indicators of 
RBFOX-dependent splicing, so the information was used for model training but not for the 
prediction of individual targets (Figure 2.4A in the main text and below).  
For motif sites, we considered both UGCAUG and VGCAUG elements, and measured 
their strength by their MECS score. Since multiple motif sites are typically present in the 
alternatively splicing region, we derived a summarized motif site score by weighting each site 
according to their strength and the distance to the splice sites, as described previously (Zhang et 
al., 2010). Each cassette exon was measured by six regional motif site cluster scores denoted as 
sUI5´ss, sUI3´ss, sE3´ss, sE5´ss, sDI5´ss, and sDI3´ss (UI: upstream intron; DI: downstream 
intron; E: exon). In each region (UI, E, and DI), the maximum of the two was used to represent 
motif site strength in the region for Bayesian network analysis. In contrast to our previous 
analysis (Zhang et al., 2010), the actual distance of motif sites to the splice sites was used for 
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weighting without adjustment. The CLIP tag cluster score in each region was obtained similarly, 
using the same weighting function based on the peak height of the clusters (Zhang et al., 2010).  
To train the model, we compiled 132 exons that have been previously validated as 
RBFOX targets in humans or mice, mostly using cell culture systems. A subset of these exons 
was analyzed by detailed mutation analysis to verify direct regulation by RBFOX, while the 
others, a majority, were validated only by RT-PCR. Therefore, we excluded a few exons that had 
inconsistent directions of splicing changes in different studies or that did not have CLIP tags or 
the (U)GCAUG motif sites in the alternatively spliced region, because these are most likely 
indirect targets. The final set of validated RBFOX targets was composed of 121 exons (87 and 
34 exons experiencing RBFOX-dependent inclusion and exclusion, respectively). A class label 
(activation or repression by RBFOX) was assigned to each of these exons. Besides these 
validated target exons, we also included additional exons satisfying any of the following criteria 
for model training: i) exons with |∆Irank|≥0.6 in the comparison of WT vs. Rbfox1 KO mice 
using exon junction microarrays; ii) exons with |∆I|≥0.08 in the comparison of control vs. 
shRbfox2 in HeLa cell RNA-Seq data; iii) exons with |∆I|≤0.08 in the comparison of brain or 
cerebellum vs. other tissues and in comparison of heart vs. other tissues. These exons were not 
assigned a class label during model training. Overall, we obtained 551 non-redundant exons to 
estimate model parameters, with a relatively balanced representation of exons likely to be 
activated or repressed by RBFOX and of non-target exons.  
The trained Bayesian network model was then applied to 16,034 cassette exons to predict 
direct RBFOX targets. The same model was also applied to 4,074 events of tandem cassette 
exons and 960 events of mutually exclusive exons, assuming these alternative splicing events are 
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regulated by RBFOX through similar mechanisms. 
 
Conditional Probability Distributions Learned by Bayesian Network 
The following observations were made from the estimated Bayesian network model 
parameters. First, stronger motif sites are more likely to be bound by the protein. For example, 
MECS scores of 10 and 20 predict RBFOX binding with probabilities of 0.92 and >0.99, 
respectively (Figure 2.4B). Second, regions bound by RBFOX are supported by more CLIP tags 
than regions not bound by RBFOX. About 18% of regions predicted to be bound by RBFOX 
have a CLIP tag cluster score ≥10, as compared to 0.9% for regions predicted to have no 
RBFOX binding (Figure 2.4C). In addition, we also confirmed and quantified the position-
dependent RNA map: binding of RBFOX in the downstream intron resulted in RBFOX-
dependent inclusion with a probability of 0.99, while binding of RBFOX in the upstream intron 
or exon results in repression with a probability of 0.75 and 0.61, respectively; binding of RBFOX 
in both exon and upstream intron increases the probability of repression to 0.84 (Figure 2.4D). 
This analysis also showed that altered splicing after perturbation of RBFOX in HeLa cells or in 
the RBFOX1 KO mouse model, as well as differential splicing in different tissues, are 
informative for identifying RBFOX target exons in the brain; exons inferred to be activated or 
repressed by RBFOX or those with no response had different means of splicing changes. 
However, the discriminative power is moderate, as reflected in the largely overlapping 
distributions of splicing changes (Figures 2-4E and 2-5 A-C). Finally, alternative splicing of 
RBFOX target exons is much more likely to preserve the reading frame than that of non-target 
exons (85% versus 42%) and such alternative splicing events are also more likely observed in 
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other mammalian species (Figure 2.5 D,E). 
 
Comparison of RBFOX Target Exons Defined by Bayesian Network with Previously Validated 
Exons 
In total, 88 of 121 previously validated exons were predicted as RBFOX targets (69/87 
exons with RBFOX-dependent inclusion and 19/34 exons with RBFOX-dependent exclusion). 
This comparison gives a sensitivity of 73% to our Bayesian network prediction, with a 
conservative assumption that all of these previously validated exons are directly regulated by 
RBFOX. However, it is important to note that some of these previously validated RBFOX-
dependent exons are likely indirect RBFOX targets, which appears to be particularly true for 
exons showing RBFOX-dependent exclusion. To address this issue, we focused on 14 cassette 
exons for which the direct regulation by RBFOX has been previously validated by mutagenesis 
or RNA IP. Among these, 11 exons were predicted as RBFOX targets by the Bayesian network 
analysis, indicating a sensitivity of 79%. 
 
Comparison of RBFOX Target Exons Defined by Bayesian Network and Exons by Previous 
Studies 
We compared the results of the Bayesian network analysis to our previous motif-based 
bioinformatic predictions (Zhang et al., 2008). Among the 432 previously predicted RBFOX 
target cassette exons conserved between human and mouse, 273 (63%) were identified by 
integrative modeling. While this overlap is substantial (p<1.8×10-263; Fisher’s exact test), we 
were able to identify important differences in the results. For instance, integrative modeling 
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identified a greatly expanded set of target exons missed by our previous motif-based predictions, 
presumably using information obtained from the CLIP and other data, while eliminating a 
number of exons having conserved motif sites but lacking supporting evidence from the other 
complementary datasets.  
Another recent study predicted 933 RBFOX target exons in human using a “leading-
edge” analysis based on the presence of RBP motif sites and the correlation of exon splicing with 
RBP expression in different human tissues and cell lines (Ray et al., 2013). Among the 703 
exons annotated as cassette exons in our database, 117 exons have mouse orthologs predicted by 
our Bayesian network analysis, representing a very significant overlap (p<2.2×10-90; Fisher’s 
exact test). Again, however, these results suggest that a majority of exons predicted by the two 
methods are distinct. Target exons predicted by the Bayesian network analysis more frequently 
have conserved splicing patterns between human and mouse (78% vs. 26%), preserved reading 
frame (89% vs. 57%, as judged from whether the exon size is a multiple of three), smaller exon 
size (median: 69 nt vs 96 nt; p<10-17), and relatively higher expression in the brain (median of 
expression quantile across all genes: 0.19 vs. 0.25; p<3.3×10-7). While these differences are not 
completely unexpected, they suggest that Bayesian network analysis is effective for integrating 
features that are known to be consistent with tight regulation of alternative splicing events (Xing 
and Lee, 2006). 
 
Gene Ontology (GO) and Protein Domain Analysis 
GO and protein domain analysis was performed using the online tool DAVID using all 




Candidate Autism-Susceptibility Genes 
The list of candidate autism-susceptibility genes was obtained from the Simons 
Foundation Autism Research Initiative (SFARI) autism gene database (http://gene.sfari.org) 
(Basu et al., 2009). The mouse ortholog of each human gene was determined using the 




All statistical analyses were performed using the statistical software R (R Development 




Generation of RNA-seq libraries. 
Wild type (WT) C57BL/6 male mice aged E14.5, E16.5, P0, P4, P7, P15, P30, P110 and 
21 months were used for sample collection. Total RNA was extracted from whole cortices of 
individual animals, with duplicates at each age. RNA-Seq libraries were prepared using the 
TruSeq RNA Sample Preparation Kit (Illumina) and PE 2×101-nt reads were generated using the 
Illumina HiSeq 2000. This dataset will be deposited into NCBI Gene Expression Omnibus 
(GEO). 
In total, we analyzed seven RNA-Seq datasets in this study: 1) mouse developing cortex 
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as described above (PE 101-nt reads); 2) mouse developing frontal cortex (E11 to 22 months, SE 
101-nt reads) (Lister et al., 2013); 3) human developing middle/frontal cortex (PE/SE 101-nt 
reads) (Lister et al., 2013); 4) CNS cell types (PE 101-nt reads) (Zhang et al., 2014); 5) Ptbp2 
WT vs. KO brains (PE 100-nt reads) (Li et al., 2014); 6) Mbnl2 WT vs. KO hippocampi (PE 40-
nt reads) (Charizanis et al., 2012); 7) Upf2 WT vs. KO liver (SE 75-nt reads; 
SRP005384)(Weischenfeldt et al., 2012). In particular, discovery of new exon junctions and AS 
events in the mouse and human cortex transcriptomes was based on the first two datasets and the 
third dataset, respectively.  
 
Annotation of exon junctions and AS events based on existing gene models, cDNAs and ESTs.  
A database of annotated exons, introns and AS events was generated from alignment of 
cDNAs and ESTs to the genome using a splicing graph-based approach, as previously described 
(Zhang et al., 2010). In brief, the pipeline first defined a set of genes based on aligned RefSeq 
transcripts downloaded from the UCSC genome browser and their Entrez gene IDs. Genomic 
sequences of these genes (denoted gene contigs) were extracted with 3kb extension on both ends. 
cDNA/EST sequences in UniGene (mouse build 192 and human build 232) and RefSeq (release 
53) were then aligned to gene contigs using exonerate (Slater and Birney, 2005) by requiring 
95% identity and 50% coverage in the aligned region. A splicing graph was built for each gene 
based on these alignments. In the splicing graph, each splice site is represented by a node and 
each exon or intron is represented by an edge which also stores information about the supporting 
transcripts. AS of different types is represented by specific sub-graph patterns. Supporting 
transcripts for each isoform of an AS event can be retrieved by traversing the paths representing 
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different isoforms. The mouse and human AS events generated by this pipeline are referred to as 
known AS events in this study. 
The pipeline also produced a list of exon junctions detected in RefSeq transcripts, cDNAs 
and ESTs. To further increase the coverage, we also extracted exon junctions from aligned 
RefSeq transcripts and UCSC gene transcripts downloaded from the UCSC genome browser, 
which together resulted in 250,993 junctions in mouse and 327,444 junctions in human, that we 
refer to as known exon junctions in this study.  
 
Assessment of the known exon junction and AS database.  
We compiled a database of GU/AG canonical exon junctions and AS events based on 
transcript evidence in existing gene models, cDNAs and ESTs, which we refer to as known exon 
junctions and AS events (Methods).  
We evaluated the comprehensiveness of our exon-junction database (using 250,993 
junctions in mouse for demonstration) by comparing it with exon junctions annotated in Gencode 
(Harrow et al., 2012). Gencode gene models (MV4) consist of 239,727 unique GU/AG exon 
junctions, among which 218,850 (91.3%) were included in our database. We note that our 
database is based on transcript evidence in mouse while Gencode incorporated evidence of 
related species through the use of the automatic Ensembl genebuild pipeline, which may explain 
why our database missed some of the Gencode junctions. Indeed, if we include exon junctions 
we identified in human and rat for comparison, 223,493 (93.2%) Gencode junctions are covered.  
Our database of mouse AS events consists of 33,795 events of different types, including 
16,034 cassette exons. To evaluate its comprehensiveness, we used AS events defined in the 
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UCSC genome browser (the UCSC Alt Events track). The comparison is somewhat complicated 
by differences in defining AS events.  For example, the UCSC “cassette” exons are defined as 
exons that overlap with introns of other transcripts, and these would include single cassette 
exons, tandem cassette exons, and mutually exclusive cassette exons, based on classifications 
commonly used by the community. They also include more complicated AS events such as AS 
of multiple exons coupled with alternative promoters and polyadenylation sites. Nevertheless, we 
compared the 12,429 UCSC “cassette” exons with a combined set of unique exons annotated as 
single or tandem cassette exons or mutually exclusive exons in our database (18,487 exons in 
total) and identified 8,172 exons (65.7% of the UCSC dataset) in common. We manually 
checked a subset of the remaining UCSC “cassette” exons to find out why they were not 
included in our database. Different reasons were found although the relative frequency is 
difficult to quantify: 1) Gene models (e.g. long noncoding RNAs) were not in the Entrez gene 
database and were thus excluded by our pipeline when we built our AS database; 2) Transcripts 
supporting the exon were not aligned successfully (we used exonerate while UCSC used BLAT); 
3) Exons are not cassette, tandem cassette or mutually exclusive exons based on the strict 
definition we adopted; 4) Exons involve non GU/AG (such as GC/AG or AU/AC) splice sites. 
Despite the possibility that our database might miss some AS events observed in existing 
cDNAs/ESTs, our database clearly has a much higher coverage. To keep consistent definitions of 
AS events, we refer to AS events in this database as known AS events to compare with AS 
events identified in RNA-Seq data throughout our analysis. Inclusion of additional AS events 
from UCSC is not expected to qualitatively change any conclusions described in this study (for 
example, among the 1,640 newly discovered non-redundant cassette exons under strong 
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purifying selection, only 211 were included in the UCSC cassette exons; see below). 
 
RNA-Seq data read mapping and junction detection. 
Raw RNA-Seq reads in each of the seven datasets were mapped and processed using the 
previously established Quantas pipeline (Charizanis et al., 2012; Weyn-Vanhentenryck et al., 
2014) (http://zhanglab.c2b2.columbia.edu/index.php/Quantas). Except for the Mbnl2 dataset, all 
other datasets were mapped by OLego v1.1.2 (Wu et al., 2013) using the default seed size (15-nt 
seed with 1-nt overlap) allowing 4 mismatches; the Mbnl2 dataset was mapped using 14-nt seeds 
with 1-nt overlap to improve sensitivity, allowing 2 mismatches in each read. In addition to the 
reference genome (mm10 and hg19 for mouse and human, respectively), a comprehensive 
database of known exon junctions in human, mouse, or rat as described above was provided 
during read mapping for all datasets (available for download on the Quantas website). For the 
Mbnl2 and Upf2 datasets, which have shorter read length (75 nt and 40 nt, respectively), new 
exon-junctions detected in the developing mouse cortex (see more details below) were also 
provided for read mapping in addition to the previously annotated exon junctions. A minimal 
anchor size of 8-nt was required for mapping to new exon junctions and 5-nt was required for 
mapping to known exon junctions, which is the default. Only reads with unambiguous mapping 
to unique loci (i.e., single hits) were included for further analysis. 
To identify unique exon junctions, we collapsed individual reads supporting each 
candidate exon junction. The overlap of a candidate junction with the upstream and downstream 
exons was defined as the maximum overlap of all supporting reads with the exon on each side of 
the junction. Only canonical GU/AG exon junctions were considered for this study. We then 
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filtered candidate junctions by requiring a minimum of 12-nt overlap on each side to reduce false 
positives (Wu et al., 2013). 
 
Estimation of RNA-Seq read mapping accuracy.  
For de novo discovery of exon junctions and AS events from RNA-Seq data, it is critical 
to minimize mapping errors, which were assessed with several different measures in our 
analysis. First, for each junction read, we examined the distance from the read start to the exon 
junction. In the ideal scenario without mapping errors, this distance is expected to follow a 
uniform distribution due to random fragmentation of RNA—independent of the positions of the 
splice sites—during preparation of RNA-Seq libraries. In practice, a higher mapping error rate is 
expected when the overlap of the read with either side of the exon junction (i.e., anchor size) is 
small, owing to an increase in the chance of random matches for shorter anchors. When we 
examined the distribution of the distance resulted from read mapping in mouse and human, we 
found it largely follows a uniform distribution, without any bias towards shorter anchor size, 
indicating qualitatively that the mapping error is low. There is a slight decrease on the right side 
of the distribution that reflects the decrease in sequencing quality near the end of the reads by the 
Illumina platform, which makes it more difficult to successfully map short anchors near the end 
of the reads. 
As a second measure, we examined the number of reads supporting each unique exon 
junction. We grouped junctions into three categories: known junctions in manually curated 
RefSeq transcripts, known junctions supported by existing cDNA/EST sequences but not by 
RefSeq transcripts (i.e., “other” known junctions), and new junctions supported only by RNA-
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Seq reads. The distribution roughly follows a power law. For RefSeq exon junctions, the number 
of junctions supported by a smaller number of reads is lower than one would expect from the 
power law distribution, presumably because manual curation biases towards abundant transcript 
variants. 
Lastly, to estimate the mapping error of junction reads more directly, we generated mock 
junction reads in silico by swapping the 5´ and 3´ end of each mapped junction read. This 
approach largely preserves the nucleotide composition of the original reads and was used in a 
previous study for a similar purpose (Pan et al., 2008). The mock exon-junction reads were 
mapped by OLego to the reference genome together with the same database of exon junctions 
using the same parameters. Using read1 derived from a mouse cortex sample (21mo replicate a) 
as a representative example, OLego mapped 11,004,367 of the original exon-junctions reads 
unambiguously with a minimum of 12-nt on each side of the exon junctions. In contrast, only 
550 mock reads derived from these junction reads were mapped unambiguously, giving an 
estimated false discovery rate (FDR) <0.005%.  
 
Detecting new AS events with RNA-Seq data. 
We define an AS event as known if all its isoforms are supported by cDNA/ESTs, as 
described above. A new AS event, on the other hand, has isoforms supported either completely 
by RNA-Seq reads or by a combination of cDNA/ESTs and RNA-Seq reads.  
To detect new AS events, we combined exon junctions identified from RNA-Seq data 
with the known exon junctions previously identified from cDNAs and ESTs, as we described 
above. To further increase the reliability and reduce the chance of detecting splicing errors, we 
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excluded newly discovered exon junctions supported by only single reads (resulting in 250,993 
known and 342,093 new exon junctions for mouse, and 327,444 known and 280,393 new exon 
junctions for human). Each of these exon junctions was weighted by the number of supporting 
reads; for known exon junctions, an additional weight of 2 was added to account for the previous 
evidence in cDNA/EST data.   
We made several adaptations in our splicing graph-based pipeline used to detect AS 
events. Due to the relatively small size of RNA-Seq reads, individual RNA-Seq reads frequently 
do not span whole exons or multiple junctions. Therefore, as a first step in detecting new AS 
events, new exons were predicted by pairing nearby 3´ and 5´ splice sites in order (separated by 
≤ 250 nt) and “pseudo” edges were added for such predicted exons. Previously annotated and 
new exons and introns were combined to generate splice graphs and detect AS events. We define 
AS events if each edge (exon or intron) in the AS sub-graph is supported by either cDNA/ESTs 
or RNA-Seq reads. For the AS events analyzed in this study, we require each intron to be 
supported by ≥ 1 cDNA/ESTs, or two RNA-Seq junction reads, or both. This study analyzed 
cassette exons, tandem cassette exons (inclusion or skipping of two but not more exons for this 
study), alternative 5´ and 3´ splice sites, and mutually exclusive exons in the mouse and cortex 
brain transcriptomes. 
The inclusion level of known and newly discovered cassette exons was quantified by the 
number of supporting exon junction reads for each isoform, with data derived from all 
developmental stages pooled together. Conservation of each AS event between human and 
mouse was determined by mapping the coordinates of mouse cassette exons together with the 
upstream and downstream flanking exons to human using the liftOver program (downloaded 
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from the UCSC genome browser at http://genome.ucsc.edu). The resulting human genomic 
coordinates were then used to compare with AS events detected in the human transcriptome and 
determine 1-to-1 orthologs.  
 
Estimation of genes with AS in the mouse cortex transcriptome.  
We identified 25,474 known and 421,396 new AS events with both isoforms detected in 
the cortex. These AS events are from 14,859 genes with Entrez gene IDs.  To estimate the 
percentage of genes with AS in the cortex transcriptome, we limited our analysis to 20,196 
multi-exon genes supported by RefSeq or UCSC gene transcripts. Among these, 14,501 (71.8%) 
genes have at least one AS event with both isoforms reproducibly detected in the mouse cortex.  
 
Summary of new exon junctions and AS events in the human cortex transcriptome.  
The human RNA-Seq dataset used in this study profiled human middle or dorsal frontal 
cortex at seven ages (35 days to 53 years old) (Lister et al., 2013).  This dataset was analyzed 
using the same pipeline, including the use of OLego to map read to the reference genome (hg19) 
and a comprehensive database of exon junctions.  
 We detected 826,536 unique exon junctions with a minimum overlap of 12 nt on each 
side of the exon junction, including 262,172 of 327,444 known exon junctions and 564,364 new 
exon junctions (63% of all junctions). To detect AS events, our analysis included all 327,444 
known exon junctions as well as 280,393 new exon junctions supported by ≥2 reads. In total, our 
analysis detected 479,217 new AS events, as compared to 90,543 known events. These included 
132,639 new cassette exons (as compared to 42,761 known cassette exons). A subset of 27,665 
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known and 121,937 new cassette exons have both isoforms reproducibly detected in the cortex 
(each exon junction supported by ≥2 reads).  
 
Annotation of alternative coding capacity and NMD targets. 
A transcript is predicted to be targeted by the nonsense mediated decay (NMD) pathway 
if it harbors a premature termination codon (PTC) ≥50 nt upstream of an exon junction (Maquat, 
2004). AS coupled with NMD (AS-NMD) has been studied previously (Baek and Green, 2005; 
Lewis et al., 2003). In this study, we focused on AS events that “trigger” NMD. For a pair of 
transcripts that differ in an AS exon under consideration, if one transcript but not the other is 
subject to NMD, the AS event is defined as an NMD-triggering event. We further distinguish 
whether NMD is triggered upon exon inclusion (NMD_in) or exclusion (NMD_ex). If both 
isoforms are protein-coding transcripts, the AS event is called alternative coding. All other cases 
(e.g., neither isoform is productive or the open reading frame (ORF) cannot be determined) are 
grouped into the “other” category. 
A practical challenge to annotating NMD exons is the determination of the ORF, which 
requires full-length transcripts and identification of the correct start codon. Given the low 
abundance of the minor isoform for many AS events, it is frequently difficult to have complete 
transcripts for both isoforms, even for those supported by cDNA/ESTs. We implemented a 
pipeline to annotate AS events and determine whether they trigger NMD with two treatments 
important for high accuracy and sensitivity. First, we focused on AS events for which at least one 
isoform (typically the major isoform) has full-length supporting transcripts. For each of the full-
length transcripts, we generated the transcript supporting the other isoform of the AS event in 
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silico. This in silico transcript differs from the original transcript only in the AS region under 
consideration, facilitating determination of whether the AS triggers NMD. Second, while a 
standard practice to computationally determine the ORF is to search for the longest ORF, this 
approach will introduce annotation errors for NMD target transcripts if the PTC is near the 5´ 
end and a longer ORF can be found downstream (i.e., an upstream ORF is present). In this case, 
an NMD-triggering event can be mistakenly classified as affecting 5´ UTR. Although the 
ribosome can sometimes skip one or more AUGs, it generally initiates translation at the 5´ most 
AUG of an mRNA (Kozak, 1989). We therefore used the first AUG that is known to initiate 
translation based on all overlapping RefSeq and UCSC Known Gene transcripts to determine the 
reading frame and detect the PTC (based on the 50-nt rule). 
For each AS event, we then count:  
i) The number of transcripts expected to be targeted by NMD when the exon is included, 
but not if the exon is excluded NIn; 
ii) The number of transcripts expected to be targeted by NMD when the exon is excluded, 
but not if the exon is included NEx;  
iii) The number of transcripts encoding protein products for both isoforms Nc. 
 
An AS event is defined as 
i) NMD upon inclusion (NMD_in), if NIn >0, NEx =0, and NIn > 2× Nc; 
ii) NMD upon exclusion (NMD_ex), if NIn =0, NEx >0, and NEx >2× Nc;  
iii) Alternative coding, if Nin=0, Nex =0, and Nc >0; 




We noted that the classification of exons was very consistent when we compared orthologous 
cassette exons in mouse and human (98% of cases that can be assigned in both species), despite 
the fact that some AS events may switch categories during evolution. We therefore combined the 
classification of exons in the two species to increase the coverage when we annotate exons under 
tissue- or cell-type-specific regulation or under strong purifying selection pressure. Specifically, 
for exons which were assigned to the first three categories (NMD_in, NMD_ex, or coding) in 
human, but “other” in mouse, we re-assigned the categories of the mouse events based on 
category of their human orthologs, and vice versa. 
 
NMD classification of mouse and human cassette exons.  
To assess the accuracy of NMD annotation, we first examined 28 mouse NMD exons 
previously identified by inhibiting the NMD pathway using exon-junction microarrays (Ni et al., 
2007). Among these, 26 are annotated as cassette exons and included in our analysis. Our 
pipeline assigned 23 of 26 exons to the same categories as the manual annotations in the 
published study. Among the three exons which were previously predicted to cause NMD due to 
frame-shift but were classified by us as coding, one creates a premature termination codon (PTC) 
in the penultimate exon but does not follow the “50-nt rule” (Ppp1r2a, or AK035230 in ref. (Ni 
et al., 2007)), one does not create PTCs despite the frame shift (Nipsnap1), and one is a 
symmetric exon that does not cause frame-shifts (Brd8, exon size=219). These cases could 
reflect exceptions to the currently understood rules of NMD, which were implemented in our 
computational analysis. Therefore, our pipeline achieved high coverage of AS events with very 
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high accuracy.  
We then examined changes of isoform abundance upon liver-specific depletion of Upf2, 
a key regulator in the NMD pathway (Weischenfeldt et al., 2012), taking advantage of transcripts 
that are expressed in both cortex and liver. We detected Upf2-dependent changes of isoform 
ratios for 186 non-redundant cassette exons, including 69 newly discovered AS exons (37.1%) 
((|∆I|≥0.1, coverage≥20, FDR≤0.05). Importantly, among the 133 exons that are classified as 
NMD_in or NMD_ex, 125 (94%) show a relative increase in the NMD isoform (i.e., increase of 
the inclusion or exclusion isoform for NMD_in and NMD_ex exons, respectively, upon Upf2 
depletion), suggesting that they are likely direct targets of NMD with coupled AS regulation. 
Due to the relatively moderate sequencing depth (~20 million SE 50-nt reads for each of the two 
samples), we also reduced the stringency in the threshold used to detect exons with Upf2-
dependent splicing (|∆I|≥0.1, P<0.05 without multiple-test correction and requirement on read 
coverage). With this relaxed threshold, we detected Upf2-dependent changes of isoform ratios 
for 784 non-redundant cassette exons. Among these, 553 exons are expected to be targeted by 
NMD and 529 of them (95.7%) show a relative increase in the NMD isoform, again suggesting 
that a majority of these exons are direct NMD targets.  
Lastly, we examined 21,065 one-on-one pairs of orthologous cassette exons in mouse and 
human. Among them, 98.0% are in the same categories with regard to the NMD exon 
classification, with the classification performed independently in each species. The remaining 
exons might represent either erroneous assignment or genuine alterations of alternative coding 
capacity during evolution. Taken together, these data suggest that only a small fraction of exons 
have an incorrect NMD classification. 
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If we analyze the complete set of cassette exons using our pipeline, we were able to 
assign NMD categories (NMD_in, NMD_ex and alternative coding) to 11,167 of 16,034 known 
cassette exons for mouse (69.6%). Among these, 6,046 (54.1%) events result in coding variants, 
while the rest potentially trigger NMD. For new cassette exons, we were able to categorize 
48,632 of 146,705 events (33%). Among these, 18,865 (38.8%) represent alternative coding 
variants. 
For human, we were able to assign NMD categories to 27,228 of the 42,761 total known 
cassette exons (63.7%). Among these, 12,866 exons (47.3%) result in coding variants, while the 
rest potentially trigger NMD. For new cassette exons, we were able to categorize 43,885 of 
132,639 events (33%). Among these, 17,422 (39.7%) represent coding variants. 
 
Identification of non-redundant cassette exons. 
To define a set of non-redundant cassette exons in the mouse transcriptome, we grouped 
overlapping cassette exons. Exons in each group were ranked by applying each of the following 
criteria in the order given below to select a representative exon for each group. 
• AS pattern (i.e., both isoforms) conserved in human (1) or not (0) 
• The cassette event is known (1) or newly discovered (0) 
• The number of supporting transcripts (from cDNA/ESTs) for the minor isoform (for 
known AS events); zero for new events 
• The total number of supporting transcripts (from cDNA/ESTs) for either isoform (for 
known AS events); zero for new events 
• The number of supporting RNA-Seq reads for the minor isoform min(in1,in2,ex), 
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where in1, in2, and ex represent the number of reads supporting the two exon junctions of the 
inclusion isoform and the exon junction of the exclusion isoform, respectively. 
• The total number of supporting reads for either isoform [min(in1, in2)+ex] 
• Both splice sites conserved in human (1), or otherwise (0) 
• The NMD type (with human data integrated) is known (1), or otherwise (0) 
The top-ranking exon in each group was selected as a representative to define the set of 
non-redundant cassette exons. 
 
Detection of differential AS with RNA-Seq data. 
Differential AS was identified as previously described using the Quantas pipeline 
(Charizanis et al., 2012; Weyn-Vanhentenryck et al., 2014) 
(http://zhanglab.c2b2.columbia.edu/index.php/Quantas). For SE RNA-Seq data, the number of 
reads supporting each AS exon and junction was counted directly. For PE RNA-Seq data, a 
statistical model was used to infer the transcript structure in the AS regions that were not 
sequenced directly before reading counting (Charizanis et al., 2012). A Fisher’s exact test was 
used to evaluate the statistical significance of splicing changes unless specified otherwise (see 
below), and the false discovery rate (FDR) was estimated by the Benjamini-Hochberg procedure 
(Benjamini and Hochberg, 1995). An AS event was called to have differential splicing in the two 
compared conditions if the event had sufficient read coverage (coverage≥20), proportional 
change of exon inclusion |∆I|≥0.1, and Benjamini FDR≤0.05.  
A slightly different method was used to identify CNS cell type-specific splicing. We first 
compared exon inclusion level of each cell type with all other cell types (e.g., neuron vs. all non-
  
183 
neuron cell types). To account for the variation among multiple cell types in the second group, 
we used a generalized linear model (GLM) to test for statistical significance of differential AS 
(Mazin et al., 2013), followed by multiple testing correction as described above.  An exon is 
called significant if coverage≥20, |∆I|≥0.2, and Benjamini FDR≤0.05. The initial list of cell type-
specific exons was then filtered further. If an exon is called significant in multiple comparisons 
(e.g., neuron-specific inclusion and astrocyte-specific exclusion), only the one with the most 
significant changes (smallest FDR) was kept. 
 
RNA-map of tissue- or cell-type-specific RBPs. 
Normalized-complexity RNA maps that predict the direction of neuron-specific splicing 
or splicing change upon depletion of specific RBPs from CLIP data or RBP motif sites were 
generated as described previously (Charizanis et al., 2012). Unique RBFOX (Weyn-
Vanhentenryck et al., 2014), NOVA (Zhang et al., 2010) and PTBP2 (Licatalosi et al., 2012b) 
CLIP tags were obtained from published studies. Bioinformatically predicted RBFOX (motif 
enrichment and conservation scores (Weyn-Vanhentenryck et al., 2014)) and NOVA (YCAY 
clusters (Charizanis et al., 2012)) binding sites were also generated previously. 
 
Quantification of evolutionary selection pressure driven by regulated AS. 
Evolutionary selection pressure driven by regulated AS was assessed using cross-species 
sequence conservation in the alternative exon and flanking intronic sequences. For each exon, an 
intronic conservation score was derived by averaging 40-way mammalian phyloP scores (Pollard 
et al., 2010) in flanking intronic sequences (200 nt upstream + 200 nt downstream). In the exonic 
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region, taking advantage of the nucleotide resolution of the phyloP score, we considered the 
conservation of the wobble position, which has the least selection pressure driven by protein 
coding. Since NMD_in exons without overlap with protein-coding sequences do not have codons 
or wobble positions per se, we used a phylogenetic approach to infer the wobble position. 
Specifically, we calculated the average phyloP scores in the exonic region for the three possible 
reading frames separately, and inferred the wobble positions based on the minimum of the three 
averages.  
To evaluate the discriminative power of this approach, we compiled 3,113 exons that are 
constitutively spliced in both human and mouse (≥10 supporting cDNA/ESTs) as a negative 
control of regulated AS exons. For a positive control, we compiled a set of 133 NMD_in exons 
with conserved AS patterns previously annotated in both human and mouse. In addition, these 
NMD_in exons do not overlap with any protein-coding sequences compiled from human, mouse, 
or rat.  
We assumed the whole population of cassette exons represents a mixture of those under 
functional selection, and those produced by leaky splicing or as evolutionary intermediates. We 
decomposed the two groups using a Gaussian mixture model (GMM) whose parameters were 
estimated through an expectation maximization (EM) procedure (Bilmes, 1998). More 
specifically, denote an exon k as , in which si and sw are conservation score in the 
flanking intron and in the wobble positions, respectively. 
  .                      (1) 
where  represents all model parameters.  The first component represents 
AS events without evolutionary constraints, and the second component represents conserved AS 
xk = (si, sw )
P(xk |Θ) =αnP(xk |θn )+αcP(xk |θc )
Θ = α n ,θn ,α c ,θc( )
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events.  and  represent the prior probability of each population.  denotes the 
mean and covariance matrix of exons in each group, and  
                          (2) 
is the distribution of each group of exon (the index n or c is dropped here for simplicity).  
 
When we fit the data, we fixed  ( , and ), which 
were estimated from constitutive exons.  Parameters of the second component were estimated 
by the EM procedure ( , and ).  The prior was estimated to 
be αn=0.84, and αc=0.16, which represents the proportion of exons in each group.   
 
Each exon can then be ranked by the posterior probability.     
                     (3)  
 
The expected number of exons under selection can also be estimated:  
   ,                                          (4) 
which can be applied to all exons (Nc=Nαc), or known and new exons separately. 
 
We note that neither the proportion of exons in each component nor the FDRs can distinguish 
α n α c θ = (µ,Σ)
P(xk |θ ) =
1


























P(c | xk ,Θ) =
α cP(xk |,θc )
α nP(xk |θn )+α cP(xk |θc )




between negative or positive selection, although this study primarily focuses on exons under 
negative purifying selection.  We therefore used stringent thresholds to identify exons under 
strong negative selection by requiring that si and sw are both above two standard deviations of 
the mean estimated from constitutive exons (Figure 3.6B). We note that among the 3,058 non-
redundant cassette exons above this threshold, 3,028 exons (99%) have GMM FDR<0.05 and the 
remaining exons have FDR<0.08. Furthermore, this set included 79 of the 133 conserved 
noncoding NMD_in exons (59%) used as our positive control; in contrast, only 0.48% of 
constitutive exons are above the threshold, confirming the discriminative power of our scoring 
method.  
 
Evolutionary selection pressure driven by regulated AS.  
As sequencing depth increases, the apparent conservation of AS patterns across different 
species, such as mouse and human, becomes insufficient to ascertain evolutionary constraints or 
functionality because skipping of the orthologous exons can be detected relatively easily, 
especially in abundant genes. Several previous studies have attempted to predict exons with 
conserved AS using cross-species sequence conservation, reading-frame preservation, exon and 
intron size, splice site strength, and other sequence features (Dror et al., 2005; Sorek et al., 2004; 
Yeo et al., 2005). These methods typically use features that favor protein-coding exons, which is 
not suitable for our analysis, and pairwise alignment (e.g., human and mouse) to measure 
sequence conservation, which is limited in statistical power. Another study (Lu et al., 2009) 
evaluated the ratio of synonymous to non-synonymous mutations in exons as a measure of 
selection pressure driven by AS regulation, which is again not suitable for noncoding exons and 
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does not consider signals in introns. We therefore sought a more quantitative and specific 
measure of selection pressure driven by regulated AS without biasing toward coding or 
noncoding exons.  
We note that AS events that trigger NMD upon exon inclusion are not under selection 
pressure of protein coding if the exon does not overlap with other protein-coding exon variants. 
These exons are typically skipped to produce protein-coding transcripts. Therefore, if these 
alternative exons are conserved during evolution (e.g., between human and mouse), the AS 
events are presumably functional by induction of the NMD isoform, and the selection pressure in 
the alternative exons and flanking introns is driven by the maintenance of AS regulation and 
NMD. We also expect that at the sequence level the selection pressure driven by AS regulation is 
much stronger than that driven by NMD since the latter requires only a PTC with proper distance 
from the downstream exon junctions. Based on these arguments, we compiled 133 NMD_in 
cassette exons with conserved splicing patterns in mouse and human as a positive control dataset 
for regulated AS events of functional significance.  Importantly, these exons do not overlap with 
coding sequences (either in mouse, human, or rat). To get a negative control set of regulated AS 
events, we compiled 3,113 exons that are constitutively spliced in both human and mouse (≥10 
cDNA/EST transcripts).  
At the population level, we first measured the selection pressure of each exon driven by 
regulated AS using the 40-way mammalian phastCons score (Pollard et al., 2010) in the exonic 
and flanking intronic sequences. On average, constitutive exons have high level of conservation 
in the exonic sequence, but very low in the flanking intronic sequences. In contrast, NMD_in 
exons have dramatically elevated conservation in flanking intronic sequences and, notably, in 
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exonic sequences as well, reflecting constraints to preserve additional regulatory sequences 
important for splicing regulation (Figure 3.5A). We then examined alternative coding and 
NMD_ex exons with different inclusion levels. Alternative coding and NMD_ex exons with low 
or median inclusion levels (i.e., the minor isoform is relatively abundant) are similarly associated 
with elevated sequence conservation, especially in the flanking intronic sequences (Figure 3.5A) 
and importantly, those with high exon inclusion level (i.e. the minor skipping isoform is of low 
abundance) only have moderately increased level of conservation compared to constitutive 
exons. 
We also examined the selection pressure on the three different codon positions separately 
for each group of exons using the 40-way mammalian phyloP scores (Pollard et al., 2010). 
Presumably, for coding exons, the wobble position has fewer protein-coding constraints 
compared to the other two positions, which helps to determine the AS-driven selection pressure 
superimposed on the protein-coding sequences (Xing and Lee, 2006). On the other hand, 
NMD_in exons, which do not overlap with coding sequences, have essentially similar level of 
conservation at each of the three “codon” positions. We inferred the wobble positions of exons 
using two approaches. In the first approach, we directly inferred wobble positions based on the 
ORF of the supporting transcripts (ORF-based). In the second approach, we calculated the 
average 40-way mammalian phyloP scores for the three possible reading frames, and inferred the 
wobble positions based on the minimum of the three averages (phylogenetic). These two 
approaches agree on over 90% of exons with orthologous sequences in mouse and human. 
However, an important advantage of the phylogenetic approach is that it is not limited to 
transcripts with known ORFs and is unbiased with regard to the comparison between coding and 
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noncoding exons. We therefore used this approach to infer wobble positions for the results 
presented in this work. 
Compared to constitutive exons, we observed substantially higher conservation in the 
wobble positions for NMD_in exons, as well as alternative coding and NMD_ex exons in which 
the skipping isoform is relatively abundant (Figure 3.5B). In contrast, the other two groups, 
coding_major and NMD_ex_major exons, show only a moderate, though statistically significant, 
increase in conservation. The similarity of coding_major, NMD_ex_major, and constitutive 
exons suggests that as the sequencing depth increases, leaky splicing products (the rare exclusion 
isoform) are sampled and sequenced by chance in both human and mouse, so that the apparent 
conservation of splicing pattern is not a sufficient indicator of their functional importance (Baek 
and Green, 2005). Instead, a vast majority of these events (where the skipping form is rare) 
might have no functional significance (Lu et al., 2009; Sorek and Ast, 2003; Xing and Lee, 
2005). 
 
Phylogenetic analysis of highly conserved NMD exons. 
Three groups of cassette exons under selection—NMD_in exons without any overlap 
with protein-coding sequences, NMD_ex exons, and alternative coding exons—were compared 
using constitutive exons conserved between human and mouse as a control. 
Since transcriptome data is not available for a majority of the sequenced vertebrate 
species, we used conservation of the exon sequences with intact splice sites as a proxy. For each 
exon, multiple alignments of 60 vertebrate species (Pollard et al., 2010) were retrieved, with 200 
nt extension on each side to include splice sites. The conservation of the exon between mouse 
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and each of the other 59 species is determined by the presence of AG/GU splice sites at the 
boundary of exons. For each group of exons, we obtained a matrix with 1 indicating conservation 
of the exon, and 0 indicating the lack of conservation (at the sequence level). Centroid-linkage 
hierarchical clustering of exons was performed to re-order exons based on edit distance.  
 
RNA binding proteins. 
A list of 393 previously annotated RNA-binding proteins (RBPs) was downloaded from 
RBPDB (Cook et al., 2011). 
 
Gene Ontology (GO) analysis and chromatin regulators. 
GO and functional annotation analysis was performed using the online tool DAVID 
(Dennis et al., 2003). The foreground gene list was derived from genes with NMD exons under 
strong purifying selection; 14,629 genes with either known or new cassette exons were used as 
the background. A total of 52 genes encoding chromatin regulators were identified from a cluster 
of gene ontology and functional annotation terms (e.g. chromatin organization, chromatin 
regulator, and histone modification; Table S.5). 
 
Data availability. 
RNA-Seq data generated in this study has been deposited to the NCBI Sequence Read 
Archive (SRP055008). The complete list of known and newly discovered AS events, as well as 





Generation and compilation of RNA-seq data 
A summary of RNA-seq data generated for this study or compiled from the public 
domain is provided online in Supplementary Table 1. 
To determine the dynamics of the mammalian brain transcriptome in depth, we 
performed RNA-seq using mouse cortex at 9 developmental stages (E14.5, E16.5, P0, P4, P7, 
P15, P30, 4 months, 21 months), each stage in duplicates using the standard Illumina TruSeq 
poly-dT protocol. All RNA samples used for this analysis have RIN>8.5. In total, we obtained 
987 million paired-end (PE) 101-nt reads (54.8 million per sample on average)(Yan et al., 2015). 
This dataset has been deposited to NCBI Short Read Archive (SRA) under accession 
SRP055008. 
To further evaluate neural maturation based on developmental regulated alternative 
exons, we collected 346 public RNA-seq samples that can be classified into three categories: 
cortex or spinal cord tissues, purified neuronal subtypes and ESC-derived neurons. Technical or 
biological replicates were merged to obtain a final list of 111 samples, of which 41 are from 
tissues, 39 are purified neurons and 31 are ESC-derived neurons. In total, these data are 
composed of about 13 billion reads or read-pairs, providing an unprecedented depth and scope to 
study dynamic splicing changes during neural development.  
RNA-seq data derived from Ptbp2 WT/KO and Nova2 WT/KO brains were obtained 
from published studies (Li et al., 2014; Saito et al., 2016a). For Mbnl, the mammalian brain 
expresses Mbnl1 and Mbnl2, which both regulate splicing with a certain degree of redundancy. 
To identify the comprehensive list of Mbnl-dependent exons, we generated a Mbnl1-/-; Mbnl2 
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loxP/loxP; Nestin-Cre mouse line to deplete both Mbnl1 and Mbnl2 in the central nervous 
system (referred to Mbnl1/2 double-KO or dKO). Deep RNA-seq was performed using high-
quality RNA (RIN≥8) extracted from frontal cortices of adult Mbnl dKO and control mice, each 
group in triplicates using the standard Illumina TruSeq poly-dT protocol (PE 101-nt reads, ~60 
million reads per sample). We are in the process of depositing this dataset to SRA.  
To compare the splicing profiles of neurons and glial cells, we obtained the RNA-seq 
dataset that profiled all major CNS cell types in the mouse cortex (Zhang et al., 2014). To 
evaluate potential differences of pyramidal neurons and interneurons, we used a single-cell 
RNA-seq dataset derived from primary visual cortex of adult mice (Tasic et al., 2016). 
 
Analysis of RNA-seq data and quantification of AS 
All RNA-seq data were mapped by OLego v1.1.2 (ref.(Wu et al., 2013)) to the reference 
genome (mm10) and a comprehensive database of exon junctions was provided for read 
mapping. Only reads unambiguously mapped to the genome or exon junctions (single hits) were 
used for downstream analysis.  
To quantify AS, we used a comprehensive list of both known and novel AS events, as we 
described previously (Yan et al., 2015). Inclusion of known and novel alternative exons (percent 
spliced in or Ψ) was then quantified based on the number of exon junction reads using the 
Quantas pipeline (http://zhanglab.c2b2.columbia.edu/index.php/Quantas), as we described 
previously. To reduce uncertainty in estimating Ψ, we kept the estimation only for exons with 
read coverage ≥20 and standard deviation <0.1 (based on binomial distribution). Gene expression 
was quantified using the same pipeline. For all quantifications, biological replicates were 
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combined. For the single-cell RNA-seq analysis (Tasic et al., 2016), we used cell types defined 
in the original paper, and pooled cells that were assigned to each cell type as core members for 
AS quantification.  
To identify exons with differential splicing in two compared conditions, we evaluated the 
statistical significance of splicing changes using both exonic and junction reads that support each 
of the two splice isoforms. For the pairwise comparisons of different stages of the developing 
cortex, we used the standard Fisher’s exact test by pooling read counts of the biological 
replicates. The remaining RNA-seq datasets used to measure differential splicing upon depletion 
of specific RBPs or comparing different subtypes of neurons (with an exception of the Ptbp KO 
because the Emx:Cre sample does not have replicates) were analyzed with an updated version of 
the Quantas pipeline using a generalized linear model (GLM), as described previously (Mazin et 
al., 2013). Conceptually, the advantage of the GLM method is that it explicitly models the 
variation across biological replicates. In practice, we found the results from the GLM and 
Fisher’s exact test to be highly similar, with the GLM method being slightly more stringent. The 
false discovery rate (FDR) was estimated by the Benjamini-Hochberg procedure (Benjamini and 
Hochberg, 1995). An AS event was called differentially spliced in the two compared conditions 
with the following criteria: coverage≥20, Benjamini FDR≤0.05 and |ΔΨ |≥0.2 (to identify 
developmentally regulated exons or neuron subtype-specific exons) or 0.1 (to identify RBP-
dependent exons).  
To identify exons with developmental splicing changes, we performed pairwise 
differential splicing analysis among different stages during cortex development. An exon is 
called to have developmentally regulated splicing if it is differentially spliced in at least one 
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comparison (Figure 1a). Developmentally regulated exons in cortical pyramidal neurons 
(Molyneaux et al., 2015), motor neurons (Amin et al., 2015; Bandyopadhyay et al., 2013; Zhang 
et al., 2013b) and ESC-derived glutamatergic neurons (Hubbard et al., 2013) (Figure 2b) were 
identified similarly. For each of these datasets, we also identified developmentally regulated 
exons with monotonic splicing changes if all significant changes occur in the same direction. 
For detailed analysis, we focused on a subset of 77,950 non-redundant cassette exons, 
including 13,500 cassette exons identified from previous EST/cDNA sequences (denoted known 
cassette exons) and 64,450 cassette exons identified from brain RNA-seq data de novo (denoted 
novel cassette exons). Methods to identify non-redundant cassette exons were described 
previously (Yan et al., 2015). 
 
Conservation of AS events and evaluation of purifying selection pressure 
For each cassette exon observed in the mouse transcriptome, we determined whether it 
has conserved splicing pattern in human and whether it is under strong purifying selection 
pressure in mammals, both as described previously (Yan et al., 2015). In brief, AS events in 
human were similarly identified using cDNA/ESTs and RNA-seq data derived from developing 
human brains. Selection pressure of each exon was quantified based on cross-species 
conservation in the synonymous position of the alternative exons as well as in flanking intronic 
sequences in 40 sequenced mammalian species (Pollard et al., 2010). A subset of exons with the 
highest conservation was determined to undergo strong purifying selection pressure. 
 
WGCNA to identify exon modules 
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Weighted gene coexpression network analysis (WGCNA, version 1.34)(Zhang and 
Horvath, 2005) was performed on the developing cortex data using the splicing profiles of the 
2,883 developmentally regulated exons. Pearson correlations between exons were calculated and 
raised to power 3 to determine the adjacency matrix. Exon modules were identified with default 
parameters, followed by automatic merging of modules with similar eigenvectors (using 
dissimilarity threshold=0.25, which is the default). This analysis initially resulted in 5 modules 
(Supplementary Figure 2). Inspection of the resulting modules suggested that modules 4 and 5 
show similar temporal patterns (higher/lower exon inclusion between P0 and P7). Therefore, 
these two modules were manually merged to form the final module M4 reported in the paper and 
its module eigenvector was re-calculated.  
The correlation between each individual exon and the eigenvector of the corresponding 
module was calculated and used to measure the membership of each exon to the module. For 
each module, a subset of exons with the highest correlation with the module eigenvector was 
defined as core module members (correlation p<0.001, corresponding to Pearson r=0.9 
approximately). 
 
Sigmoidal fit to determine the precise timing of the maximal developmental splicing switch 
For each exon, we parameterized the temporal pattern of exon inclusion levels by fitting a 
sigmoidal curve: 
                                                                      (1) 
in which a and k are the low and high exon inclusion levels during development and t is 
time point represented by post-conception days (pcd) in log10 scale.  Following this definition, 
Ψ = a + (k − a) (1+ e−b(t−m ) )
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the parameter m is the time point when the maximal splicing switch occurs. 
Parameters of the sigmoidal fit were estimated by nonlinear least squares (nls) curve 
fitting in R (using the port algorithm).  Quality of fit was measured by the normalized residual: 
 
                                                                             (2) 
where i is the index of the developmental time point. 
We applied this method to core members in modules M1 and M2. The sigmoidal fit was 
considered to be reliable for 964 exons satisfying ε<0.15, k-a>0.2 and m>0. 
 
Sliding window analysis of gene ontology (GO) and other functional annotations 
Developmentally regulated exons were ranked according to the timing of the maximal 
splicing switch obtained from sigmoidal fit (parameter m), as described above. For the results 
presented in the paper, we used a sliding window size of 300 exons to obtain lists of foreground 
genes. The background gene list for comparison is composed of all genes with cassette exons 
with a sufficient coverage in the cortex (coverage≥20). Gene Ontology (GO) terms were 
downloaded from http://git.dhimmel.com/gene-ontology/. The enrichment of each GO term 
among genes in each sliding window was assessed by a hypergeometric test. Benjamini-
Hochberg correction was applied to obtain the final FDR (correcting for 14,514 terms and 665 
sliding windows), and only GO terms with corrected FDR≤0.005 were kept for further analysis. 
Each significant GO term was represented by their log-transformed FDRs across all sliding 




N (k − a)
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patterns of enrichment (Figure 4.1E and Table S.7). 
We also used the same sliding window analysis to find enrichment of genes with 
additional functional annotations (Figure 4.3). These include genes encoding presynaptic 
proteins (Abul-Husn et al., 2009) and genes encoding post-synaptic densities (PSD), components 
of the mGluR5 and the NRC/MASC complexes (http://www.genes2cognition.org)(Croning et 
al., 2009). We also included genes implicated in autism obtained from two sources: genes 
compiled in the SFARI gene database(Banerjee-Basu and Packer) and genes with likely gene-
disrupting (LGD) mutations in autism patients as determined by exome sequencing (De Rubeis 
et al., 2014; Iossifov et al., 2014; Iossifov et al., 2012; Neale et al., 2012; O'Roak et al., 2012; 
Sanders et al., 2012). 
For comparison, standard GO analysis was also performed using core exons of each 
module as foreground, and the same list of genes with brain-expressed cassette exons as 
background. Statistical tests and multiple test correction were performed as described above and 
the significant terms (FDR≤0.05) are shown in Table S.8. 
The genes with differentially spliced exons between the peripheral and sensory cell types 
and mature CNS neurons are used for GO enrichment analysis with the genes with brain-
expressed cassette exons as background. Statistical tests and multiple test correction were 
performed as described above and the significant terms (FDR≤0.05) are visualized using 
Cytoscape. 
 
Evaluation of neuronal maturation based on developmental splicing changes.  
We developed a computational tool named Splicescope to evaluate neuronal maturation 
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using developmental splicing profiles and made it available at http://splicescope.splicebase.net. 
This tool can be used through either command line or the galaxy system 
(http://galaxy.splicebase.net). 
For this purpose, we first defined 6 distinct maturation stages from the mouse cortex data 
E14.5, E16.5, P0, P4, P7, and P15 or older, which are represented by stages 1-6. P15 or older 
were grouped as one stage because of high correlation between samples after P15 (Pearson 
correlation r>0.95). We did not name the stages using the actual ages because developmental 
timing of different subtypes of neurons can be different in vivo (e.g., maturation of spinal motor 
neurons is in general earlier than cortical neurons). For each sample, we obtained the splicing 
profile of the 1,909 known module cassette exons defined in the cortex reference, which was 
used to assign the sample to a specific maturation stage by comparison to the cortex reference, 
using a two-step strategy.  
Considering that different exons may have different contributions toward defining 
specific maturation stages and that the range of exon inclusion is (0, 1), we first used a beta 
regression method (betareg in R)(Cribari-Neto and Zeileis, 2010) to model the inclusion level of 
each module exon yi in each sample  in which m is the total number of module 
exons.  
 ,                                                                                (3) 
where  and . 
We then modeled the expectation of the inclusion level of each module exon with a beta 
regression: 
 y = (y1, y2 ,…, ym )
T
yi ~ beta(µi,φ)
E(yi ) = µi var(yi ) = µi (1− µi ) / (1+φ)
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 ,                                                                            (4) 
where  is the vector of regression parameters for the 9 time points, is 
the inclusion level of exon i in the reference sample j, and g(u) is a link function that maps (0,1) 
to any real number.  Here we used the logit function  in the model. 
We fitted the beta regression model to estimate parameters β and ϕ for each sample, and 
to obtain the fitted inclusion level for each exon i.  Since  is determined by a linear 
combination of the inclusion levels of the exon in the cortex reference, the regression essentially 
projects the sample into the subspace spanned by the cortex reference samples, so that we can 
evaluate the distance of a new sample to each of the reference samples in this subspace. 
 
In the second step, we defined sample distance  as the Euclidean distance of projected 
sample (the fitted exon inclusion levels) and each reference sample j. 
 ,                                                                         (5) 
where . 
The maturation stage of the sample was then assigned by the k-nearest neighbor method 
(KNN, k=1 for this study) using  as the distance measure.  The prediction 
confidence score S for each sample was calculated as: 
 .                                                                     (6) 
 
This method was applied to evaluate the overall maturation of each sample.  A prediction 
g(µi ) = xijβ jj∈T∑
β = (β1,β2,…,βt )T xij
g(µ) = log µ / (1− µ)( )
µˆi µˆi
Dj
Dj = xij − µˆi( )i=1
m∑
2
µˆi = g−1 xiT βˆ( )
 D = D1,…,Dt( )
S = 1−min(D) / max(D)
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is considered to be correct if the predicted stage is the same as the true stage, or immediately 
adjacent to account for ambiguity in assignment of the true stage (the actual age of donor mice 
sometimes falls between any two consecutive ages of the reference samples). 
For data visualization, we also applied principal component analysis (PCA, using the 
princomp package implemented in R) to the developing cortex samples and projected all the 
other samples to the space defined by the first two principle components.  
To correlate RBPs to neuronal maturation, we quantified the expression of 372 RBPs 
obtained from RBPDB (Cook et al., 2011) and ranked these RBPs based on the correlation of 
their expression with predicted maturation stages (Figure 4.9A). Differential expression analysis 
between each peripheral/sensory neuronal subtype and mature CNS neurons was performed 
using the edgeR method included in the Quantas pipeline (Figure 4.9B). 
To evaluate the contribution of the four specific RBP families we focused on neuronal 
maturation, we also predicted neuronal maturation stages based on the splicing profile of their 
direct target exons defined by the Bayesian network analysis (see below) using the same 
approach (Figure 4.8E). 
 
Motif enrichment analysis 
We performed hexamer enrichment analysis using upstream or downstream intronic 
sequences (200 nt in each region) of the core module exons in M1 and M2, as compared to all 
cassette exons used as a control. For this analysis, repeat masked sequences were extracted, and 
the enrichment of each hexamer was evaluated using a hypergeometric test (Supplementary 
Figure 4.8). Similarly, we also evaluated the enrichment of motif sites for Nova, Rbfox, Mbnl 
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and Ptbp in core module exons as compared to all cassette exons using previously established 
consensus motifs. 
 
Splicing-regulatory networks of Nova, Rbfox, Mbnl and Ptbp 
We used an integrative modeling approach we previously developed to define direct 
target exons of each RBP family, as we previously demonstrated for Nova and Rbfox (Weyn-
Vanhentenryck et al., 2014; Zhang et al., 2010). In brief, this approach employs a Bayesian 
network to weigh and combine multiple types of data, including evidence of protein-RNA 
interactions as determined by CLIP data and bioinformatics predictions of motif sites, evidence 
of RBP-dependent splicing as determined by RNA-seq or microarrays, and several evolutionary 
signatures related to regulated AS.  
For this study, we used the Nova target network we previously defined (Zhang et al., 
2010). Among the 363 Nova target cassette exons we originally identified in mm9, 359 exons 
were annotated in our current database based on mm10 and used in this analysis. An updated 
version of the Rbfox target network was built to incorporate recently published RNA-seq data. 
We also extended this approach to define the Mbnl and Ptbp target networks. To simplify 
analysis and presentation, we limited our analysis to ~16,000 known cassette exons annotated 
from mRNA/ESTs. This is because novel exons discovered de novo in RNA-seq analysis are 
frequently not covered by exon or exon-junction microarrays and they were not included in our 
previous analysis of the Nova network. More details for building each network are described 
below. 
For each network, we evaluated the performance using sensitivity and specificity. We 
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estimated sensitivity as the percentage of recovered validated target exons, which were compiled 
in previous studies. Specificity was estimated as the percentage of not-recovered non-validated 
targets. Since a subset of exons used for this evaluation was used for training of the full Bayesian 
network model, we obtained the prediction FDRs of these training exons by 10-fold cross 
validation, as described below, to avoid potential biases. We note both sensitivity and specificity 
are conservative estimates, because some validated exons might not represent direct targets of 
the RBP, and only a small subset of bona fide target exons were previously validated.  
Rbfox. In the updated network, the following datasets were used to model evidence of 
splicing changes in the Bayesian network analysis: control vs. Rbfox2 knockdown in C2C12 
cells before and after differentiation (Singh et al., 2014), and control vs. RBFOX2 knockdown in 
HeLa cells (Weyn-Vanhentenryck et al., 2014). Significance of splicing changes was estimated 
using the Quantas pipeline as described above. Since splicing changes were modeled using a 
normal distribution in the Bayesian network, we transformed the p-values using the inverse 
normal cumulative distribution function “norminv(p/2)” in R, where p is the p-value determined 
by RNA-seq analysis, and assigned the sign of the direction calculated for ΔΨ. The other 
datasets, including Rbfox CLIP tag cluster score and motif score as well as evolutionary 
signatures, were kept the same as in our previous analysis (Weyn-Vanhentenryck et al., 2014). 
For training of the Bayesian network, we used the list of 121 validated Rbfox target 
exons we compiled previously. We also included 765 exons showing splicing changes in at least 
one RNA-seq dataset (509 exons activated and 256 exons repressed), and 500 randomly sampled 
exons without evidence of Rbfox-dependent splicing but with sufficient read coverage in at least 
one RNA-seq dataset. Only the 121 validated target exons were assigned a class label during 
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training. For prediction, each cassette exon was assigned three probabilities: activation or 
repression by Rbfox or no direct regulation, from which an FDR of target prediction was 
derived. In total, 732 exons were predicted as direct Rbfox targets with FDR<0.01. Among these, 
we were able to determine the direction of splicing regulation for 654 exons with probability of 
activation or repression ≥0.7. 
To ensure that the Bayesian network model is not overfit, we performed 10-fold cross 
validation and compared the results predicted by the cross-validation models and the full model, 
as we previously described (Weyn-Vanhentenryck et al., 2014; Zhang et al., 2010), which gave 
very similar results (the same for the other RBPs described below). 
Mbnl. To minimize the redundancy of splicing regulation by Mbnl1 and Mbnl2, we 
generated RNA-seq data to compare frontal cortices of adult Mbnl1/2 dKO and control mice 
(dataset1). We also used three additional RNA-seq datasets from published studies: WT vs. 
Mbnl2 KO mouse in hippocampus (Charizanis et al., 2012) (dataset 2) and WT vs. Mbnl1 KO 
mouse in muscle and heart (Wang et al., 2012) (datasets 3 and 4). Similar to the Rbfox network, 
we used the norminv(p/2) as the representation of splicing change scores in the Bayesian 
network analysis. We assigned splicing change scores in datasets 2-4 derived from non-cortex 
tissues only for exons with read coverage≥20 (dataset 2) or 15 (datasets 3,4), to avoid 
punishment on Mbnl target exons more specifically expressed in the cortex.  
We obtained predicted Mbnl-binding clustered YGCY motif site scores from a previous 
study (Zhang et al., 2013a). In brief, the mCarts algorithm was used to integrate the number and 
distance of YGCY elements, their cross-species conservation and secondary structure using a 
hidden Markov model (HMM). To score Mbnl CLIP tag clusters as evidence of Mbnl binding, 
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we combined the unique CLIP tags for Mbnl2 in hippocampus (Charizanis et al., 2012) and 
Mbnl1 in C2C12 cells(Wang et al., 2012). We derived motif site and CLIP tag cluster scores 
with respect to splice sites in the alternatively spliced region as described previously by weighing 
the strengths of individual sites and their distance to the splice sites (Weyn-Vanhentenryck et al., 
2014; Zhang et al., 2010). 
For training of the Bayesian network, we used 964 exons showing splicing changes in at 
least one RNA-seq dataset (546 activation and 418 repression). In addition, 500 exons with 
sufficient read coverage in at least one RNA-seq dataset but no evidence of Mbnl-dependent 
splicing were also included. We compiled 94 unique cassette exons that have been previously 
validated as Mbnl1 or Mbnl2 targets in human, mouse, or rat; among them 59 exons show 
splicing changes in at least one RNA-seq datasets and were assigned a class label. The remaining 
exons were unlabeled during training. For this study, we were able to predict 295 exons as direct 
Mbnl targets with FDR<0.02. 
Ptbp. We used the following datasets to determine Ptbp2-dependent splicing in the 
mouse brain: RNA-seq of WT and CNS-specific Ptbp2 KO brains derived from either Nes-Cre 
or Emx-Cre drivers (Li et al., 2014), WT vs. Ptbp2 germline KO brains as measured by 
Affymetrix exon arrays or exon-junction arrays (Licatalosi et al., 2012b). We used the 
norminv(p/2) as the representation of splicing change scores in the Bayesian network analysis, as 
described above. 
We also predicted Ptbp2-binding motif sites using mCarts(Zhang et al., 2013a). In brief, 
we used Ptbp2 neocortex HITS-CLIP data (Licatalosi et al., 2012b) to identify 5,341 CLIP tag 
clusters with peak height ≥ 6 tags. Regions defined by these peaks extended by 50 nt in both 
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directions were used for the positive training set of Ptbp2 binding sites by the HMM. In addition, 
112,202 regions (exons extended by 1kb in both directions) containing no CLIP tags were used 
as the negative training set. We ran mCarts using the UCUY as the consensus motif recognized 
by Ptbp (Licatalosi et al., 2012b; Perez et al., 1997) and scored the predicted Ptbp-binding 
clustered UCUY motif sites for each cassette exon as described previously (Weyn-
Vanhentenryck et al., 2014; Zhang et al., 2010). 
For training of the Bayesian network, we compiled 63 unique cassette exons that have 
been previously validated as Ptbp1 or Ptbp2 targets in human, mouse, or rat. We included 992 
additional exons that show significant change in at least one of the RNA-seq or microarray 
datasets as a positive training set (|ΔΨ|≥0.1 and FDR≤0.01 for RNA-seq, p≤0.01 for exon arrays, 
and |dIrank|≥8 for junction arrays). For the negative training set, we randomly selected 300 exons 
with sufficient coverage for at least one RNA-seq dataset and that were not significantly 
differentially spliced in any of the four datasets. Only the validated target exons were assigned a 
class label during training. For this paper, we defined 469 exons as direct Ptbp targets with 
FDR<0.01. 
 
Overlap between WGCNA module exons and RBP targets 
To evaluate how well regulation by each RBP family predicts the timing of 
developmental splicing switches, we ranked all known cassette exons based on the predicted 
probability of activation or repression by each RBP (resulting from the Bayesian network 
analysis), and used the ranking to predict core members of module exons in M1 and M2 (e.g., 
M1+ core vs. remaining exons) with different thresholds. The resulting ROC curve was 
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evaluated by the partial area under curve (pAUC) focusing on the left side of the curve with high 
specificity (false positive rate or FPR<0.1); pAUC was scaled so that perfect prediction will give 
a pAUC of 1 (Figure 4.5I in the main text). In the second approach, we obtained the list of exons 
activated (or repressed) by each RBP using stringent thresholds in the Bayesian network analysis 
as described above and performed a gene set enrichment analysis (GSEA)(Subramanian et al., 
2005) using exons ranked by their module membership. The contribution of Elavl (Ince-Dunn et 
al., 2012) and nSR100 (ref. (Quesnel-Vallieres et al., 2015)) for developmental splicing switches 
was also evaluated using pAUC (Figure 4.7), but in this case, exons were ranked by the extent of 
RBP-dependent splicing, as determined by exon-junction microarrays (ΔIrank; ref.(Ince-Dunn et 
al., 2012)) and RNA-seq (FDRs), respectively.  
 
Construction of a neurodevelopmental splicing code 
To predict developmental splicing switches with specific timing, we constructed a 
database of 1,240 features relevant for splicing regulation for each known cassette exon. These 
include sequence features (exon lengths, exon and intron conservation, RBP motif scores (based 
on mCarts (Zhang et al., 2013a) or motif enrichment or conservation score, or MECS (Weyn-
Vanhentenryck et al., 2014) for the four RBPs we focused on and RNAcompete (Ray et al., 
2013) for many additional RBPs), mono-, di-, and tri-mer counts, splice site strength, exon and 
intron regulatory element counts, and exon NMD potential), CLIP features (CLIP tag cluster 
scores in each alternative exon and upstream and downstream flanking introns), perturbation 
features (differential splicing upon genetic or cell-based depletion of RBPs, as measured by 
RNA-seq or microarrays), and results of Bayesian network predictions (probabilities of target 
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and non-target for each RBP).  
We decided to use random forest to predict module membership and directions for core 
member exons in modules M1 and M2 using all or subsets of features we compiled. The 
advantages of random forest include its flexibility in accepting both quantitative and qualitative 
features, its superior classification performance demonstrated in many application domains, and 
the ability to provide a measure of feature importance (Breiman, 2001) . Specifically, we used 
the randomForest package (version 4.6.10)(Liaw and Wiener, 2002) in R for model construction 
and prediction. Four separate models for M1+, M1-, M2+, and M2- were constructed for binary 
classification of whether an exon belongs to a module of the specified direction or not (e.g., M1+ 
vs. not M1+). For each model, the positive training set consisted of core member exons in the 
currently tested module and direction, while the negative training set consisted of all remaining 
cassette exons annotated in mouse, with the exception of the non-core exons in the current 
module, because their classification is ambiguous.   
Random forest is in general very robust with regard to choice of model parameters. When 
we trained the models, we performed stratified sampling to obtain the same number of positive 
and negative training exons. We also varied different parameters including the number of trees 
(ntree) in the forest and the number of features per tree (mtry), and found that the results are in 
general very stable. For results presented in this paper, we used ntree=1000 and mtry=300 when 
we used all features to build the models (Figure 4.6A,C). For each exon, the prediction is 
represented by the out-of-bag (OOB) probability based on a bootstrap procedure used by 
randomForest. This is essentially a cross validation procedure, in which each decision tree is 
only used to predict independent samples not used for training of the tree, so it provides an 
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unbiased measure of prediction confidence. The performance of each model was evaluated by 
the area under the ROC curve (AUC) using the ROCR package (version 1.0.7)(Sing et al., 2005). 
The importance of each RBP for prediction was evaluated using the reduction of Gini impurity 
(Figure 4.5B). We note that each exon might be predicted as positive by multiple models 
depending on the threshold (e.g., both M1+ and M2+ with different confidence). To resolve 
ambiguity, OOB probabilities were transformed into false positive rate (FPR) and the prediction 
with the minimal FPR was chosen to obtain the final class label.  
We also built random forest models using subsets of features such as sequence features 
(Seq_all, mtry=100) and features related to regulation by the four RBP families we focused on 
(RBP4, mtry=2) (Figure 5a).  
 
Immunofluorescence analysis of Rbfox expression in olfactory epithelium 
Immunofluorescence was performed on coronal 14µM cryosections of young adult 
mouse (3-4 weeks old) main olfactory epithelium. Slides were dried for 10 minutes at room 
temperature, fixed in 4% PFA, PBS 1X, and washed 3 times for 5 minutes in PBST (PBS 1X, 
0.1% Triton X-100). Sections were blocked for 1 hour in blocking buffer (PBS 1X, 4% Donkey 
Serum (Sigma), 1% Triton X-100). The following primary antibodies were used at the specified 
dilution: mouse α-Rbfox1 (Millipore 1D10, 1:100), rabbit α-Rbfox2 (Bethyl Laboratories, A300-
864A, 1:1000), rabbit α-Rbfox3 (Millipore ABN78, 1:200), and goat α-Calmegin (Santa Cruz N-
16, 1:50). Primary antibodies were diluted in blocking buffer, and sections were incubated 
overnight at + 4°C. Slides were washed 3 times for 5 minutes in PBST and then incubated for 1 
hour at room temperature with blocking buffer containing secondary antibodies (Jackson 
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Immunoresearch) and DAPI. Slides were washed 3 times for 5 minutes in PBST and mounted 
with Vectashield (Vector Laboratories). Images were taken on a Zeiss LSM700. 
 
Gabrg2 exon 9 splicing reporter assay. 
The wild type GABAA receptor minigene was generated in a previous study (Dredge and 
Darnell, 2003). To generate the mutant minigene, the wild type vector was cleaved using XbaI 
restriction enzyme and a DNA fragment (gBlock, IDT) with all three TGCT Mbnl binding sites 
mutated to TGGT was integrated back into the vector backbone together with a PCR product 
containing a part of the wild type minigene using InFusion cloning mix (Clontech). Sequences 
used for cloning are listed online in Supplementary Table 2. All vectors and mutations were 
confirmed by Sanger sequencing.  
About 0.4x106 HEK293T cells were plated per single well of 6-well dish in 2ml 
1xDMEM + 10% FBS the day before transfection. Prior to transfection, culture media was 
replaced with 2ml antibiotic-free 1xDMEM + 10% FBS. Transfection mixes containing 100 µl 
Opti-mem, 10 ml Lipofectamine 2000TM (Invitrogen) and DNA (0.125 minigene + 1.5 mg RBP 
expression vector, 1.625 mg total) were prepared according to manufacturer’s instructions and 
added to the culture dishes. Note that depending on the combination of RBPs overexpressed, we 
adjusted the concentration of each expression vector so that total amount was fixed (Figure 
4.5F). 24hrs post transfection cells were scrapped in ice-cold 1xPBS and spun down. One fourth 
of the cells were resuspended in 0.5ml Trizol for RNA extraction. The remaining cells were 
resuspended in 250 m l lysis buffer (50mM Hepes pH 7.4, 100 mM NaCl, 1% Triton X-100, 
0.1% SDS, 1mM EDTA 1mM DTT, cOmplete protease inhibitors (Roche)) for protein analysis. 
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To confirm protein expression, protein samples were prepared with 1xLDS buffer 
(Invitrogen) and 50mM DTT, boiled, and loaded into 10% SDS-PAGE Novex Bis-Tris gels 
(Invitrogen). After protein transfer onto 0.45µm nitrocellulose membrane (GE Healthcare), the 
following primary antibodies were used to immunoblot Nova1, 3xFLAG-Rbfox2, 3xFLAG-
Mbnl2 and GAPDH, respectively: rabbit α-Nova1 serum (1:1000), mouse α-FLAG M2 (Sigma-
Aldrich, F1804, 1:4000) and rabbit α-GAPDH (Santa Cruz, FL-335, 1:500).  
 
Primary DRG neuron culture and lentivirus transduction 
All animal work was conducted in accordance with NIH guidelines for laboratory animal 
care and approved by the Institutional Animal Care and Use Committee of Columbia University. 
DRG neurons were isolated from rat embryos (E15) and plated on the poly-L lysine/laminin 
substrate. Cells were maintained in the media containing: Neurobasal media, B27, 2 mM 
glutamate, 20 µM 5′-fluorodeoxyuridine, 50 ng ml-1 NGF. Sensory neurons were transduced 
with lentivirus at MOI=20. Media was exchanged 24h post infection and every other day 
thereafter. Cells were collected 5 days post infection for imaging analysis and RNA isolation. 
Three replicate experiments were performed to quantify Nova expression and to test Nova-
dependent splicing of five selected exons.  
Both GFP (Mock) and Nova1 carrying lentiviruses were assembled in HEK293 cells 
using pMDLg/pRRE (Addgene plasmid # 12251) and pCMV-VSV-G (Addgene plasmid # 
8454). Lentiviral particles were concentrated 300x using ultracentrifugation. To clone Nova1 
into the lentivirus, we amplified the mRNA sequence of Nova 1 from mouse cDNA (for primer 
sequence see online Supplementary Table 2) and subcloned as a C-terminal GFP fusion in 
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modified FUGW vector3 under control of hUbC promoter (Addgene plasmid # 14883). 
For immonostaining, DRG sensory neurons were fixed (4% PFA in PBS) and blocked for 
20 min at room temperature (blocking buffer 1x PBS, 10% horse serum, 0.2% Triton X-100, 
0.05% sodium azide). Primary antibodies were diluted in Antibody buffer (1x PBS, 5% horse 
serum, 0.2% Triton X-100, 0.05% sodium azide) and incubated overnight at + 4°C. The 
following primary antibodies were used at the specified dilution: Nova1 (Abcam, ab183723, 
1:250), Neurofilament 2H3 (DSHB, 1:1000). After three PBS washes secondary antibodies were 
applied, samples were incubated for 2 hours at 4C. After three PBS washes coverslips were 
mounted on slides using DAPI fluoromount-G (southernBiotech). Images were taken using a 
Leica SP8 system. 
 
RNA isolation and cDNA preparation 
Total RNA was isolated with Trizol reagent (Invitrogen) using manufacturer instruction. 
cDNA was prepared using SuperScript III reverse transcriptase (Invitrogen) with oligodT or 
random hexamer primers. To measure exon inclusion, alternative exons of interest were 
amplified with primers listed online in Supplementary Table 2. PCR products were resolved on 
1.5-2% agarose gel. qPCR was performed using FastStart SYBR Green Master (Roche) on 





Appendix II: Supplementary Tables 




symbol Tissue expression 
Autism vs. control 
splicing change Function 
11538 Adnp non-brain-specific  Transcription factor 
11784 Apba2 brain-specific Y Neurotransmitter release 
11789 Apc non-brain-specific  Wnt signaling 
11941 Atp2b2 brain-specific  Calmodulin binding 
319974 Auts2 non-brain-specific  unknown 
30948 Bin1 non-brain-specific Y Synaptic vesicle endocytosis 
12288 Cacna1c non-brain-specific  Ion channel 
12289 Cacna1d non-brain-specific  Ion channel 
12291 Cacna1g non-brain-specific  Ion channel 
54725 Cadm1 non-brain-specific Y Cell adhesion 
320405 Cadps2 non-brain-specific Y Synaptic vesicle exocytosis 
100072 Camta1 non-brain-specific  Calmodulin binding 
67300 Cltc non-brain-specific  Receptor localization 
104318 Csnk1d non-brain-specific  Cell signaling 
74006 Dnm1l non-brain-specific  Mitochondrial and peroxisomal division 
75560 Ep400 non-brain-specific  Chromatin binding 
13876 Erg non-brain-specific  Transcription factor 
14107 Fat1 non-brain-specific  Cell adhesion 
268566 Gphn non-brain-specific  Receptor localization 
74053 Grip1 non-brain-specific  Glutamate receptor binding 
108071 Grm5 brain-specific  G-protein coupled receptor 
227753 Gsn non-brain-specific Y Cytoskeleton 
14886 Gtf2i non-brain-specific Y Transcription factor 
16531 Kcnma1 brain-specific Y Ion channel 
242274 Lrrc7 brain-specific  Synapse assembly 
18027 Nfia non-brain-specific  Transcription factor 
319504 Nrcam brain-specific Y Cell adhesion 
18189 Nrxn1 brain-specific  Cell adhesion 
18191 Nrxn3 brain-specific  Cell adhesion 
80883 Ntng1 brain-specific  Cell adhesion 
233977 Ppfia1 non-brain-specific Y Cell signaling 
353211 Prune2 non-brain-specific Y unknown 
268859 Rbfox1 non-brain-specific  RNA metabolism 
268902 Robo2 non-brain-specific  Axon guidance 
110876 Scn2a1 brain-specific  Ion channel 
20273 Scn8a brain-specific  Ion channel 
58234 Shank3 non-brain-specific  Synapse assembly 
76376 Slc24a2 brain-specific  Ion transport 
72055 Slc38a10 non-brain-specific  Ion/amino acid transport 
94229 Slc4a10 brain-specific  Ion transport 
64213 St7 non-brain-specific  Cell signaling 
53416 Stk39 non-brain-specific  Serine/threonine kinase 
20910 Stxbp1 non-brain-specific Y Neurotransmitter release 
64009 Syne1 non-brain-specific Y Cytoskeleton 
22084 Tsc2 non-brain-specific  Chaperone 
22138 Ttn low-brain-expression  Sarcomere structure 
22214 Ube2h non-brain-specific  Protein ubiquitination 
68134 Upf3b non-brain-specific  mRNA metabolism 
Tissue specificity of gene expression is based on the RNA-Seq dataset in ref. (Brawand et al., 2011) and splicing change in autistic vs. control 






Table S2. Genes encoding RBPs and with NMD exons under strong selection 
Entrez Gene 
ID Gene Symbol 
log2FC (UPF2 
KO vs. WT) Functional annotation 
67958 2610101N10Rik 0.93 (U2surp) core spliceosome 
56215 Acin1 0.11 chromatin regulator; EJC component 
13046 Celf1 0.65 tissue-specific splicing 
14007 Celf2 0.12 tissue-specific splicing 
78784 Celf3 0.09 tissue-specific splicing 
108013 Celf4 1.37 tissue-specific splicing 
208922 Cpeb3 1.20 poly-adenylation; translational regulation 
54188 Cpsf4 0.28 3' end processing 
269061 Cpsf7 1.17 3' end processing 
229663 Csde1 0.51 translational regulation 
70248 Dazap1 2.16 hnRNP: splicing, mRNA transport, translational regulation 
15572 Elavl4 0.09 tissue-specific splicing; mRNA stability 
239188 Enox1 0.09 mitochondrial plasma electron transport 
14030 Ewsr1 0.85 transcriptional regulation; miRNA biogenesis 
14265 Fmr1 0.29 translational regulation 
51886 Fubp1 0.66 transcriptional regulation; mRNA stability; translational regulation 
320267 Fubp3 0.58 mRNA stability & localization, translational regulation 
233908 Fus 0.59 
transcriptional regulation, splicing, mRNA transport, miRNA 
processing, translational regulation 
78455 Helz 0.73 RNA helicase / translational regulation 
11991 Hnrnpd 0.67 hnRNP 
59013 Hnrnph1 2.93 hnRNP 
432467 Hnrnph3 2.38 hnRNP 
15387 Hnrnpk 0.51 hnRNP 
15388 Hnrnpl 1.36 hnRNP 
74326 Hnrnpr 0.17 hnRNP 
50926 Hnrpdl 1.69 hnRNP 
72692 Hnrpll 1.32 hnRNP 
319765 Igf2bp2 1.65 mRNA localization, RNA stability, translational regulation 
140488 Igf2bp3 1.15 mRNA localization & stability, translational regulation 
56758 Mbnl1 -0.03 tissue-specific splicing 
17876 Myef2 1.82 transcriptional regulation 
664883 Nova1 0.09 tissue-specific splicing 
19017 Ppargc1a -0.27 transcriptional regulation 
226169 Pprc1 1.42 transcriptional regulation 
70767 Prpf3 1.70 core spliceosome 
66645 Pspc1 2.49 paraspeckle component 
19205 Ptbp1 1.03 hnRNP; tissue-specific splicing 
56195 Ptbp2 2.39 hnRNP; tissue-specific splicing 
80912 Pum1 0.79 translational regulation an mRNA stability 
80913 Pum2 0.60 translational regulation an mRNA stability 
268859 Rbfox1 1.09 tissue-specific splicing 
93686 Rbfox2 0.52 tissue-specific splicing 
666794 Rbm24 7.11 mRNA stability 
67039 Rbm25 1.59 splicing 
170791 Rbm39 2.32 spliceosome, alternative splicing, transcriptional regulation 
237073 Rbm41 0.79 putative RNA binding 
83486 Rbm5 0.68 core spliceosome; alternative splicing 
19654 Rbm6 0.60 alternative splicing 
56878 Rbms1 0.42 DNA replication; transcriptional regulation 
230257 Rod1 0.37 hnRNP; splicing; NMD 
224903 Safb 0.54 
chromatin regulator; transcriptional regulation, RNA Splicing and 
Metabolism 
106583 Scaf8 1.41 RNA Processing 
22668 Sf1 1.61 splicing (branch point recognition & spliceosome assembly) 
231769 Sfswap 1.04 alternative splicing 
66660 Sltm 1.99 transcriptional regulation 
20637 Snrnp70 0.74 core spliceosome 
20638 Snrpb 0.34 core spliceosome 
218543 Srek1 1.42 splicing 
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51796 Srrm1 1.06 constitutive splicing, 3'-end processing 
75956 Srrm2 -0.24 splicing regulation 
69207 Srsf11 2.05 SR protein 
20382 Srsf2 1.15 SR protein 
20383 Srsf3 1.72 SR protein 
57317 Srsf4 2.57 SR protein 
67996 Srsf6 1.16 SR protein 
225027 Srsf7 1.03 SR protein 
108014 Srsf9 0.34 SR protein 
20926 Supt6h 1.65 transcriptional regulation; mRNA processing 
70439 Taf15 1.54 transcriptional regulation 
21841 Tia1 2.04 splicing; translational regulation 
21843 Tial1 0.55 splicing; translational regulation 
233833 Tnrc6a 0.02 RNA-mediated gene silencing 
213988 Tnrc6b -0.17 RNA-mediated gene silencing 
101214 Tra2a 1.95 splicing 
20462 Tra2b 2.42 splicing 
71787 Trnau1ap 1.45 tRNA incoporation 
108121 U2af1 0.78 core spliceosome 
22185 U2af2 0.90 core spliceosome 
240255 Ythdc2 1.63 putative RNA Helicase 
229096 Ythdf3 0.04 N6-methyladenosine (m6A) RNA recognition & binding 
75553 Zc3h14 0.66 poly(A) tail length control 
330474 Zc3h4 1.16 putative post-transcriptional regulation 
106205 Zc3h7a 2.56 putative post-transcriptional regulation 





Table S3. Gene Ontology (GO) analysis for NMD cassette exons under strong selection pressure. 
 
Category Term Fold Enrichment FDR 
GOTERM_BP_FAT GO:0016071~mRNA metabolic process 3.82 4.23E-18 
GOTERM_BP_FAT GO:0006397~mRNA processing 3.75 9.07E-15 
GOTERM_BP_FAT GO:0008380~RNA splicing 3.93 2.28E-12 
GOTERM_BP_FAT GO:0006396~RNA processing 2.69 4.59E-10 
GOTERM_BP_FAT GO:0006325~chromatin organization 2.95 1.83E-07 
GOTERM_BP_FAT GO:0051276~chromosome organization 2.62 4.84E-07 
GOTERM_BP_FAT GO:0016568~chromatin modification 2.91 6.22E-06 
GOTERM_BP_FAT GO:0000398~nuclear mRNA splicing, via spliceosome 6.83 1.52E-05 
GOTERM_BP_FAT 
GO:0000375~RNA splicing, via transesterification 
reactions 6.83 1.52E-05 
GOTERM_BP_FAT 
GO:0000377~RNA splicing, via transesterification 
reactions with bulged adenosine as nucleophile 6.83 1.52E-05 
GOTERM_BP_FAT GO:0006350~transcription 1.57 9.57E-05 
GOTERM_BP_FAT GO:0000245~spliceosome assembly 10.54 6.65E-04 
GOTERM_BP_FAT GO:0010629~negative regulation of gene expression 2.30 1.20E-03 
GOTERM_BP_FAT GO:0045449~regulation of transcription 1.45 2.39E-03 
GOTERM_BP_FAT GO:0016569~covalent chromatin modification 3.60 2.97E-03 
GOTERM_BP_FAT 
GO:0031327~negative regulation of cellular 
biosynthetic process 2.19 6.07E-03 
GOTERM_BP_FAT GO:0016570~histone modification 3.58 6.37E-03 
GOTERM_BP_FAT 
GO:0009890~negative regulation of biosynthetic 
process 2.17 7.73E-03 
GOTERM_BP_FAT 
GO:0010558~negative regulation of macromolecule 
biosynthetic process 2.19 7.84E-03 
GOTERM_BP_FAT 
GO:0034622~cellular macromolecular complex 
assembly 2.71 2.18E-02 
GOTERM_BP_FAT GO:0065003~macromolecular complex assembly 2.23 3.34E-02 
GOTERM_BP_FAT GO:0016481~negative regulation of transcription 2.17 4.22E-02 
GOTERM_BP_FAT 
GO:0010605~negative regulation of macromolecule 
metabolic process 1.95 4.82E-02 
GOTERM_BP_FAT GO:0022618~ribonucleoprotein complex assembly 5.47 8.29E-02 
GOTERM_BP_FAT 
GO:0045935~positive regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid metabolic 
process 1.95 9.13E-02 
GOTERM_BP_FAT 
GO:0034621~cellular macromolecular complex subunit 
organization 2.44 9.28E-02 
GOTERM_BP_FAT 
GO:0043933~macromolecular complex subunit 
organization 2.09 9.85E-02 
GOTERM_BP_FAT GO:0016458~gene silencing 4.02 1.05E-01 
GOTERM_BP_FAT 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 1.84 1.37E-01 
GOTERM_BP_FAT GO:0044265~cellular macromolecule catabolic process 1.72 1.45E-01 
GOTERM_BP_FAT 
GO:0045934~negative regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid metabolic 
process 2.03 1.75E-01 
GOTERM_BP_FAT 
GO:0051173~positive regulation of nitrogen compound 
metabolic process 1.89 1.83E-01 
GOTERM_BP_FAT GO:0006417~regulation of translation 3.20 1.84E-01 
GOTERM_BP_FAT 
GO:0051172~negative regulation of nitrogen compound 
metabolic process 2.00 2.31E-01 
GOTERM_BP_FAT 
GO:0045892~negative regulation of transcription, 
DNA-dependent 2.18 3.20E-01 
GOTERM_BP_FAT 
GO:0051253~negative regulation of RNA metabolic 
process 2.16 3.75E-01 
GOTERM_BP_FAT GO:0045941~positive regulation of transcription 1.90 3.90E-01 
GOTERM_BP_FAT GO:0006479~protein amino acid methylation 4.43 4.91E-01 
GOTERM_BP_FAT GO:0008213~protein amino acid alkylation 4.43 4.91E-01 
GOTERM_BP_FAT GO:0010628~positive regulation of gene expression 1.86 5.98E-01 
GOTERM_BP_FAT GO:0009057~macromolecule catabolic process 1.62 6.90E-01 





catabolic process 1.71 7.11E-01 
GOTERM_BP_FAT 
GO:0019941~modification-dependent protein catabolic 
process 1.71 7.11E-01 
GOTERM_BP_FAT GO:0040029~regulation of gene expression, epigenetic 3.28 8.09E-01 
GOTERM_BP_FAT GO:0035195~gene silencing by miRNA 7.57 1.19E+00 
GOTERM_BP_FAT 
GO:0051254~positive regulation of RNA metabolic 
process 1.89 1.21E+00 
GOTERM_BP_FAT 
GO:0000122~negative regulation of transcription from 
RNA polymerase II promoter 2.28 1.37E+00 
GOTERM_BP_FAT GO:0007638~mechanosensory behavior 16.40 1.46E+00 
GOTERM_BP_FAT 
GO:0010608~posttranscriptional regulation of gene 
expression 2.44 1.70E+00 
GOTERM_BP_FAT GO:0007416~synaptogenesis 7.03 1.76E+00 
GOTERM_BP_FAT 
GO:0051603~proteolysis involved in cellular protein 
catabolic process 1.63 1.81E+00 
GOTERM_BP_FAT GO:0046907~intracellular transport 1.70 1.89E+00 
GOTERM_BP_FAT GO:0044257~cellular protein catabolic process 1.62 2.07E+00 
GOTERM_BP_FAT 
GO:0045893~positive regulation of transcription, DNA-
dependent 1.86 2.08E+00 
GOTERM_BP_FAT 
GO:0070647~protein modification by small protein 
conjugation or removal 2.67 2.12E+00 
GOTERM_BP_FAT GO:0006886~intracellular protein transport 1.89 2.26E+00 
GOTERM_BP_FAT 
GO:0010557~positive regulation of macromolecule 
biosynthetic process 1.72 2.42E+00 
        
GOTERM_CC_FAT GO:0031981~nuclear lumen 2.29 6.41E-11 
GOTERM_CC_FAT GO:0005654~nucleoplasm 2.58 1.40E-09 
GOTERM_CC_FAT GO:0070013~intracellular organelle lumen 2.00 6.36E-09 
GOTERM_CC_FAT GO:0043233~organelle lumen 2.00 6.78E-09 
GOTERM_CC_FAT GO:0044451~nucleoplasm part 2.68 9.58E-09 
GOTERM_CC_FAT GO:0031974~membrane-enclosed lumen 1.96 1.52E-08 
GOTERM_CC_FAT GO:0016607~nuclear speck 4.43 8.97E-05 
GOTERM_CC_FAT GO:0045202~synapse 2.56 2.67E-04 
GOTERM_CC_FAT GO:0016604~nuclear body 3.22 4.64E-03 
GOTERM_CC_FAT GO:0005681~spliceosome 3.09 4.60E-02 
GOTERM_CC_FAT GO:0030054~cell junction 2.01 4.79E-02 
GOTERM_CC_FAT GO:0034708~methyltransferase complex 7.26 8.67E-02 
GOTERM_CC_FAT GO:0035097~histone methyltransferase complex 7.26 8.67E-02 
GOTERM_CC_FAT GO:0005891~voltage-gated calcium channel complex 8.89 9.15E-02 
GOTERM_CC_FAT GO:0034704~calcium channel complex 8.89 9.15E-02 
GOTERM_CC_FAT GO:0016363~nuclear matrix 5.01 1.57E-01 
GOTERM_CC_FAT GO:0034703~cation channel complex 3.70 2.17E-01 
GOTERM_CC_FAT GO:0034702~ion channel complex 2.84 3.75E-01 
GOTERM_CC_FAT GO:0034399~nuclear periphery 4.33 5.15E-01 
GOTERM_CC_FAT GO:0043005~neuron projection 2.14 8.23E-01 
GOTERM_CC_FAT GO:0030529~ribonucleoprotein complex 1.79 8.52E-01 
GOTERM_CC_FAT GO:0044456~synapse part 2.27 8.92E-01 
GOTERM_CC_FAT GO:0030315~T-tubule 7.62 1.02E+00 
GOTERM_CC_FAT GO:0045211~postsynaptic membrane 2.77 1.23E+00 
GOTERM_CC_FAT GO:0000267~cell fraction 1.71 1.24E+00 
GOTERM_CC_FAT GO:0019717~synaptosome 3.44 1.55E+00 
GOTERM_CC_FAT GO:0000932~cytoplasmic mRNA processing body 6.73 1.92E+00 
GOTERM_CC_FAT GO:0005635~nuclear envelope 2.40 2.42E+00 
GOTERM_CC_FAT GO:0019898~extrinsic to membrane 1.69 3.18E+00 
GOTERM_CC_FAT GO:0001518~voltage-gated sodium channel complex 12.70 3.43E+00 
GOTERM_CC_FAT GO:0005856~cytoskeleton 1.42 3.45E+00 
GOTERM_CC_FAT GO:0042995~cell projection 1.59 4.29E+00 
GOTERM_CC_FAT GO:0005626~insoluble fraction 1.65 5.59E+00 
GOTERM_CC_FAT GO:0034706~sodium channel complex 10.89 5.71E+00 
        
GOTERM_MF_FAT GO:0003723~RNA binding 2.84 5.06E-20 




GO:0008331~high voltage-gated calcium channel 
activity 15.06 1.04E-02 
GOTERM_MF_FAT GO:0000166~nucleotide binding 1.33 3.79E-02 
GOTERM_MF_FAT GO:0003682~chromatin binding 2.64 6.45E-02 
GOTERM_MF_FAT GO:0051020~GTPase binding 3.63 1.20E-01 
GOTERM_MF_FAT GO:0017016~Ras GTPase binding 3.69 2.02E-01 
GOTERM_MF_FAT GO:0031267~small GTPase binding 3.56 2.94E-01 
GOTERM_MF_FAT GO:0003725~double-stranded RNA binding 4.67 6.36E-01 
GOTERM_MF_FAT GO:0016564~transcription repressor activity 2.19 1.02E+00 
GOTERM_MF_FAT GO:0003712~transcription cofactor activity 2.24 1.05E+00 
GOTERM_MF_FAT GO:0016881~acid-amino acid ligase activity 2.22 1.14E+00 
GOTERM_MF_FAT GO:0019899~enzyme binding 1.98 1.48E+00 
GOTERM_MF_FAT GO:0005245~voltage-gated calcium channel activity 5.55 1.54E+00 





Table S4. Genes encoding chromatin regulators and with NMD exons under strong selection 
Gene ID 
Gene 
Symbol Gene Name 
log2FC (UPF2 KO 
vs. WT) 
74112 Usp16 ubiquitin specific peptidase 16 1.92 
15260 Hira histone cell cycle regulation defective homolog A (S. cerevisiae) 1.73 
24127 Xrn1 5'-3' exoribonuclease 1 1.44 
104263 Kdm3a lysine (K)-specific demethylase 3A 1.39 
72692 Hnrpll heterogeneous nuclear ribonucleoprotein L-like; glutathione peroxidase 4 1.32 
22289 Kdm6a 4lysine (K)-specific demethylase 6A 1.31 
94246 Arid4b AT rich interactive domain 4B (RBP1-like) 1.30 
320713 Mysm1 similar to mKIAA1915 protein; myb-like, SWIRM and MPN domains 1 1.21 
13831 Epc1 enhancer of polycomb homolog 1 (Drosophila) 1.17 
64707 Suv39h2 suppressor of variegation 3-9 homolog 2 (Drosophila) 1.16 
233545 
2210018M1
1Rik RIKEN cDNA 2210018M11 gene 1.14 
69188 Mll5 myeloid/lymphoid or mixed-lineage leukemia 5 1.12 
14056 Ezh2 enhancer of zeste homolog 2 (Drosophila) 1.09 
93759 Sirt1 
sirtuin 1 (silent mating type information regulation 2, homolog) 1 (S. 
cerevisiae) 1.05 
14050 Eya3 eyes absent 3 homolog (Drosophila) 1.03 
78656 Brd8 bromodomain containing 8 1.02 
109151 Chd9 chromodomain helicase DNA binding protein 9 0.94 
235626 Setd2 SET domain containing 2 0.90 
11789 Apc similar to adenomatosis polyposis coli; adenomatosis polyposis coli 0.90 
71175 Nipbl Nipped-B homolog (Drosophila) 0.86 
103677 Smg6 Smg-6 homolog, nonsense mediated mRNA decay factor (C. elegans) 0.74 
53605 Nap1l1 
similar to nucleosome assembly protein 1-like 1; nucleosome assembly 
protein 1-like 1 0.73 
217218 Atxn7l3 ataxin 7-like 3 0.71 
18193 Nsd1 nuclear receptor-binding SET-domain protein 1 0.70 
59026 Huwe1 HECT, UBA and WWE domain containing 1 0.69 
66923 Pbrm1 polybromo 1 0.69 
54169 Myst4 MYST histone acetyltransferase monocytic leukemia 4 0.68 
231051 Mll3 myeloid/lymphoid or mixed-lineage leukemia 3 0.68 
93765 Ube2n 
ubiquitin-conjugating enzyme E2N; similar to ubiquitin-conjugating enzyme 
E2 UbcH-ben; similar to ubiquitin-conjugating enzyme E2N; predicted gene 
5943 0.67 
75410 Wbp7 WW domain binding protein 7 0.61 
17257 Mecp2 methyl CpG binding protein 2 0.59 
192285 Phf21a PHD finger protein 21A 0.59 
71389 Chd6 chromodomain helicase DNA binding protein 6; predicted gene 8291 0.55 
30841 Kdm2b lysine (K)-specific demethylase 2B 0.55 
228012 Tlk1 similar to tousled-like kinase 1; tousled-like kinase 1 0.55 
16798 Lats1 large tumor suppressor 0.48 
13435 Dnmt3a DNA methyltransferase 3A 0.42 
433759 Hdac1 
similar to histone deacetylase HD1; similar to histone deacetylase; predicted 
gene 5824; histone deacetylase 1; predicted gene 4864 0.42 
67155 Smarca2 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 2 0.33 
192195 Ash1l ash1 (absent, small, or homeotic)-like (Drosophila) 0.29 
26914 H2afy H2A histone family, member Y 0.23 
57376 Smarce1 
similar to SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily e, member 1; predicted gene 1815; predicted gene 
8494; SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily e, member 1; predicted gene 4811 0.22 
245688 Rbbp7 retinoblastoma binding protein 7; predicted gene 6382 0.14 
207165 Bptf bromodomain PHD finger transcription factor 0.11 
56215 Acin1 apoptotic chromatin condensation inducer 1 0.11 
238247 Arid4a AT rich interactive domain 4A (RBP1-like) 0.07 
227867 Epc2 
enhancer of polycomb homolog 2 (Drosophila); similar to Enhancer of 
polycomb homolog 2 -0.01 
74026 Msl1 




79221 Hdac9 histone deacetylase 9 -0.21 
26926 Aifm1 apoptosis-inducing factor, mitochondrion-associated 1 -0.22 
70088 Meaf6 RIKEN cDNA 2310005N01 gene -0.28 





Table S5. Genes with NMD exons conserved in vertebrates 
AS ID gene id symbol Exon BLS Functional annotation 
CA-230753-32267-32381-32574-33829[INC][1/25] 230753 Thrap3 0.752228072 RNA metabolism 
CA-51796-9480-9769-9899-11545[INC][2/98] 51796 Srrm1 0.923907732 RNA metabolism 
CA-67996-3635-4307-4575-4918[INC][2/101] 67996 Srsf6 0.812812349 RNA metabolism 
CA-20462-3189-9668-9944-13812[INC][6/74][UPT] 20462 Tra2b 0.851690222 RNA metabolism 
CA-sr-chr11f-639[INC][430|658/7342] 103573 Xpo1 0.913960277 RNA metabolism 
CA-sr-chr2r-1256[INC][17|11/14795] 170791 Rbm39 0.783752846 RNA metabolism 
CA-101214-3215-13944-14245-14537[INC][1/47][UPT] 101214 Tra2a 0.804130205 RNA metabolism 
CA-sr-chrXf-1446[INC][76|8/7549] 108155 Ogt 0.8644392 chromatin modification? 
CA-237943-20877-22012-22047-30992[INC][2/2] 237943 Gpatch8 0.876410304 RNA metabolism 
CA-666794-6606-6976-7089-13654[INC][2/10][DNT] 666794 Rbm24 0.872214721 RNA metabolism 
CA-21841-19193-22387-22453-23126[INC][3/44] 21841 Tia1 0.853784072 RNA metabolism 
CA-237943-20877-27828-27846-30992[INC][2/2] 237943 Gpatch8 0.958022011 RNA metabolism 
CA-237943-31065-48897-48942-50947[INC][2/5] 237943 Gpatch8 0.887761451 RNA metabolism 
CA-67684-31985-32439-32518-33333[INC][1/5][DNT] 67684 Luc7l3 0.9077653 RNA metabolism 
CA-sr-chr13r-385[INC][502|599/3246] 218543 Srek1 0.893984724 RNA metabolism 
CA-sr-chr9r-1489[INC][667|730/1821] 192287 Slc25a36 0.890390907 solute transporter 
CA-328110-21987-22100-22200-22304[INC][4/2] 328110 Prpf39 0.915803167 RNA metabolism 
CA-50926-6119-6483-6588-7238[INC][30/91][DNT] 50926 Hnrpdl 0.909768064 RNA metabolism 
CA-11991-19424-19734-19841-
20605[INC][4/93][DNT] 11991 Hnrnpd 0.921526878 RNA metabolism 
CA-sr-chr14f-2729[INC][4|58/2439] 69634 Clybl 0.91087121   
CA-sr-chrXr-1698[INC][463|233/386] 320940 Atp11c 0.85713407 ATPase 
CA-sr-chr12f-2646[INC][3240|2350/173] 18191 Nrxn3 0.970496045 synaptic scaffolding 
CA-sr-chr13f-1138[INC][118|434/4523] 212880 Ddx46 0.857074446 RNA metabolism 
CA-sr-chr15f-2939[INC][309|228/279] 20273 Scn8a 0.876256561 Ion channel 
CA-sr-chr13f-188[INC][8|11/883] 14634 Gli3 0.873305943 chromatin binding 
CA-71435-115787-116489-116764-117652[INC][1/17] 71435 Arhgap21 0.887435708 
Golgi organization, 
cytoskeleton 
CA-sr-chr16f-263[INC][34|42/40] 268859 Rbfox1 0.828003018 RNA metabolism 
CA-sr-chr1r-4013[INC][40|51/18393] 14660 Gls 0.766401156 neurotransmitter synthesis 
CA-18087-15385-22207-22235-24941[INC][4/18] 18087 Nktr 0.764448518 protein folding 
CA-sr-chr5f-4295[INC][197|160/259] 58212 Srrm3 0.867862836 RNA metabolism 
CA-14800-113507-114048-114089-114357[INC][1/8] 14800 Gria2 0.811252218 Ion channel 
CA-235567-109117-112554-112663-
113507[INC][1/16][DNT] 235567 Dnajc13 0.787047464 membrane trafficking 
CA-sr-chr5f-3979[INC][37|874/3933] 231769 Sfswap 0.871037937 RNA metabolism 






Table S6. Sliding window gene ontology enrichment. 





1 GO:0098590_plasma_membrane_region_cellular_component 3.5E-06 2.1E-03 P9 
2 GO:0098589_membrane_region_cellular_component 3.1E-06 1.9E-03 E15.5 
3 GO:0016323_basolateral_plasma_membrane_cellular_component 5.5E-06 2.8E-03 E15.5 
4 GO:0051049_regulation_of_transport_biological_process 1.7E-07 1.9E-04 P7 
5 GO:0032879_regulation_of_localization_biological_process 6.2E-08 8.3E-05 E10.5 
6 GO:0065008_regulation_of_biological_quality_biological_process 1.8E-06 1.2E-03 E11.5 
7 GO:1990351_transporter_complex_cellular_component 3.7E-08 5.5E-05 E11.5 
8 GO:1902495_transmembrane_transporter_complex_cellular_component 2.4E-08 3.9E-05 E11.5 
9 GO:0034702_ion_channel_complex_cellular_component 6.0E-09 1.2E-05 E11.5 
10 GO:0086010_membrane_depolarization_during_action_potential_biological_process 7.5E-08 9.7E-05 E10.5 
11 GO:0043269_regulation_of_ion_transport_biological_process 9.7E-08 1.2E-04 E11.5 
12 GO:0034765_regulation_of_ion_transmembrane_transport_biological_process 2.1E-09 5.1E-06 E11.5 
13 GO:0034762_regulation_of_transmembrane_transport_biological_process 6.1E-09 1.3E-05 E11.5 
14 GO:0070588_calcium_ion_transmembrane_transport_biological_process 2.7E-06 1.7E-03 E11.5 
15 GO:0015085_calcium_ion_transmembrane_transporter_activity_molecular_function 1.0E-05 4.7E-03 E11.5 
16 GO:0098662_inorganic_cation_transmembrane_transport_biological_process 2.3E-08 3.8E-05 E10.5 
17 GO:0098655_cation_transmembrane_transport_biological_process 4.5E-07 4.3E-04 E10.5 
18 GO:0098660_inorganic_ion_transmembrane_transport_biological_process 5.2E-08 7.3E-05 E10.5 
19 GO:0046873_metal_ion_transmembrane_transporter_activity_molecular_function 2.0E-09 5.0E-06 E10.5 
20 
GO:0022890_inorganic_cation_transmembrane_transporter_activity_molecular_functio
n 2.0E-07 2.2E-04 E10.5 
21 GO:0008324_cation_transmembrane_transporter_activity_molecular_function 3.9E-06 2.3E-03 E10.5 
22 GO:0034220_ion_transmembrane_transport_biological_process 7.8E-07 6.6E-04 E10.5 
23 GO:0015075_ion_transmembrane_transporter_activity_molecular_function 8.2E-06 3.9E-03 E10.5 
24 GO:0022836_gated_channel_activity_molecular_function 1.8E-10 6.8E-07 E11.5 
25 GO:0022803_passive_transmembrane_transporter_activity_molecular_function 8.2E-09 1.6E-05 E11.5 
26 GO:0015267_channel_activity_molecular_function 8.2E-09 1.6E-05 E11.5 
27 GO:0022838_substrate-specific_channel_activity_molecular_function 5.4E-09 1.1E-05 E11.5 
28 GO:0005216_ion_channel_activity_molecular_function 4.0E-09 8.7E-06 E11.5 
29 GO:0006811_ion_transport_biological_process 9.2E-06 4.2E-03 E10.5 
30 GO:0030001_metal_ion_transport_biological_process 7.1E-09 1.4E-05 E10.5 
31 GO:0006812_cation_transport_biological_process 2.2E-06 1.4E-03 E10.5 
32 GO:0005261_cation_channel_activity_molecular_function 1.3E-09 3.7E-06 E11.5 
33 GO:0006873_cellular_ion_homeostasis_biological_process 5.8E-06 3.0E-03 E10.5 
34 GO:0022892_substrate-specific_transporter_activity_molecular_function 2.0E-06 1.3E-03 E10.5 
35 GO:0005215_transporter_activity_molecular_function 4.2E-06 2.4E-03 E11.5 
36 GO:0034703_cation_channel_complex_cellular_component 1.2E-10 5.0E-07 E11.5 
37 GO:0022843_voltage-gated_cation_channel_activity_molecular_function 3.3E-11 1.6E-07 E11.5 
38 GO:0022832_voltage-gated_channel_activity_molecular_function 2.0E-11 1.0E-07 E11.5 
39 GO:0005244_voltage-gated_ion_channel_activity_molecular_function 2.0E-11 1.0E-07 E11.5 
40 GO:1903522_regulation_of_blood_circulation_biological_process 8.1E-06 3.8E-03 E10.5 
41 GO:0006816_calcium_ion_transport_biological_process 7.8E-07 6.6E-04 E11.5 
42 GO:0014070_response_to_organic_cyclic_compound_biological_process 1.1E-05 4.8E-03 E13.5 
43 GO:0005245_voltage-gated_calcium_channel_activity_molecular_function 8.6E-06 4.0E-03 E11.5 
44 GO:0001508_action_potential_biological_process 8.5E-07 7.1E-04 E11.5 
45 GO:0019228_neuronal_action_potential_biological_process 4.2E-06 2.4E-03 E11.5 
46 GO:0007268_synaptic_transmission_biological_process 4.7E-08 6.8E-05 E15.5 
47 GO:0007267_cell-cell_signaling_biological_process 9.1E-07 7.4E-04 E15.5 
48 GO:0023052_signaling_biological_process 2.5E-07 2.7E-04 E13.5 
49 GO:0044700_single_organism_signaling_biological_process 1.5E-07 1.8E-04 E13.5 
50 GO:0008331_high_voltage-gated_calcium_channel_activity_molecular_function 9.1E-06 4.2E-03 E11.5 
51 GO:0005516_calmodulin_binding_molecular_function 4.8E-09 1.0E-05 E16.5 
52 GO:0001505_regulation_of_neurotransmitter_levels_biological_process 4.8E-06 2.6E-03 E16.5 
53 GO:0006836_neurotransmitter_transport_biological_process 1.5E-06 1.1E-03 E16.5 
54 GO:0007269_neurotransmitter_secretion_biological_process 6.8E-06 3.3E-03 P2 
55 GO:0050804_regulation_of_synaptic_transmission_biological_process 3.5E-06 2.1E-03 E15.5 
56 GO:0050806_positive_regulation_of_synaptic_transmission_biological_process 7.7E-09 1.5E-05 E15.5 
57 GO:0016082_synaptic_vesicle_priming_biological_process 4.2E-06 2.4E-03 E15.5 
58 GO:0051046_regulation_of_secretion_biological_process 1.7E-06 1.2E-03 E16.5 
  
222 
59 GO:0016529_sarcoplasmic_reticulum_cellular_component 7.8E-06 3.7E-03 E17.5 
60 GO:0030315_T-tubule_cellular_component 4.7E-07 4.5E-04 E17.5 
61 GO:0050808_synapse_organization_biological_process 1.0E-06 8.1E-04 E17.5 
62 GO:0016192_vesicle-mediated_transport_biological_process 1.0E-05 E16.5 
63 GO:0051962_positive_regulation_of_nervous_system_development_biological_process 3.2E-07 3.2E-04 P4 
64 GO:0051094_positive_regulation_of_developmental_process_biological_process 1.3E-06 9.6E-04 P4 
65 
GO:0051240_positive_regulation_of_multicellular_organismal_process_biological_pro
cess 6.5E-07 5.7E-04 P4 
66 GO:0051899_membrane_depolarization_biological_process 2.5E-07 2.6E-04 E17.5 
67 GO:0042391_regulation_of_membrane_potential_biological_process 1.4E-08 2.4E-05 E17.5 
68 GO:0016020_membrane_cellular_component 5.9E-06 3.0E-03 P4 
69 
GO:0051130_positive_regulation_of_cellular_component_organization_biological_proc
ess 3.8E-06 2.2E-03 P4 
70 GO:2000026_regulation_of_multicellular_organismal_development_biological_process 2.6E-06 1.7E-03 P5 
71 GO:0050793_regulation_of_developmental_process_biological_process 3.7E-06 2.2E-03 P3 
72 GO:0051960_regulation_of_nervous_system_development_biological_process 9.7E-08 1.2E-04 P5 
73 GO:0051239_regulation_of_multicellular_organismal_process_biological_process 1.3E-07 1.6E-04 P4 
74 GO:0051965_positive_regulation_of_synapse_assembly_biological_process 7.7E-06 3.7E-03 P5 
75 GO:0051963_regulation_of_synapse_assembly_biological_process 3.7E-06 2.2E-03 P5 
76 GO:0050807_regulation_of_synapse_organization_biological_process 6.0E-08 8.2E-05 P5 
77 GO:0030534_adult_behavior_biological_process 4.8E-06 2.6E-03 P3 
78 GO:0044449_contractile_fiber_part_cellular_component 8.2E-08 1.1E-04 P5 
79 GO:0030018_Z_disc_cellular_component 2.4E-07 2.6E-04 P5 
80 GO:0030673_axolemma_cellular_component 4.1E-06 2.3E-03 P4 
81 GO:0005488_binding_molecular_function 3.9E-07 3.9E-04 P5 
82 GO:0048869_cellular_developmental_process_biological_process 4.7E-08 6.7E-05 P5 
83 GO:0008017_microtubule_binding_molecular_function 8.1E-06 3.8E-03 P3 
84 GO:0017124_SH3_domain_binding_molecular_function 3.0E-06 1.9E-03 P5 
85 GO:0044707_single-multicellular_organism_process_biological_process 9.1E-07 7.4E-04 P6 
86 GO:0032501_multicellular_organismal_process_biological_process 1.1E-06 8.9E-04 P6 
87 GO:0043194_axon_initial_segment_cellular_component 7.4E-10 2.3E-06 E17.5 
88 GO:0050877_neurological_system_process_biological_process 1.8E-06 1.2E-03 P6 
89 GO:0003008_system_process_biological_process 1.7E-06 1.2E-03 P2 
90 GO:0051649_establishment_of_localization_in_cell_biological_process 1.0E-05 4.6E-03 P7 
91 GO:0045202_synapse_cellular_component 3.6E-11 1.7E-07 P9 
92 GO:0007165_signal_transduction_biological_process 1.2E-06 9.1E-04 P9 
93 GO:0001725_stress_fiber_cellular_component 3.0E-06 1.8E-03 P9 
94 GO:0032432_actin_filament_bundle_cellular_component 3.9E-06 2.3E-03 P9 
95 GO:0042641_actomyosin_cellular_component 1.9E-06 1.3E-03 P9 
96 GO:0032403_protein_complex_binding_molecular_function 2.3E-07 2.5E-04 P5 
97 GO:0005737_cytoplasm_cellular_component 3.0E-08 4.7E-05 P7 
98 GO:0003779_actin_binding_molecular_function 1.5E-07 1.8E-04 P9 
99 GO:0008092_cytoskeletal_protein_binding_molecular_function 6.9E-13 5.4E-09 P6 
100 GO:0044456_synapse_part_cellular_component 1.3E-17 1.3E-10 P6 
101 GO:0014069_postsynaptic_density_cellular_component 5.7E-15 2.1E-10 P6 
102 GO:0097481_neuronal_postsynaptic_density_cellular_component 1.2E-10 5.1E-07 P9 
103 GO:0045211_postsynaptic_membrane_cellular_component 8.2E-10 2.5E-06 P6 
104 GO:0097060_synaptic_membrane_cellular_component 5.8E-13 4.6E-09 P6 
105 GO:0032989_cellular_component_morphogenesis_biological_process 2.7E-07 2.8E-04 P5 
106 GO:0051128_regulation_of_cellular_component_organization_biological_process 1.0E-06 8.1E-04 P9 
107 GO:0033267_axon_part_cellular_component 2.4E-09 5.7E-06 P6 
108 GO:0044463_cell_projection_part_cellular_component 1.5E-15 9.9E-11 P7 
109 GO:0006810_transport_biological_process 7.6E-07 6.4E-04 P9 
110 GO:0051234_establishment_of_localization_biological_process 1.5E-07 1.8E-04 P6 
111 GO:0051179_localization_biological_process 2.5E-10 9.1E-07 P6 
112 GO:0030425_dendrite_cellular_component 1.6E-08 2.8E-05 P9 
113 GO:0007409_axonogenesis_biological_process 1.0E-05 4.5E-03 P9 
114 GO:0005856_cytoskeleton_cellular_component 2.0E-11 1.1E-07 P7 
115 GO:0005911_cell-cell_junction_cellular_component 2.4E-10 8.6E-07 P8 
116 GO:0030054_cell_junction_cellular_component 5.7E-16 4.8E-11 P7 
117 GO:0007010_cytoskeleton_organization_biological_process 5.8E-07 5.3E-04 P8 
118 GO:0016043_cellular_component_organization_biological_process 8.2E-13 6.2E-09 P8 
119 GO:0071840_cellular_component_organization_or_biogenesis_biological_process 2.3E-12 1.5E-08 P8 
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120 GO:0044430_cytoskeletal_part_cellular_component 5.3E-08 7.5E-05 P9 
121 GO:0070161_anchoring_junction_cellular_component 7.8E-06 3.7E-03 P8 
122 GO:0030030_cell_projection_organization_biological_process 8.8E-08 1.1E-04 P8 
123 GO:0050789_regulation_of_biological_process_biological_process 1.3E-07 1.5E-04 P9 
124 GO:0050794_regulation_of_cellular_process_biological_process 4.9E-08 6.9E-05 P9 
125 GO:0065007_biological_regulation_biological_process 1.0E-09 3.0E-06 P9 
126 GO:0005623_cell_cellular_component 4.5E-07 4.3E-04 P7 
127 GO:0005886_plasma_membrane_cellular_component 5.0E-11 2.3E-07 P9 
128 GO:0032990_cell_part_morphogenesis_biological_process 1.1E-06 8.5E-04 P7 
129 GO:0048858_cell_projection_morphogenesis_biological_process 3.6E-07 3.6E-04 P7 
130 GO:0048812_neuron_projection_morphogenesis_biological_process 3.3E-07 3.4E-04 P7 
131 GO:0048522_positive_regulation_of_cellular_process_biological_process 3.1E-06 1.9E-03 P7 
132 GO:0048518_positive_regulation_of_biological_process_biological_process 1.3E-06 9.6E-04 P7 
133 GO:0044459_plasma_membrane_part_cellular_component 1.8E-15 1.1E-10 P6 
134 GO:0097458_neuron_part_cellular_component 1.7E-17 3.2E-11 P6 
135 GO:0042995_cell_projection_cellular_component 3.2E-15 1.4E-10 P7 
136 GO:1902578_single-organism_localization_biological_process 1.3E-08 2.3E-05 P9 
137 GO:0045216_cell-cell_junction_organization_biological_process 5.4E-06 2.8E-03 P8 
138 GO:0044763_single-organism_cellular_process_biological_process 7.2E-09 1.4E-05 P9 
139 GO:0019904_protein_domain_specific_binding_molecular_function 1.0E-05 4.7E-03 P9 
140 GO:0071822_protein_complex_subunit_organization_biological_process 9.2E-07 7.6E-04 P9 
141 GO:0044802_single-organism_membrane_organization_biological_process 8.7E-06 4.0E-03 P7 
142 GO:0051641_cellular_localization_biological_process 8.7E-06 4.1E-03 P6 
143 GO:0072657_protein_localization_to_membrane_biological_process 6.6E-07 5.8E-04 P6 
144 GO:1902580_single-organism_cellular_localization_biological_process 1.0E-05 4.6E-03 P6 
145 GO:0006928_movement_of_cell_or_subcellular_component_biological_process 6.1E-06 3.1E-03 P5 
146 GO:0060627_regulation_of_vesicle-mediated_transport_biological_process 1.3E-07 1.5E-04 P7 
147 GO:0044297_cell_body_cellular_component 3.6E-08 5.5E-05 P7 
148 GO:0043025_neuronal_cell_body_cellular_component 1.9E-09 4.7E-06 P7 
149 GO:0022607_cellular_component_assembly_biological_process 2.0E-08 3.4E-05 P9 
150 GO:0044699_single-organism_process_biological_process 7.1E-08 9.3E-05 P9 
151 GO:0009987_cellular_process_biological_process 4.5E-06 2.5E-03 P9 
152 GO:0030165_PDZ_domain_binding_molecular_function 8.3E-07 6.9E-04 P9 
153 GO:0022610_biological_adhesion_biological_process 1.3E-06 9.7E-04 P8 
154 GO:0007155_cell_adhesion_biological_process 1.3E-06 9.7E-04 P8 
155 GO:0044765_single-organism_transport_biological_process 4.5E-06 2.5E-03 P9 
156 GO:0043005_neuron_projection_cellular_component 1.9E-10 7.2E-07 E10.5 
157 GO:0032502_developmental_process_biological_process 1.1E-05 4.8E-03 E9.5 





Table S7. Gene Ontology enrichment in module exons 
GO term M1 M2 M3 M4 min FDR 
Top 
module 
GO:0097458_neuron_part_cellular_component 1.48E-12 4.45E-09 1.00E+00 1.00E+00 1.48E-12 1 
GO:0044456_synapse_part_cellular_component 1.59E-12 3.37E-03 1.00E+00 1.00E+00 1.59E-12 1 
GO:0030054_cell_junction_cellular_component 2.51E-11 2.56E-05 1.00E+00 1.00E+00 2.51E-11 1 
GO:0042995_cell_projection_cellular_component 3.16E-11 1.08E-06 1.00E+00 1.00E+00 3.16E-11 1 
GO:0044459_plasma_membrane_part_cellular_compon
ent 3.49E-11 6.56E-07 1.00E+00 1.00E+00 3.49E-11 1 
GO:0044463_cell_projection_part_cellular_component 7.12E-11 1.70E-04 1.00E+00 1.00E+00 7.12E-11 1 
GO:0014069_postsynaptic_density_cellular_component 1.87E-10 3.68E-02 1.00E+00 2.12E-01 1.87E-10 1 
GO:0008092_cytoskeletal_protein_binding_molecular_f
unction 1.34E-09 4.03E-03 1.00E+00 1.00E+00 1.34E-09 1 
GO:0005856_cytoskeleton_cellular_component 8.76E-09 5.38E-01 1.00E+00 1.00E+00 8.76E-09 1 
GO:0097481_neuronal_postsynaptic_density_cellular_c
omponent 1.19E-07 6.53E-01 1.00E+00 2.17E-01 1.19E-07 1 
GO:0097060_synaptic_membrane_cellular_component 2.94E-07 4.99E-02 1.00E+00 1.00E+00 2.94E-07 1 
GO:0016043_cellular_component_organization_biologic
al_process 2.99E-07 1.20E-01 1.00E+00 1.00E+00 2.99E-07 1 
GO:0043005_neuron_projection_cellular_component 6.68E-07 7.14E-05 1.00E+00 1.00E+00 6.68E-07 1 
GO:0071840_cellular_component_organization_or_biog
enesis_biological_process 7.73E-07 1.89E-01 1.00E+00 1.00E+00 7.73E-07 1 
GO:0051179_localization_biological_process 1.06E-06 1.09E-03 1.00E+00 1.00E+00 1.06E-06 1 
GO:0045211_postsynaptic_membrane_cellular_compon
ent 2.10E-06 1.91E-01 1.00E+00 1.00E+00 2.10E-06 1 
GO:0005911_cell-cell_junction_cellular_component 3.02E-06 4.55E-01 1.00E+00 1.00E+00 3.02E-06 1 
GO:0044430_cytoskeletal_part_cellular_component 3.83E-06 9.08E-01 1.00E+00 1.00E+00 3.83E-06 1 
GO:0030425_dendrite_cellular_component 1.31E-05 3.62E-02 1.00E+00 1.00E+00 1.31E-05 1 
GO:0005515_protein_binding_molecular_function 2.86E-05 8.61E-05 1.00E+00 1.00E+00 2.86E-05 1 
GO:0007010_cytoskeleton_organization_biological_pro
cess 3.10E-05 3.03E-01 1.00E+00 1.00E+00 3.10E-05 1 
GO:0065007_biological_regulation_biological_process 3.19E-05 2.74E-01 1.00E+00 1.00E+00 3.19E-05 1 
GO:0005737_cytoplasm_cellular_component 3.25E-05 8.42E-01 1.00E+00 1.00E+00 3.25E-05 1 
GO:0043025_neuronal_cell_body_cellular_component 3.44E-05 7.15E-03 1.00E+00 1.00E+00 3.44E-05 1 
GO:1902578_single-
organism_localization_biological_process 7.30E-05 3.12E-03 1.00E+00 1.00E+00 7.30E-05 1 
GO:0043194_axon_initial_segment_cellular_component 7.46E-05 8.69E-03 1.00E+00 1.00E+00 7.46E-05 1 
GO:0030030_cell_projection_organization_biological_p
rocess 8.61E-05 6.92E-01 1.00E+00 1.00E+00 8.61E-05 1 
GO:0044763_single-
organism_cellular_process_biological_process 1.11E-04 2.95E-02 1.00E+00 1.00E+00 1.11E-04 1 
GO:0003779_actin_binding_molecular_function 1.72E-04 8.66E-01 1.00E+00 1.00E+00 1.72E-04 1 
GO:0033267_axon_part_cellular_component 1.73E-04 8.07E-03 1.00E+00 1.00E+00 1.73E-04 1 
GO:0050794_regulation_of_cellular_process_biological
_process 2.47E-04 4.76E-01 1.00E+00 1.00E+00 2.47E-04 1 
GO:0044297_cell_body_cellular_component 2.53E-04 2.48E-02 1.00E+00 1.00E+00 2.53E-04 1 
GO:0051234_establishment_of_localization_biological_
process 6.91E-04 1.10E-02 1.00E+00 1.00E+00 6.91E-04 1 
GO:0050789_regulation_of_biological_process_biologic
al_process 8.20E-04 2.17E-01 1.00E+00 1.00E+00 8.20E-04 1 
GO:0001725_stress_fiber_cellular_component 8.56E-04 1.00E+00 1.00E+00 1.00E+00 8.56E-04 1 
GO:0060627_regulation_of_vesicle-
mediated_transport_biological_process 9.02E-04 4.20E-02 1.00E+00 1.00E+00 9.02E-04 1 
GO:0044707_single-
multicellular_organism_process_biological_process 9.11E-04 2.88E-02 1.00E+00 1.00E+00 9.11E-04 1 
GO:0051128_regulation_of_cellular_component_organi
zation_biological_process 9.11E-04 2.39E-01 1.00E+00 5.01E-01 9.11E-04 1 
GO:0051640_organelle_localization_biological_process 9.86E-04 2.47E-01 1.00E+00 1.00E+00 9.86E-04 1 
GO:0032501_multicellular_organismal_process_biologi
cal_process 1.07E-03 2.37E-02 1.00E+00 1.00E+00 1.07E-03 1 
GO:0042641_actomyosin_cellular_component 1.08E-03 7.91E-01 1.00E+00 1.00E+00 1.08E-03 1 
GO:0032432_actin_filament_bundle_cellular_componen




_biological_process 1.44E-03 3.77E-01 1.00E+00 1.00E+00 1.44E-03 1 
GO:0044449_contractile_fiber_part_cellular_component 1.77E-03 1.04E-02 1.00E+00 1.00E+00 1.77E-03 1 
GO:0070161_anchoring_junction_cellular_component 2.13E-03 1.00E+00 1.00E+00 1.00E+00 2.13E-03 1 
GO:0048812_neuron_projection_morphogenesis_biologi
cal_process 2.61E-03 1.00E+00 1.00E+00 1.00E+00 2.61E-03 1 
GO:0065008_regulation_of_biological_quality_biologic
al_process 2.69E-03 1.74E-02 1.00E+00 1.00E+00 2.69E-03 1 
GO:0007165_signal_transduction_biological_process 2.88E-03 9.77E-01 1.00E+00 1.00E+00 2.88E-03 1 
GO:0006928_movement_of_cell_or_subcellular_compo
nent_biological_process 3.27E-03 6.93E-02 1.00E+00 1.00E+00 3.27E-03 1 
GO:1990351_transporter_complex_cellular_component 3.29E-03 3.80E-03 1.00E+00 1.00E+00 3.29E-03 1 
GO:0003008_system_process_biological_process 3.35E-03 2.17E-02 1.00E+00 1.00E+00 3.35E-03 1 
GO:0051641_cellular_localization_biological_process 3.40E-03 5.14E-01 1.00E+00 1.00E+00 3.40E-03 1 
GO:0005912_adherens_junction_cellular_component 3.79E-03 1.00E+00 1.00E+00 1.00E+00 3.79E-03 1 
GO:0044699_single-
organism_process_biological_process 3.81E-03 2.72E-02 1.00E+00 1.00E+00 3.81E-03 1 
GO:0043232_intracellular_non-membrane-
bounded_organelle_cellular_component 4.14E-03 1.00E+00 1.00E+00 1.00E+00 4.14E-03 1 
GO:0043228_non-membrane-
bounded_organelle_cellular_component 4.14E-03 1.00E+00 1.00E+00 1.00E+00 4.14E-03 1 
GO:0048869_cellular_developmental_process_biologica
l_process 4.21E-03 2.55E-01 1.00E+00 1.00E+00 4.21E-03 1 
GO:0032989_cellular_component_morphogenesis_biolo
gical_process 5.11E-03 1.00E+00 1.00E+00 1.00E+00 5.11E-03 1 
GO:0032502_developmental_process_biological_proces
s 5.11E-03 1.25E-01 1.00E+00 1.00E+00 5.11E-03 1 
GO:0022607_cellular_component_assembly_biological_
process 5.15E-03 3.62E-02 1.00E+00 1.00E+00 5.15E-03 1 
GO:0050793_regulation_of_developmental_process_bio
logical_process 5.16E-03 3.42E-01 1.00E+00 1.00E+00 5.16E-03 1 
GO:0007155_cell_adhesion_biological_process 5.21E-03 1.00E+00 1.00E+00 1.00E+00 5.21E-03 1 
GO:0022610_biological_adhesion_biological_process 5.21E-03 1.00E+00 1.00E+00 1.00E+00 5.21E-03 1 
GO:0048522_positive_regulation_of_cellular_process_b
iological_process 5.83E-03 6.78E-01 1.00E+00 1.00E+00 5.83E-03 1 
GO:0051239_regulation_of_multicellular_organismal_p
rocess_biological_process 6.09E-03 1.37E-02 1.00E+00 1.00E+00 6.09E-03 1 
GO:0051130_positive_regulation_of_cellular_componen
t_organization_biological_process 6.10E-03 4.01E-01 1.00E+00 1.00E+00 6.10E-03 1 
GO:0048858_cell_projection_morphogenesis_biological
_process 7.57E-03 9.24E-01 1.00E+00 1.00E+00 7.57E-03 1 
GO:0044767_single-
organism_developmental_process_biological_process 7.84E-03 1.14E-01 1.00E+00 1.00E+00 7.84E-03 1 
GO:0030165_PDZ_domain_binding_molecular_functio
n 8.95E-03 1.00E+00 1.00E+00 1.00E+00 8.95E-03 1 
GO:0006810_transport_biological_process 8.96E-03 3.01E-02 1.00E+00 1.00E+00 8.96E-03 1 
GO:0007409_axonogenesis_biological_process 9.23E-03 1.00E+00 1.00E+00 1.00E+00 9.23E-03 1 
GO:0030100_regulation_of_endocytosis_biological_pro
cess 9.23E-03 4.81E-01 1.00E+00 1.00E+00 9.23E-03 1 
GO:0051960_regulation_of_nervous_system_developme
nt_biological_process 1.00E-02 8.15E-02 1.00E+00 1.00E+00 1.00E-02 1 
GO:0005623_cell_cellular_component 1.01E-02 3.88E-02 1.00E+00 1.00E+00 1.01E-02 1 
GO:0032403_protein_complex_binding_molecular_func
tion 1.01E-02 2.31E-01 1.00E+00 1.00E+00 1.01E-02 1 
GO:0005913_cell-
cell_adherens_junction_cellular_component 1.04E-02 1.00E+00 1.00E+00 1.00E+00 1.04E-02 1 
GO:0019904_protein_domain_specific_binding_molecul
ar_function 1.13E-02 1.00E+00 1.00E+00 1.00E+00 1.13E-02 1 
GO:0050877_neurological_system_process_biological_
process 1.14E-02 4.85E-01 1.00E+00 1.00E+00 1.14E-02 1 
GO:0060284_regulation_of_cell_development_biologica
l_process 1.17E-02 6.93E-01 1.00E+00 1.00E+00 1.17E-02 1 
GO:0005874_microtubule_cellular_component 1.39E-02 9.93E-01 1.00E+00 1.00E+00 1.39E-02 1 
GO:0030695_GTPase_regulator_activity_molecular_fun




ess 1.73E-02 8.84E-01 1.00E+00 1.00E+00 1.73E-02 1 
GO:0022604_regulation_of_cell_morphogenesis_biologi
cal_process 1.74E-02 1.00E+00 1.00E+00 5.82E-02 1.74E-02 1 
GO:0030018_Z_disc_cellular_component 1.74E-02 1.35E-01 1.00E+00 1.00E+00 1.74E-02 1 
GO:0032589_neuron_projection_membrane_cellular_co
mponent 1.75E-02 1.00E+00 1.00E+00 1.00E+00 1.75E-02 1 
GO:0072657_protein_localization_to_membrane_biolog
ical_process 1.79E-02 1.00E+00 1.00E+00 1.00E+00 1.79E-02 1 
GO:0033270_paranode_region_of_axon_cellular_compo
nent 1.92E-02 1.00E+00 1.00E+00 1.00E+00 1.92E-02 1 
GO:0045807_positive_regulation_of_endocytosis_biolo
gical_process 2.11E-02 1.00E+00 1.00E+00 1.00E+00 2.11E-02 1 
GO:0009987_cellular_process_biological_process 2.14E-02 1.00E+00 1.00E+00 1.00E+00 2.14E-02 1 
GO:0031256_leading_edge_membrane_cellular_compo
nent 2.30E-02 6.08E-01 1.00E+00 1.00E+00 2.30E-02 1 
GO:0005096_GTPase_activator_activity_molecular_fun
ction 2.37E-02 7.52E-01 1.00E+00 1.00E+00 2.37E-02 1 
GO:0055083_monovalent_inorganic_anion_homeostasis
_biological_process 2.63E-02 2.87E-01 1.00E+00 1.00E+00 2.63E-02 1 
GO:0006996_organelle_organization_biological_process 2.72E-02 1.00E+00 1.00E+00 1.00E+00 2.72E-02 1 
GO:0051656_establishment_of_organelle_localization_b
iological_process 2.72E-02 1.65E-01 1.00E+00 1.00E+00 2.72E-02 1 
GO:0048471_perinuclear_region_of_cytoplasm_cellular
_component 2.72E-02 5.67E-01 1.00E+00 1.00E+00 2.72E-02 1 
GO:0007045_cell-
substrate_adherens_junction_assembly_biological_proce
ss 2.73E-02 1.00E+00 1.00E+00 1.00E+00 2.73E-02 1 
GO:0035418_protein_localization_to_synapse_biologica
l_process 2.73E-02 1.00E+00 1.00E+00 1.00E+00 2.73E-02 1 
GO:0048041_focal_adhesion_assembly_biological_proc
ess 2.73E-02 1.00E+00 1.00E+00 1.00E+00 2.73E-02 1 
GO:0072661_protein_targeting_to_plasma_membrane_b
iological_process 2.73E-02 1.00E+00 1.00E+00 1.00E+00 2.73E-02 1 
GO:0005488_binding_molecular_function 3.21E-02 4.56E-02 1.00E+00 1.00E+00 3.21E-02 1 
GO:0071822_protein_complex_subunit_organization_bi
ological_process 3.39E-02 4.80E-01 1.00E+00 1.00E+00 3.39E-02 1 
GO:0045686_negative_regulation_of_glial_cell_differen
tiation_biological_process 3.40E-02 1.00E+00 1.00E+00 1.00E+00 3.40E-02 1 
GO:0050767_regulation_of_neurogenesis_biological_pr
ocess 3.41E-02 4.28E-01 1.00E+00 1.00E+00 3.41E-02 1 
GO:0008017_microtubule_binding_molecular_function 3.62E-02 2.54E-01 1.00E+00 1.00E+00 3.62E-02 1 
GO:0045664_regulation_of_neuron_differentiation_biol
ogical_process 3.62E-02 9.80E-01 1.00E+00 9.23E-01 3.62E-02 1 
GO:0051647_nucleus_localization_biological_process 3.64E-02 5.03E-01 1.00E+00 1.00E+00 3.64E-02 1 
GO:0070509_calcium_ion_import_biological_process 3.64E-02 1.33E-01 1.00E+00 1.00E+00 3.64E-02 1 
GO:0034705_potassium_channel_complex_cellular_co
mponent 3.69E-02 1.15E-01 1.00E+00 1.00E+00 3.69E-02 1 
GO:0007017_microtubule-
based_process_biological_process 3.82E-02 1.00E+00 1.00E+00 1.00E+00 3.82E-02 1 
GO:0005813_centrosome_cellular_component 3.86E-02 1.00E+00 1.00E+00 1.00E+00 3.86E-02 1 
GO:0006612_protein_targeting_to_membrane_biologica
l_process 4.20E-02 1.00E+00 1.00E+00 1.00E+00 4.20E-02 1 
GO:0060589_nucleoside-
triphosphatase_regulator_activity_molecular_function 4.33E-02 7.99E-01 1.00E+00 1.00E+00 4.33E-02 1 
GO:0045216_cell-
cell_junction_organization_biological_process 4.34E-02 9.79E-01 1.00E+00 1.00E+00 4.34E-02 1 
GO:0045185_maintenance_of_protein_location_biologic
al_process 4.34E-02 1.00E+00 1.00E+00 1.00E+00 4.34E-02 1 
GO:0009653_anatomical_structure_morphogenesis_biol
ogical_process 4.57E-02 5.53E-02 1.00E+00 1.00E+00 4.57E-02 1 
GO:0072509_divalent_inorganic_cation_transmembrane
_transporter_activity_molecular_function 4.84E-02 8.13E-02 1.00E+00 1.00E+00 4.84E-02 1 
GO:0051651_maintenance_of_location_in_cell_biologic
al_process 4.98E-02 1.00E+00 1.00E+00 1.00E+00 4.98E-02 1 
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GO:0005886_plasma_membrane_cellular_component 3.01E-06 1.47E-06 1.00E+00 1.00E+00 1.47E-06 2 
GO:0022843_voltage-
gated_cation_channel_activity_molecular_function 2.64E-03 2.14E-06 1.00E+00 1.00E+00 2.14E-06 2 
GO:0005244_voltage-
gated_ion_channel_activity_molecular_function 7.78E-03 3.27E-06 1.00E+00 1.00E+00 3.27E-06 2 
GO:0022832_voltage-
gated_channel_activity_molecular_function 7.78E-03 3.27E-06 1.00E+00 1.00E+00 3.27E-06 2 
GO:0045202_synapse_cellular_component 5.51E-05 3.91E-06 1.00E+00 1.00E+00 3.91E-06 2 
GO:0034765_regulation_of_ion_transmembrane_transp
ort_biological_process 3.38E-03 5.54E-06 1.00E+00 1.00E+00 5.54E-06 2 
GO:0034762_regulation_of_transmembrane_transport_b
iological_process 6.85E-03 1.93E-05 1.00E+00 1.00E+00 1.93E-05 2 
GO:0022836_gated_channel_activity_molecular_functio
n 6.14E-03 3.14E-05 1.00E+00 1.00E+00 3.14E-05 2 
GO:0034703_cation_channel_complex_cellular_compon
ent 5.13E-03 3.47E-05 1.00E+00 1.00E+00 3.47E-05 2 
GO:0042391_regulation_of_membrane_potential_biolog
ical_process 5.38E-02 7.40E-05 1.00E+00 1.00E+00 7.40E-05 2 
GO:0023052_signaling_biological_process 5.51E-02 8.96E-05 1.00E+00 1.00E+00 8.96E-05 2 
GO:0005516_calmodulin_binding_molecular_function 7.09E-03 9.63E-05 1.00E+00 1.00E+00 9.63E-05 2 
GO:0032879_regulation_of_localization_biological_pro
cess 4.00E-04 9.82E-05 1.00E+00 1.00E+00 9.82E-05 2 
GO:0046873_metal_ion_transmembrane_transporter_act
ivity_molecular_function 6.45E-03 1.33E-04 1.00E+00 1.00E+00 1.33E-04 2 
GO:0043269_regulation_of_ion_transport_biological_pr
ocess 5.64E-03 1.49E-04 1.00E+00 1.00E+00 1.49E-04 2 
GO:0044700_single_organism_signaling_biological_pro
cess 4.02E-02 1.64E-04 1.00E+00 1.00E+00 1.64E-04 2 
GO:0044057_regulation_of_system_process_biological_
process 3.66E-01 1.79E-04 1.00E+00 1.00E+00 1.79E-04 2 
GO:0005261_cation_channel_activity_molecular_functi
on 4.23E-03 1.80E-04 1.00E+00 1.00E+00 1.80E-04 2 
GO:0007268_synaptic_transmission_biological_process 1.58E-01 2.17E-04 1.00E+00 1.00E+00 2.17E-04 2 
GO:0030001_metal_ion_transport_biological_process 3.46E-02 2.31E-04 1.00E+00 1.00E+00 2.31E-04 2 
GO:0005216_ion_channel_activity_molecular_function 1.65E-02 4.45E-04 1.00E+00 1.00E+00 4.45E-04 2 
GO:0022838_substrate-
specific_channel_activity_molecular_function 1.98E-02 5.91E-04 1.00E+00 1.00E+00 5.91E-04 2 
GO:0051049_regulation_of_transport_biological_proces
s 2.58E-03 6.92E-04 1.00E+00 1.00E+00 6.92E-04 2 
GO:0015267_channel_activity_molecular_function 2.60E-02 8.61E-04 1.00E+00 1.00E+00 8.61E-04 2 
GO:0022803_passive_transmembrane_transporter_activi
ty_molecular_function 2.60E-02 8.61E-04 1.00E+00 1.00E+00 8.61E-04 2 
GO:0006816_calcium_ion_transport_biological_process 2.20E-01 9.18E-04 1.00E+00 1.00E+00 9.18E-04 2 
GO:0034702_ion_channel_complex_cellular_componen
t 2.26E-03 9.42E-04 1.00E+00 1.00E+00 9.42E-04 2 
GO:1903522_regulation_of_blood_circulation_biologica
l_process 1.00E+00 1.08E-03 1.00E+00 1.00E+00 1.08E-03 2 
GO:0098662_inorganic_cation_transmembrane_transpor
t_biological_process 6.07E-02 1.09E-03 1.00E+00 1.00E+00 1.09E-03 2 
GO:0001508_action_potential_biological_process 3.15E-01 2.33E-03 1.00E+00 1.00E+00 2.33E-03 2 
GO:0086010_membrane_depolarization_during_action_
potential_biological_process 1.02E-01 2.34E-03 1.00E+00 1.00E+00 2.34E-03 2 
GO:1902495_transmembrane_transporter_complex_cell
ular_component 5.76E-03 2.93E-03 1.00E+00 1.00E+00 2.93E-03 2 
GO:0003012_muscle_system_process_biological_proces
s 6.45E-01 2.93E-03 1.00E+00 1.00E+00 2.93E-03 2 
GO:0050806_positive_regulation_of_synaptic_transmiss
ion_biological_process 1.00E+00 2.93E-03 1.00E+00 1.00E+00 2.93E-03 2 
GO:0098660_inorganic_ion_transmembrane_transport_
biological_process 3.01E-02 3.06E-03 1.00E+00 1.00E+00 3.06E-03 2 
GO:0006936_muscle_contraction_biological_process 4.28E-01 3.17E-03 1.00E+00 1.00E+00 3.17E-03 2 
GO:0055074_calcium_ion_homeostasis_biological_proc
ess 4.80E-01 3.35E-03 1.00E+00 1.00E+00 3.35E-03 2 




ess 2.00E-01 5.13E-03 1.00E+00 1.00E+00 5.13E-03 2 
GO:0006873_cellular_ion_homeostasis_biological_proc
ess 7.05E-01 5.13E-03 1.00E+00 1.00E+00 5.13E-03 2 
GO:0016020_membrane_cellular_component 5.92E-02 5.63E-03 1.00E+00 7.34E-01 5.63E-03 2 
GO:0022890_inorganic_cation_transmembrane_transpor
ter_activity_molecular_function 5.61E-02 6.08E-03 1.00E+00 1.00E+00 6.08E-03 2 
GO:0006874_cellular_calcium_ion_homeostasis_biologi
cal_process 4.03E-01 6.48E-03 1.00E+00 1.00E+00 6.48E-03 2 
GO:0055082_cellular_chemical_homeostasis_biological
_process 1.00E+00 7.79E-03 1.00E+00 1.00E+00 7.79E-03 2 
GO:0070588_calcium_ion_transmembrane_transport_bi
ological_process 1.07E-01 7.80E-03 1.00E+00 1.00E+00 7.80E-03 2 
GO:0005245_voltage-
gated_calcium_channel_activity_molecular_function 6.07E-02 9.18E-03 1.00E+00 1.00E+00 9.18E-03 2 
GO:0072507_divalent_inorganic_cation_homeostasis_bi
ological_process 4.48E-01 9.74E-03 1.00E+00 1.00E+00 9.74E-03 2 
GO:0006939_smooth_muscle_contraction_biological_pr
ocess 1.00E+00 1.01E-02 1.00E+00 1.00E+00 1.01E-02 2 
GO:0098589_membrane_region_cellular_component 3.65E-01 1.01E-02 1.00E+00 1.00E+00 1.01E-02 2 
GO:0030029_actin_filament-
based_process_biological_process 4.56E-02 1.04E-02 1.00E+00 7.96E-01 1.04E-02 2 
GO:0034220_ion_transmembrane_transport_biological_
process 4.35E-01 1.09E-02 1.00E+00 1.00E+00 1.09E-02 2 
GO:0098655_cation_transmembrane_transport_biologic
al_process 1.79E-01 1.10E-02 1.00E+00 1.00E+00 1.10E-02 2 
GO:0030003_cellular_cation_homeostasis_biological_pr
ocess 9.92E-01 1.11E-02 1.00E+00 1.00E+00 1.11E-02 2 
GO:0072503_cellular_divalent_inorganic_cation_homeo
stasis_biological_process 5.46E-01 1.16E-02 1.00E+00 1.00E+00 1.16E-02 2 
GO:0006875_cellular_metal_ion_homeostasis_biologica
l_process 7.80E-01 1.17E-02 1.00E+00 1.00E+00 1.17E-02 2 
GO:0007269_neurotransmitter_secretion_biological_pro
cess 6.77E-01 1.20E-02 1.00E+00 1.00E+00 1.20E-02 2 
GO:0019725_cellular_homeostasis_biological_process 1.00E+00 1.28E-02 1.00E+00 1.00E+00 1.28E-02 2 
GO:0042383_sarcolemma_cellular_component 1.86E-01 1.28E-02 1.00E+00 1.00E+00 1.28E-02 2 
GO:0008016_regulation_of_heart_contraction_biologica
l_process 1.00E+00 1.37E-02 1.00E+00 1.00E+00 1.37E-02 2 
GO:0070838_divalent_metal_ion_transport_biological_
process 5.35E-01 1.46E-02 1.00E+00 1.00E+00 1.46E-02 2 
GO:0072511_divalent_inorganic_cation_transport_biolo
gical_process 5.35E-01 1.46E-02 1.00E+00 1.00E+00 1.46E-02 2 
GO:0044765_single-
organism_transport_biological_process 1.98E-02 1.47E-02 1.00E+00 1.00E+00 1.47E-02 2 
GO:0016082_synaptic_vesicle_priming_biological_proc
ess 1.68E-01 1.54E-02 1.00E+00 1.00E+00 1.54E-02 2 
GO:0015085_calcium_ion_transmembrane_transporter_
activity_molecular_function 2.60E-02 1.59E-02 1.00E+00 1.00E+00 1.59E-02 2 
GO:0007416_synapse_assembly_biological_process 1.00E+00 1.62E-02 1.00E+00 1.00E+00 1.62E-02 2 
GO:0044425_membrane_part_cellular_component 6.02E-01 1.63E-02 1.00E+00 1.00E+00 1.63E-02 2 
GO:0022892_substrate-
specific_transporter_activity_molecular_function 1.00E+00 1.67E-02 1.00E+00 1.00E+00 1.67E-02 2 
GO:0001505_regulation_of_neurotransmitter_levels_bio
logical_process 1.00E+00 1.96E-02 1.00E+00 1.00E+00 1.96E-02 2 
GO:0019228_neuronal_action_potential_biological_proc
ess 1.00E+00 2.13E-02 1.00E+00 1.00E+00 2.13E-02 2 
GO:0035637_multicellular_organismal_signaling_biolo
gical_process 2.73E-02 2.13E-02 1.00E+00 1.00E+00 2.13E-02 2 
GO:0010959_regulation_of_metal_ion_transport_biolog
ical_process 1.00E+00 2.47E-02 1.00E+00 1.00E+00 2.47E-02 2 
GO:0006812_cation_transport_biological_process 1.91E-01 2.70E-02 1.00E+00 1.00E+00 2.70E-02 2 
GO:0098771_inorganic_ion_homeostasis_biological_pr
ocess 2.10E-01 2.72E-02 1.00E+00 1.00E+00 2.72E-02 2 
GO:0008331_high_voltage-




ogical_process 2.59E-01 3.45E-02 1.00E+00 1.00E+00 3.45E-02 2 
GO:0055065_metal_ion_homeostasis_biological_proces
s 5.03E-01 3.69E-02 1.00E+00 1.00E+00 3.69E-02 2 
GO:0006836_neurotransmitter_transport_biological_pro
cess 1.00E+00 3.69E-02 1.00E+00 1.00E+00 3.69E-02 2 
GO:0030315_T-tubule_cellular_component 2.19E-01 4.25E-02 1.00E+00 1.00E+00 4.25E-02 2 
GO:0005509_calcium_ion_binding_molecular_function 1.00E+00 4.31E-02 1.00E+00 1.00E+00 4.31E-02 2 
GO:0005891_voltage-
gated_calcium_channel_complex_cellular_component 8.70E-01 4.32E-02 1.00E+00 1.00E+00 4.32E-02 2 
GO:0006468_protein_phosphorylation_biological_proce
ss 1.00E+00 4.41E-02 1.00E+00 1.00E+00 4.41E-02 2 
GO:0005215_transporter_activity_molecular_function 1.00E+00 4.86E-02 1.00E+00 1.00E+00 4.86E-02 2 
GO:0055080_cation_homeostasis_biological_process 5.78E-01 4.99E-02 1.00E+00 1.00E+00 4.99E-02 2 
GO:0050775_positive_regulation_of_dendrite_morphog
enesis_biological_process 1.00E+00 1.00E+00 1.00E+00 2.01E-02 2.01E-02 4 
GO:0048814_regulation_of_dendrite_morphogenesis_bi
ological_process 1.00E+00 1.00E+00 1.00E+00 2.33E-02 2.33E-02 4 
 
 
